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RESUME EN FRANCAIS  
 
La Dystrophie Musculaire de Duchenne (DMD) est une des maladies les plus fréquentes : 
elle touche un garçon sur 3500. Cette maladie se caractérise par une dégénérescence 
progressive des muscles, si bien que les enfants qui en souffrent doivent utiliser une chaise 
roulante à partir d’une dizaine d’années et ils meurent en général entre 20 et 30 ans à la 
suite d’arrêt respiratoire ou cardiaque. Malgré le fait que cette maladie soit très répandue, 
aucune lignée cellulaire humaine n’était utilisée jusqu’à aujourd’hui. Nous avons voulu 
combler ce manque par l’immortalisation de cellules musculaires.  
Afin d’immortaliser des myoblastes, nous avons utilisé des myoblastes issus de la culture 
de cellules satellites humaines provenant de biopsies de muscles. Les cellules satellites 
sont des cellules qui sont localisées soit directement sur les muscles, soit à proximité des 
muscles, dans la matrice extracellulaire. Ces cellules font partie de la lignée musculaire, si 
bien qu’elles peuvent fusionner entre elles et former des muscles ou réparer des muscles. 
Lorsque de telles cellules sont activées et prolifèrent, elles sont nommées myoblastes.  
Nous avons utilisé des cellules humaines, afin d’obtenir des cellules modèles de la 
Dystrophie Musculaire de Duchenne, mais aussi afin de mieux connaître les événements 
menant à l’immortalisation de myoblastes. Or, il a été observé que les cellules animales, et 
particulièrement murines, sont beaucoup plus faciles à immortaliser que les cellules 
humaines. Cela vient du fait que les cellules humaines possèdent des mécanismes que les 
souris n’ont pas, et qui permettent plus de divisions cellulaires, tout en prévenant beaucoup 
de phénotypes cancéreux. En effet, les cellules murines se divisent beaucoup moins que les 
cellules humaines, 1011 mitoses contre 1016. Cette différence de divisions permet aux 
humains d’avoir une taille plus grande,  car la différence de taille entre les organismes 
humains et murins est comblée par un plus grand nombre de cellules et non par une plus 
grande taille des cellules. Or, il se trouve que les souris ont un risque de cancer de 30% à 
1.5 ans et ce même risque de cancer est retrouvé dans des personnnes de 80 ans.  
Une telle capacité de contrôler le cancer est possible chez l’homme, malgré un plus grand 
nombre de divisions cellulaires que chez la souris, grâce à différents mécanismes anti-
cancéreux que la souris ne possède pas. Les cellules humaines, par exemple, régulent la 
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télomérase, afin d’empêcher que n’importe quelle cellule puisse se diviser indéfiniment. 
Cette enzyme a pour but de maintenir une longueur suffisante à la fin des chromosomes, 
les télomères. Si cette enzyme n’est pas activée chez l’humain, les télomères s’érodent au 
cours des divisions cellulaires, et une cellule ne pourra faire en général au plus qu’une 
cinquantaine de divisions cellulaires avant de mourir, dans un processus qui est nommé 
sénescence. Comme il existe plus de mécanismes cancéreux chez l’homme, il est 
compréhensible que davantage de barrières anti-cancéreuses doivent être dépassées avant 
d’obtenir une immortalisation avec des cellules humaines en comparaison des cellules 
murines.  
Différentes méthodes peuvent permettre d’immortaliser des cellules dont notamment la 
mutagenèse chimique ou l’insertion d’oncogènes.  
La mutagenèse chimique peut être très efficace afin d’obtenir les mutations conduisant à 
l’immortalisation de cellules. Toutefois, alors, les mutations induites conduisant à 
l’immortalisations ne sont pas connues. De même, on ne sait pas si des mutations qui sont 
inutiles pour l’immortalisation se sont produites. De telles mutations pourraient être 
négatives pour la qualité de la lignée cellulaire résultante car elles pourraient parfois avoir 
lieu dans des gènes importants pour la lignée en question ce qui fait que la lignée résultante 
pourrait avoir des phénotypes très différents de cellules primaires.  
Sachant cela, nous avons choisi d’immortaliser les cellules par l’insertion d’oncogènes afin 
de connaître précisément les modifications apportées aux cellules primaires. Non 
seulement il est plus intéressant de travailler avec une lignée cellulaire dont on peut 
connaître précisément les modifications, mais, de plus, une telle approche permet de 
disséquer toutes les étapes menant à l’immortalisation. 
Les gènes que nous avons utilisés afin d’immortaliser les myoblastes étaient TAg, Bmi-1, 
hTERT, Bcl-2. TAg est l’antigène large du virus simien SV40 et a déjà été utilisé 
précédemment pour ses vertus immortalisantes, notamment des cellules murines. Quant à 
Bmi-1, il a été montré récemment qu’il joue un rôle dans la sénescence des cellules, et 
quelques essais ont prouvé également ses propriétés immortalisantes, notamment pour les 
cellules endothéliales sinusoïdales du foie. La partie catalytique de l’enzyme télomérase 
(hTERT) a aussi été utilisée dans des essais d’immortalisation, surtout humains, afin 
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d’empêcher les télomères de ces cellules de s’éroder. Enfin, nous avons encore utilisé le 
gène Bcl-2 dans nos essais d’immortalisation car ce gène est connu pour avoir des effets 
anti-apoptotiques.  
Après avoir choisi les gènes pouvant mener à une immortalisation, restait à choisir une 
méthode afin d’introduire ces gènes dans les myoblastes. Dans ce but, nous avons utilisé 
des vecteurs lentiviraux, dérivés du virus responsable du SIDA (Syndrome 
d’ImmunoDéficience Acquise), le VIH (Virus de l’Immunodéficience Humaine). De tels 
vecteurs lentiviraux sont très éloignés par divers aspects du VIH, car ils ont subi la délétion 
de la quasi-totalité du génome du VIH. Cela permet l’utilisation de tels vecteurs afin de 
transférer du matériel génétique, sans provoquer le SIDA. Dans le cas présent, nous avons 
utilisés de tels vecteurs car la capacité de leur capside était suffisante afin de contenir les 
gènes que nous voulions utiliser afin d’immortaliser les myoblastes. Toutefois, nous avons 
choisi ces vecteurs pour d’autres raisons: leur efficacité à insérer des gènes dans le génome 
des cellules et à produire souvent une bonne expression de ces gènes. A cet égard, nous 
avons d’abord vérifié que de tels vecteurs sont capables d’insérer des gènes dans des 
myoblastes à de très hautes efficacités. Nous avons aussi contrôlé que ces vecteurs peuvent 
permettre l’expression de transgènes à de hauts niveaux, ceci étant probablement possible 
grâce à une insertion dans les régions riches en gènes du génome de la cellule cible.  
Différents mélanges de vecteurs encodant des transgènes ayant des qualités potentiellement 
oncogéniques furent utilisés dans les immortalisations. Ces mélanges de vecteurs étaient 
composés soit des vecteurs encodant Bmi-1, TAg ou hTERT seulement, soit des mélanges 
de vecteurs encodant Bmi-1+hTERT ou TAg + hTERT ou Bmi-1 + hTERT + Bcl-2. Il 
s’est avéré que seuls les mélanges de vecteurs Bmi-1 + hTERT ou TAg ou TAg + hTERT 
ou TAg + Bmi-1 + Bcl-2 + hTERT ont pu réellement conduire à l’immortalisation des 
myoblastes. Cela signifie que, dans nos expériences, les cocktails minimums d’oncogènes 
capables d’immortaliser les myoblastes furent TAg seul ou Bmi-1 + hTERT.  
TAg a déjà été utilisé dans le passé pour l’immortalisation de différentes cellules, dont les 
myoblastes. Cependant, nous avons montré que les cellules qui étaient immortalisées avec 
TAg n’avaient pas un phénotype normal, elles étaient notamment beaucoup plus larges que 
les même cellules non immortalisées. Après analyse, il s’est avéré que ces cellules avaient 
un caryotype approchant la tétraploïdie alors que les cellules normales sont diploïdes. Nous 
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avons aussi pu constater que ces cellules avaient souvent subi des réarrangements 
chromosomiques, prenant la forme de translocations ou de cassures de chromosomes. Ces 
observations sont en accord avec d’autres articles décrivant les effets mutagènes que TAg 
peut avoir.  
Au contraire de TAg, nous avons montré que bmi-1 et hTERT étaient capables non 
seulement de conduire à l’immortalisation de myoblastes, mais aussi de permettre à ce que 
la ligée cellulaire obtenue reste très proche des cellules primaires. Ceci a pu être montré 
notamment par une forme et un caryotype normaux de ces cellules. De plus, de telles 
cellules avaient une prolifération similaire aux cellules contrôles, ce qui n’était pas le cas 
des cellules immortalisées avec TAg. Enfin, nous avons montré que les cellules 
immortalisées avec bmi-1 et hTERT avaient la capacité d’arrêter leur prolifération en 
milieu de différenciation comme les cellules contrôles. Cela n’était pas le cas pour les 
cellules immortalisées avec TAg.  
Malgré le fait que les cellules immortalisées avec TAg avaient beaucoup d’anomalies 
chromosomiques, nous avons noté que ces cellules n’étaient pas tumorigéniques après 
injections sous-cutanée dans des souris nude. Les souris nude ont comme caractéristiques 
d’être blanches, sans poils, et sans thymus. Ce phénotype est probablement dû à un défaut 
dans le développement de l’ectoderme. Comme ces souris n’ont quasiment pas de cellules 
T, elles ne peuvent pas empêcher la croissance des cellules tumorales. En conséquence, 
elles sont devenues un  des modèles pour caractériser des cellules tumorales in vivo. 
Même les cellules qui ont été immortalisées avec le plus d’oncogènes (TAg + Bmi-1 + 
hTERT + Bcl-2), n’ont pas été tumorigéniques après transplantation dans des souris nude. 
A l’opposé, l’injection sous-cutanée de cellules HeLa dans ces souris a conduit à de 
grandes tumeurs. Malgré de tels résultats, nous n’excluons pas que les lignées cellulaires 
que nous avons obtenues ne forment pas de tumeurs dans le long terme. En fait, nous 
pensons que les cellules qui contiennent TAg et qui ont été démontrées comme étant 
instables d’un point de vue génétique, peuvent être particulièrement aptes à produire des 
mutations qui pourraient permettre à ces cellules de devenir tumorigéniques. Quant aux 
autres lignées que nous avons produites et qui n’ont pas un caryotype instable, elles ont 
certainement moins la capacité de devenir tumorigéniques.  
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Un clone de myoblastes provenant d’un patient atteint de dystrophie musculaire de 
Duchenne a pu être utilisé dans ces immortalisations. Avec ce clone, nous avons pu obtenir 
une cellule immortalisée humaine contenant une mutation conduisant à la maladie de 
Duchenne. Jusqu’à maintenant, nous avons montré que cette lignée cellulaire a toutes les 
capacités de base des myoblastes primaires. Elle a un phénotype, un caryotype, et une 
prolifération qui sont normaux. De plus, cette nouvelle lignée est capable de proliférer et 
de fusionner normalement, jusqu’à 70% de fusion, comme les cellules contrôles. Cette 
lignée exprime encore Myf5 qui est un marqueur de surface caractéristique des myoblastes. 
Lorsqu’elle est placée en milieu de différentiation, cette lignée active aussi l’expression de 
Mef2, Desmin et Myogenin, ce qui est aussi caractéristique des myoblastes primaires 
placés en milieu de différentiation et qui deviennent des myotubes.  
Par rapport aux myoblastes provenant de donneurs sains, toutefois, les cellules de 
Duchenne, que nous avons obtenues après immortalisation avec Bmi-1 et hTERT, ont une 
cinétique de fusion légèrement retardée dans le temps. Ceci peut être dû au fait que ces 
cellules ont une mutation de Duchenne, ou au fait qu’elles surexpriment Bmi-1 ou hTERT, 
ou encore à une différence clonale entre ces cellules. Pour savoir si le retard de fusion est 
dû à la mutation Duchenne ou à l’addition d’oncogènes ou à des mutations, il faudrait 
utiliser des cellules qui soient isogéniques par rapport à notre lignée Duchenne et qui 
contiennent ou non les oncogènes Bmi-1 ou hTERT. Même si nous avons pu obtenir une 
lignée Duchenne qui fusionne dans le long terme, tous les clones de myoblastes  
immortalisés avec bmi-1 et hTERT n’ont pas eu cette caractéristique. Ce fait pourrait être 
expliqué si certaines lignées subissent des mutations ou si différents types de myoblastes 
peuvent être immortalisés. Selon cette seconde hypothèse, il se pourrait donc que nous 
n’ayons pas toujours choisi les bons clones au début des essais d’immortalisation.  
Même si nous n’avons pas observé d’aberrations chromosomiques dans les cellules 
immortalisées avec bmi-1, nous n’excluons pas que de telles cellules ont pu subir des 
mutations au niveau de quelques nucléotides provoquant des mutations. Il est en effet 
reconnu que les cellules peuvent subir soit des mutations visibles au niveau des 
chromosomes soit des mutations souvent issues d’instabilité de microsatellites, et celles-ci 
ne sont pas visibles dans les caryotypes. De telles mutations pourraient expliquer pourquoi 
nous n’avons obtenu que peu de clones qui fusionnent dans le long terme. Toutefois, 
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l’existence de différents types de cellules satellites et de myoblastes pourrait peut-être 
mieux expliquer ce fait. En effet, les cellules satellites sont connues pour leur hétérogénéité 
à différents niveaux. D’abord, il est connu que différentes populations de cellules satellites 
existent déjà in vivo et sont caractérisés par différentes expressions de marqueurs 
cellulaires. Ensuite, si un clone de ces cellules est cultivé in vitro, nous savons que de telles 
cellules conduisent aussi à une hétérogénéité de cellules dans un pétri. C’est ainsi que si un 
clone de cellules est soumis à un milieu de différentiation, seul environ 70% des cellules 
fusionnent. Quant aux 30% des cellules restantes, il est connu que seul un petit nombre 
d’entre elles peuvent se remettre à proliférer, si l’on revient en milieu de prolifération. Une 
telle hétérogénéité dans les myoblastes peut aussi expliquer pourquoi les clones que nous 
avons utilisés pour immortalisation n’ont pas pu tous produire des cellules avec des 
capacités de fusion dans le long terme.  
Malgré l’obtention de clones ne fusionnant pas dans le long terme, nous avons pu obtenir 
une lignée cellulaire de myoblastes d’origine Duchenne, qui ressemblent beaucoup aux 
cellules primaires. En résumé, ces cellules ont donc un phénotype, un caryotype et surtout 
des capacités de différentiation normales qui sont très proches de celles des cellules 
primaires normales. Dans l’article décrivant l’obtention de cette lignée cellulaire, j’avais 
proposé que cette lignée cellulaire soit employée dans différents protocoles impliquant des 
myoblastes. Ce fut effectivement le cas, car cette lignée cellulaire nous a été demandée par 
différents laboratoires dans le monde. Parmi ceux-ci, nous avons fait une collaboration 
avec le groupe d’Antoine de Vries (Section de Thérapie Génique, Centre Médical de 
l’Université de Leiden, Leiden, Pays-Bas). Ce groupe travaille sur la thérapie génique de la 
Dystophie Musculaire de Duchenne. Cette collaboration leur a permis d’utiliser l’unique 
ou le quasi unique modèle humain disponible de la maladie de Duchenne. Quant à nous, 
cette collaboration nous a permis de profiter de leur expérience avec des vecteurs 
particulièrement adaptés pour corriger la Dystrophie musculaire. En effet, Manuel 
Goncalves, qui travaille dans ce groupe, a déjà élaboré de nouveaux vecteurs dont le but 
est de corriger cette maladie. 
La Dystrophie Musculaire est provoquée par une mutation dans le gène humain le plus 
long connu : la dystrophine. Ce gène s’étend sur 2.5 Mbp, ce qui correspond à 0.1% du 
génome humain. On comprendra dès lors pourquoi la Dystrophie Musculaire est si 
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répandue : c’est parce qu’il est plus probable qu’un gène long soit muté par rapport à un 
gène court. Le fait que ce gène soit très long pose toutefois de grands problèmes dans sa 
correction telle qu’elle est envisagée dans les protocoles de thérapie génique. En effet, le 
cDNA de ce gène mesure 14 kb, ce qui est plus grand que la capacité de beaucoup de 
vecteurs, dont les vecteurs lentiviraux. C’est ainsi que les vecteurs lentiviraux ont été 
utilisés dans le but de corriger la Dystrophie Musculaire de Duchenne, seules des versions 
raccourcies de la dystrophine (appelées minidystrophines) ont été utilisées. Toutefois, le 
fait que ces versions soient ou non totalement fonctionnelles est un sujet de débat. Afin de 
ne pas entrer dans ce débat, nos collaborateurs ont au contraire opté pour la livraison d’une 
version complète de la dystrophine. Dans ce but, ils ont créé un nouveau vecteur qui est 
une version hybride de deux autres vecteurs connus. Des vecteurs dérivés des Adénovirus 
existent déjà, ils ont la capacité d’insérer dans des cellules de grandes quantités 
d’informations génétiques et donc de longs gènes. Par contre, ces vecteurs n’ont pas de 
capacités d’intégration. Au contraire, les vecteurs issus de Virus Adéno Associés (VAA) 
ne peuvent contenir que peu d’informations génétiques et donc que de courts gènes. Par 
contre, ces vecteurs ont la capacité intéressante de s’intégrer dans le locus AAV1 du 
chromosome 19. Sachant cela, nos collaborateurs ont fait le design d’un nouveau vecteur 
combinant la capacité des Adénovirus de contenir beaucoup d’informations génétiques et 
la capacité des virus Adéno associés de s’intégrer dans le locus AAV1. Le vecteur résultant 
de cette manipulation est un mélange VAA-Adéno, et il a la capacité de contenir non 
seulement une version codante de la dystrophine, mais deux.  
Un tel design VAA-Adéno a déjà été utilisé dans le passé et a pu conduire à la plus efficace 
correction de la Dystrophie Musculaire à ce jour. En effet, dans l’article relatant les 
résultats d’une telle manipulation, un vecteur codant deux unités d’expression de la 
dystrophine a permis jusqu’à 42% de correction de fibres du tibia antérieur de souris mdx.  
Les cellules que nous avons obtenues précédemment ont été encore utilisées afin de 
démontrer la faisabilité de la correction de la dystrophine avec les vecteurs bi-Adéno-
VAA. Avant de faire de telles expériences, la quantité de récepteurs CAR et CD46 a été 
contrôlée sur les myoblastes. Cela a été fait, car les vecteurs Adéno peuvent utiliser 
différents récepteurs, dont CAR et CD46 font partie, et si un type cellulaire a beaucoup 
d’un de ces récepteurs, il est plus judicieux d’utiliser un vecteur Adéno qui utilise le 
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récepteur en question, afin de rentrer au mieux dans ces cellules. Lors du contrôle de la 
quantité des récepteurs CAR et CD46, il a été démontré que les myoblastes contrôles mais 
aussi les myoblastes provenant de patients atteint de DMD et encore notre lignée cellulaire 
obtenue après immortalisation de cellules Duchenne avec Bmi-1 et hTERT, exprimaient 
tous à leur surface le récepteur CD46 et quasiment pas le récepteur CAR.  
Prenant en compte ce dernier résultat, les vecteurs Adéno-VAA furent modifiés dans le but 
d’exprimer à leur surface une nouvelle fibre, la fibre 50 de l’Adénonovirus 50 (Ad50) qui 
lie CD46. Le but de cette modification était de créer des vecteurs qui pourraient s’attacher 
au mieux aux récepteurs CD46 présents sur les myoblastes et finalement de rentrer mieux 
dans ces cellules. Pour ce faire, le virus Adéno Aideur employé dans la production des 
vecteurs Adéno-VAA a été modifié afin d’arborer la fibre 50 du virus Ad50. Dès lors, le 
virus Aideur résultant fut nommé plox-Aideur-Adéno-fibre50. Il est à noter en passant que, 
dès le départ, tous les vecteur Adéno Aideurs qui ont employés ici ont été modifiés afin 
d’arborer de chaque côté de leur séquence d’encapsidation psi une séquence plox. Ces 
séquences plox permettent aux virus de type sauvage d’être en grande partie supprimés, car 
les cellules productrices Adéno-VAA expriment la recombinase Cre, qui permet l’excision 
de la séquence Ψ. L’élément Ψ étant la séquence clé pour l’encapsidation du génome viral, 
la séquence d’ADN codant pour le virus Adéno n’entrera pas dans la capside protéique 
virale, ce qui a pour effet d’empêcher la propagation du virus de type sauvage. 
Les vecteurs résultants de toutes ces manipulations peuvent être nommés hc-bi-Adéno-
AAV-fibre50. En effet, de tels vecteurs ont une haute capacité d’accueillir des transgènes 
si bien qu’ils permettent l’introduction de deux unités d’expression de la dystrophine (de là 
leur préfixe hc-bi) mais ils sont aussi composés à la fois du virus Adéno et de la capacité 
des vecteurs VAA de s’intégrer dans le locus AAV1 du chromosome 19. Enfin, de tels 
vecteurs ont été produits avec la fibre 50 à leur surface afin de permettre une entrée 
optimale dans les myoblastes, car ceux-ci expriment à de plus hauts niveaux le récepteur 
qui est associé à la fibre 50 : le CD46.  
Il fut montré que les vecteurs hc-bi-Adéno-AAV-fibre50 pouvaient être produits aussi bien 
que les vecteurs n’étant pas composés avec la fibre 50. De plus, de tels vecteurs avec la 
fibre 50 pouvaient transduire des myoblastes beaucoup plus efficacement que les vecteurs 
avec la fibre 5. En fait, 30 fois moins de vecteurs ayant à leur surface la fibre 50 (qui lie 
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CD46) était nécessaire pour arriver au même niveau de transduction qu’avec les vecteurs 
arborant la fibre 5 (qui lie CAR). Tout cela a été possible, rappelons-le, parce qu’il y a sur 
les myoblastes plus de récepteurs CD46 pour la fibre 50, que de récepteurs CAR pour la 
fibre 5. 
De tels vecteurs furent ensuite employés dans le but de corriger notre lignée cellulaire pour 
l’expression de la Dystrophine. Leur utilisation permit non seulement de produire la 
dystrophine, mais aussi la localisation normale du Beta-dystroglycan. En effet, après une 
mutation de type Duchenne, il est connu que le complexe associé à la dystrophine est 
détruit, ce qui mène à une localisation cytoplasmique. Au contraire, dans les myoblastes et 
muscles normaux, le béta-dystroglycan est localisé au plasmalemme, et après adjonction 
des vecteurs dystrophine sur notre lignée cellulaire, nous avons aussi pu observer la 
redistribution du beta-dystroglycan au plasmalemme.  
Une des nouveautés de cet article est non seulement l’utilisation et le développement de 
nouveaux types de vecteurs basés sur les Adénovirus et les Virus Adéno Associés mais 
aussi la correction du phénotype Duchenne dans des cellules d’origine humaine. En effet, 
jusqu’ici, pour de tels travaux, en général, seules les cellules murines C2C12 ont été 
utilisées. Or, il est connu que le phenotype humain de la Dystrophie Musculaire de 
Duchenne est très différent par rapport à ce qui peut être vu dans les organismes murins. 
En effet, des souris avec une mutation dans la dystrophine sont souvent très similaires aux 
souris contrôles et elles n’ont des problèmes avec leurs muscles que tard dans leur vie. De 
telles différences ne sont pas encore totalement comprises mais proviennent au moins en 
partie de différences qu’il y a dans la régulation des cellules satellites humaines et murines. 
En sachant cela, il n’y aurait rien d’étonnant que la nouvelle lignée humaine obtenue ici ait 
la potentialité d’être beaucoup plus utile que des lignées murines dans les recherches sur la 
Dystrophie Musculaire de Duchenne.  
Les articles présentés dans cette thèse montrent donc, d’abord, que l’on a pu obtenir une 
nouvelle lignée cellulaire Duchenne. Cette lignée a, en bref, un phénotype, un caryotype, et 
une différentiation qui sont normaux. Toutes ces caractéristiques font de la lignée 
Duchenne obtenue ici certainement la meilleure lignée humaine de myoblastes obtenue 
jusqu’ici. Ensuite, ils montrent que cette lignée a pu être utilisée afin d’étudier la 
Dystrophie musculaire de Duchennne mais aussi sa correction. A l’occasion de la 
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correction en dystrophine de notre lignée cellulaire de Duchenne, un nouveau type de 
vecteur a été obtenu ici.  
L’obtention d’un nouveau modèle cellulaire de la maladie de Duchenne, pourra permettre 
un développement de la recherche dans le domaine de la Dystrophie Musculaire. 
L’obtention de ce modèle a aussi permis de mieux comprendre les étapes nécessaires à 
l’immortalisation des myoblastes. Quant à l’obtention du nouveau vecteur hc-bi-Adéno-
AAV-fibre50, il pourra être utilisé dans d’autres protocoles de thérapie génique. De 
manière générale, la lignée cellulaire et le nouveau vecteur obtenu dans les articles 
présentés dans cette thèse permettront certainement le développement de la connaissance 
dans le domaine de la Dystrophie musculaire. Cela pourra être fait par nos groupes, mais 
aussi par d’autres, et je souhaite dès lors plein succès à tous ceux qui seraient tentés par 
cette approche.  
D’autres possibilités peuvent encore découler de l’obtention de cette lignée de myoblastes 
humains. On peut penser qu’il pourrait être intéressant de fusionner de telles cellules, de 
les encapsuler, et de leur faire relâcher un produit thérapeutique. Par exemple, jusqu’à 
maintenant, les cellules murines C2C12 ont déjà été encapsulées dans le but de relâcher 
une molécule thérapeutique. Or, dans de telles expériences, il est connu que les cellules 
C2C12 subissaient toujours une mortalité importante dans les capsules, et cela pourrait être 
dû soit au fait que les cellules C2C12 prolifèrent encore dans la capsule soit au fait que 
beaucoup de cellules au centre de la capsule meurent car elles ne sont pas bien fusionnées 
aux autres. Les faits que notre lignée cellulaire puisse complètement arrêter de proliférer en 
milieu de différentiation et fusionne facilement pourraient suggérer que nos cellules 
peuvent être plus intéressantes à utiliser dans des encapsidations, car leurs mortalités 
pourraient être plus faible dans des capsules que de cellules C2C12. De plus, même si cela 
n’a pas été démontré, il se peut que les cellules C2C12, même encapsulées, relâchent un 
produit murin qui pourrait ne pas être bien toléré par l’homme, ou créer une réaction 
immunitaire. Au contraire, nos cellules ont l’avantage d’être humaines et très proches des 
cellules primaires, et donc, si elles sont injectées dans un hôte, elles pourraient être mieux 
tolérées par l’organisme et par le système immunitaire humain de l’hôte. Sachant cela, 
quelques essais de thérapies géniques non reliés au domaine des muscles pourraient être 
envisagés par exemple pour relâcher une molécule thérapeutique dans le sang. Toutefois, 
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sans attendre l’élaboration de telles expériences au résultat encore imprévisible, cette 
lignée est déjà utilisée par différents groupes dans différentes recherches académiques, et 
c’était bien là le but premier de sa fabrication.  
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ABSTRACT 
Duchenne Muscular Dystrophy is a genetic muscle wasting disease touching 1 out of 3500 
boys. However, the study of this disease was particularly difficult because no human cellular 
line with the features of these primary cells existed. During my thesis, I thus aimed at the 
fabrication of a human cellular model of this disease.  
In this respect, myoblasts from muscle biopsies of normal or Duchenne patients were 
immonartalized. These cells could be immortalized with different cocktails of oncogenes, 
consisting of Bmi-1, Large T antigen, Bcl-2, and human telomerase (hTERT). For this 
purpose, lentiviral vectors were used because they have sufficient capacities for the transgenes 
we wanted to use, but also because they allowed successful incorporation and transcription of 
them in myoblasts. After characterisation of the resulting cell lines, it was observed that TAg-
immortalized cells were bigger and rounder than their primary counterpart. TAg cell lines had 
also a karyotype in the tetraploid range, with numerous karyotipic anomalies, including 
translocations and chromosomal breaks. All these anomalies were not observed with cells 
immortalized with Bmi-1 and hTERT, which were shown to have a normal phenotype and a 
normal karyotype. A myoblast cell line with a Duchenne mutation could be established after 
immortalization with Bmi-1 and hTERT. This cell line had not only normal phenotypic 
karyotypic properties, but also a fusion very similar to normal primary cells. This cell line 
was also shown to express all the typical myogenic markers, once studied in proliferation or 
differentiation conditions.    
This new cell line was then complemented with Dystrophin, to obtain a normal muscle cell 
line, with the same genetic background as our Duchenne cell line. This experiment was also 
the occasion to test the utility of our Duchenne cell line in the studies aiming to correct DMD, 
especially in gene therapy experiments. For this purpose, hich capacity vectors were used, 
which were combining the properties of the Adeno Associated Virus (AAV) to insert their 
genetic material into the AAV1 locus of chromosome 19 and the properties of the Adeno virus 
to package large quantities of genetic material. At this occasion, the fibre on the surface of the 
vector was modified, to permit better entry into the myoblasts. This finally allowed the 
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complementation of our Duchenne cell line with Dystrophin, with correction of the DMD 
phenotype, as seen by visualization of Dystrophin in muscles, but also by correct 
relocalization of the beta-Dystroglycan complex at the plasmalemme.  
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ABBREVIATIONS 
Ai6 apoptosis inhibitor-6  
AML  acute myelogenous leukaemia  
Apc adenomatosis polyposis coli 
AAV Adeno-Associated Virus 
AAV1 Preferred integration locus of the AAV1 virus 
Bmi-1 B lymphoma Mo-MLV insertion region 
Brca breast cancer 
CDK cyclin-dependent kinase 
CDKI cyclin-dependent kinase inhibitor 
CIN chromosomal instabilities neoplasias 
CMV human cytomegalovirus immediate early promoter 
CTLs cytotoxic T lymphocytes  
Cx  connexin  
Cyc cyclin 
DGC Dystoglycan complex 
EGFP enhanced green fluorescent protein 
FKHR Forkhead in human rhabdomyosarcoma  
GH Growth hormone 
GTPases guanosine triphosphatases  
HIV Human Immunodeficiency Virus 
HLA human leukocyte antigens  
HSV1-TK thymidine kinase of herpes simplex virus type 1.  
INK4 inhibitors of CDK4
IGF-I Insulin-like Growth Factor-I 
IRES internal ribosomal entry site of the encephalomyocarditis virus 
KIRs killer cell inhibitory receptors  
KO knockout  
LT Large T antigen  
MAPK mitogen-activated protein kinase 
MDM2 murine double minute 2 
MIN microsatellite instabilities neoplasias  
Mo-MLV Moloney Murine Leukemia Virus 
mSP murine bone marrow side population  
MyHC myosin heavy chain 
Nf neurofibromatosis 
NK natural killer  
NOD/SCID non-obese diabetic/severe combined immunodeficient 
NPM nucleophosmin 
PAF-AH  platelet-activating factor acetylhydrolase 
PI3K phosphatidylinositol 3-kinase  
PLD phospholipase D 
PP2A phosphatase 2A  
RAL–GEFs RAL guanine-nucleotide exchange factors 
Rb retinoblastoma 
RDC1 chemokine orphan receptor 1  
RRE Rev-responsive element 
SA splice acceptor 
SCID severe combined immunodeficient 
SD splice donor 
SMT somatic mutation theory of carcinogenesis  
SP side population 
ST small T antigen  
STASIS STress or Aberrant Signaling Induced Senescence 
SV40 Simian Virus 40 
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Terc telomerase RNA component 
TJP tight junction protein  
TOFT tissue organization field theory of carcinogenesis and metastasis 
Ub Ubiquitin 
VCAM vascular cell adhesion molecule  
VLA very late antigen 
VSV-G Vesicular stomatitis virus G protein 
Ψ packaging signal  
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CHAPTER 1: INTRODUCTION 
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1.1 General concepts of senescence and oncogenesis 
1.1.1 Senescence and immortalization 
 
Normal somatic cells do not propagate indefinitely. Somatic cells can grow in vitro under 
appropriate culture conditions, but they have a limited doubling potential. After to have 
followed about 50 divisions (which often corresponds to less than one year in culture), most 
of the cell strains degenerate, and follow a process called senescence (Hayflick and 
Moorhead, 1961). However, it has been shown that the introduction of a limited number of 
viral-borne or tumor-derived genes was sufficient to render rodent cells immortal (Bishop, 
1985). While the introduction of a single gene failed to immortalize these cells, two genes 
were sufficient to immortalize these cells, but also contributed to their transformation to a 
tumorigenic state (Land et al., 1983; Ruley, 1983). The transforming oncogenes were termed 
viral or tumor oncogenes, and they were found to have gain-of-function mutations compared 
to normal human genes, called proto-oncogenes. Many reports have subsequently identified 
numerous pairs of oncogenes that were capable to render rodent cells tumorigenic (Hunter, 
1991). Nevertheless, despite the success of some pairs of oncogenes to immortalize and 
transform rodent cells, they often failed to immortalize human primary cells (Stevenson and 
Volsky, 1986). Such findings led to the proposal that a greater number of alterations are 
necessary to transform human cells than to transform murine cells.  
1.1.2 Differences in senescence and oncogenesis between human and 
mouse cells 
 
Apart from having a probable causal role in aging, the senescence mechanisms may suppress 
the development of cancer in mammals (Campisi et al., 2001; Reddel, 2000; Wright and Shay, 
2001).  
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Figure 1. Cancer risks in mice and humans with age. Mice data are from (Pompei et al., 
2001). Human data are from the American Cancer Society, Cancer Facts and Figures 2003. 
Figure redrawn from (Rangarajan and Weinberg, 2003). 
 
 
The need for additional barriers to carcinogenesis in human certainly stems from the fact that 
human cells divide more than murine cells. Humans are about 3,000 times larger than mice, 
but they also have more cells, and live longer than mice. In fact, humans undergo about 105 
more cell divisions in a lifetime (1016 divisions in humans versus 1011 mitosis in mice) 
(Rangarajan and Weinberg, 2003). Nevertheless, the risk to develop cancer during the life of 
mice or humans is comparable (Figure 1) (Rangarajan and Weinberg, 2003). However, 
humans live longer than mice, and this increase in lifespan with comparable cancer risks was 
possible since 80 million years after the development of new antineoplastic mechanisms 
(Hanahan and Weinberg, 2000). 
Considering these facts, we can better understand why both similarities and discrepancies 
have been found between mouse and human carcinogenesis. This has been particularly 
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observed after the comparison of mouse knockout (KO) models and family inherited 
mutations in humans (Figure 2).  
 
Tumour-
suppresor 
gene 
Spectrum of 
tumours in 
conventional 
mouse KO models 
Spectrum of 
tumours in 
humans (loss of 
function) 
Recent genetic 
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Spectrum of 
tumours in 
modified KO 
models 
Ink4a 
Fibrosarcoma, 
lymphoma, 
squamous- cell 
carcinoma 
Familial melanoma, 
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brain tumours 
Crossed with Arf +/– 
mice 
Metastatic 
melanoma, 
sarcoma, carcinoma, 
lymphoma 
Trp53 
Osteosarcoma, 
lymphoma, soft-tissue 
sarcoma 
Breast carcinoma, 
brain, sarcomas, 
leukaemia 
Additional loss of 
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Breast and other 
carcinomas 
Apc (ApcMIN, Apc 716, 
Apc 580) 
Multiple polyps in 
small intestine 
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progressing to 
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specific inactivation Polyps in colon 
Rb Brain, pituitary Retinoblastoma, osteosarcoma 
Additional loss of 
p107 Retinoblastoma 
Brca1 No tumour susceptibility Breast, ovary 
Conditionalmammary-
specific inactivation of 
Brca1 
Mammary tumours 
Brca2 No tumour susceptibility Breast, ovary 
Conditional 
mammary-specific 
inactivation of Brca2 
and Trp53 
Mammary tumours 
Nf1 Pheochromocytoma, myeloid leukaemia 
Neural-crest-derived 
benign neurofibroma 
and malignant 
fibrosarcoma 
Additional loss of 
Trp53 
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Nf2 
Osteosarcoma, 
fibrosarcoma, lung 
adenocarcinoma, 
hepatocellular 
carcinoma 
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Figure 2. Comparisons between mouse KO models and family inherited human alterations in 
tumor suppressor genes. Apc, adenomatosis polyposis coli; Brca, breast cancer; KO, 
knockout; Nf, neurofibromatosis; Rb, retinoblastoma; Terc, telomerase RNA component. 
Figure taken from (Rangarajan and Weinberg, 2003). 
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1.1.3 Are there senescence clocks? 
 
Normal cells have a finite life span that seems to be counted, before they finally die. But if the 
life span is counted, what is the counting mechanism?  
After the discovery that some nucleoproteins, named telomeres, shorten with every cycle of 
cell growth, the hypothesis that these structures could be the counting mechanism for cell 
senescence appeared. In such a model, progressive erosion of telomeres with cell divisions 
would trigger senescence, once a minimal threshold of telomere length is reached (Harley et 
al., 1990b). This mechanistic model was partially verified, because, at least in some cell types, 
ectopic expression of the catalytic unit of telomerase enzyme, hTERT (human telomerase 
reverse transcriptase), was sufficient to lead to extension of cellular life span (Bodnar et al., 
1998a; Vaziri and Benchimol, 1998b).  
Different telomerase expression levels may also explain differences observed in the 
immortalization of murine and human cells. Indeed, telomerase is expressed in most murine 
tissues (Prowse and Greider, 1995), but it is expressed only transiently and at low levels in 
normal human cells (Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995; 
Masutomi et al., 2003). However, additional differences still exist between the phenotypes 
produced by the loss of telomerase in humans and mice. While telomerase loss produces 
affects after about 50 cell divisions in most human cells types, the effect of telomerase loss in 
mice is only visible at the sixth generation, despite of continued telomere shortening. This 
discrepancy may be explained at least in part because there are less cellular divisions in mice. 
However, murine telomeres are also longer, they measure from 20 to 50 kb, and human 
telomeres sizes range between 8 and 15 kb. Then, both reduced lifetime of mice and longer 
telomere lengths may explain why it is only after six generations of telomerase knock-out in 
mice that abnormalities are observed. They include fusion of chromosomes, aneuploidy, and 
also sterility (Lee et al., 1998). 
Additional observations suggested that telomere length is probably not the sole counting 
mechanism for cell life. Indeed, oxygen levels were found to have an effect on the lifespan of 
culture human fibroblasts. In fact, it was observed that when fibroblasts are propagated in 1-
3% oxygen instead of 20% oxygen, they are able to undergo more divisions prior to 
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senescence. In the contrary, when oxygen levels are higher than 20%, their lifespan shortens 
(Chen et al., 1995; Packer and Fuehr, 1977; von Zglinicki et al., 1995). Other experiments 
have shown that senescence can also be induced by some forms of DNA damage (for 
example, oxidative stress), and by certain oncogenes (Campisi, 2001; Wright and Shay, 
2002). This led to the conclusion that senescence can be induced by environmental stresses, 
and such phenomenon was variously termed premature senescence, culture shock, stress-
induced senescence, or STASIS (STress or Aberrant Signaling Induced Senescence) (Shay 
and Wright, 2004). 
At this point, it was suggested that there is not only a telomerase-based clock in normal cells, 
but also a stress-based clock that also contributes to aging. Then, it would be the combined 
effect of these two clocks that would define the onset time of senescence.  
Until now, at least these two clocks are thought to collaborate in defining the age of 
senescence of cells and in inducing of senescence, but other clocks may be possible. It could 
still be possible that only telomerase length is a real clock for senescence and that stress 
stimuli may have effects on telomeres, and finally on senescence. This is true to a certain 
extent at least in some cells have where telomeres have been shown to shorten more quickly 
in high oxygen environments (von Zglinicki et al., 1995). Nevertheless, senescence was also 
shown not to depend only on telomere lengths. Indeed, senescence can happen even with long 
telomeres, and such form of stress-related senescence can not be prevented by ectopic hTERT 
expression (Gorbunova et al., 2002; Wei et al., 1999).  
These data, and other data that will be presented now, suggest that telomere length is not the 
only determinant of senescence. They also suggest that replicative senescence and stress-
induced senescence are not as different as depicted until now: they use the same mechanisms 
and they generate one response program. At this point, the conceptual ideas of senescence 
clocks should be reexamined in view of the facts that pathways of replicative senescence and 
stress-induced senescence are mechanistically bound. The emerging picture is that different 
stimuli can activate senescence, and whether this occurs rapidly, or gradually, following a 
period of proliferation, is mainly determined by the combined levels of the stresses involved. 
Then, it seems that it is not one clock, two clocks, or more, that should be considered in the 
accomplishment of the senescence program, but, best, the integrated measure of different 
stresses.  
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1.1.4 Pathways toward senescence  
Some genes have been shown to induce senescence, even in cells that are considered to be 
immortal, such as tumor cells (Figure 3) (Roninson, 2003). Such experiments, and others, that 
will be discussed now, have permitted to uncover the pathways leading to senescence.  
Gene Tumor cell line 
 p53 EJ bladder caa; NSCLC H358 lung ca 
 p63 EJ bladder ca 
 p73 EJ bladder ca 
 RB MDA-MB-468 breast ca; 5637 bladder ca; 
Saos-2 osteosarcoma 
 p21Waf1/Cip1/Sdi1 HT1080 fibrosarcoma; EJ bladder carcinoma; 
H1299 lung ca 
 p16Ink4A U-1242 MG glioma; U251 glioma; U2-OS 
osteosarcoma 
 P57Kip2 U343 MG-A, U87 MG, and U373 MG 
astrocytoma 
 p15Ink4B U251 glioma 
 E2 papillomavirus protein (inhibitor of   
 E6 and E7) 
HeLa, HT-3, and CaSki cervical ca 
 IGFBP-rP1 M12 prostate ca; MCF-7 breast ca 
 Activated RAF-1 LNCaP prostate ca 
 Activated MKK6 U2-OS osteosarcoma 
 
Figure 3. Genes that induce senescence-like phenotype in tumor cells.  a ca, carcinoma; 
NSCLC, non-small cell lung cancer. Figure taken from (Roninson, 2003). 
 
Two main different pathways of senescence can be triggered and need to be bypassed for 
immortalization. These pathways of senescence can be p16INK4a-retinoblastoma (p16INK4a-Rb) 
dependant, or ARF-p53 dependant (Figure 4). These pathways have also a role in oncogenesis 
(Sherr, 2001).  
 
 p16INK4a                                               Rb Family 
                               
Oncogenic 
stress (e.g. 
Myc, E2F) 
 
p21Cip1
Telomere  
shortening, 
oncogenic 
stress  
G1 arrest 
(including 
senescence) 
CDK4,6 
Cyclin D 
Telomere shortening,  
DNA damage, etc. 
p53-independant  
senescence functions ? 
ARF                     MDM2                    p53                  Apoptosis 
Figure 4. The p16INK4a-Rb dependant, or ARF-p53 dependant pathways of senescence. Figure 
modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; Sharpless, 2004; Sherr, 
2001; Sherr, 2004). 
 
 
The tumor suppressors p16INK4a and ARF are implicated separately in the measure of lifespan. 
This was demonstrated by the fact that the lifespan of mice strains deprived of p16INK4a or 
ARF is shorter than wild-type animals but longer than the strains deprived of both (Kamijo et 
al., 1997; Serrano et al., 1996; Sharpless et al., 2001; Sharpless et al., 2004).  
Nevertheless, disruptions of the p16INK4a and ARF pathways can lead to different phenotypes 
in different cell types, and in different organisms. Most MEFs acquire characteristic 
senescence-related morphologies by an ARF mechanism. In the contrary, murine 
lymphocytes, macrophages, astrocytes, and a variety of human cells, were reported to senesce 
in vitro by a p16INK4a–dependent mechanism (reviewed by (Sharpless, 2004)). 
Characterization of cancer cells showed inverse correlation between the presence of p16INK4a 
and wildtype RB, suggesting the existence of a link between p16INK4a and RB (Otterson et al., 
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1994; Shapiro et al., 1995). Genetic observations also linked the tumor suppressor ARF to 
p53 (Chin et al., 1997; Kamijo et al., 1997; Pomerantz et al., 1998). The genetic linkage of  
pRB and p53 with senescence were verified by further experiments. They include the 
following ones: 
 
• Inactivation of p53 extends the lifespan of human fibroblasts (Itahana et al., 2001), 
whereas  MEFs from p53 null mice do not senesce (Harvey et al., 1993). 
• MEFs with targeted disruption of all pRB family of proteins (pRb, p107, and p130) do not 
senesce (Dannenberg et al., 2000; Sage et al., 2000).  
• Human cells that lose p53 and pRB functions are generally refractory to multiple 
senescence-inducing stimuli (Dimri et al., 2000; Serrano et al., 1997).  
 
The p16INK4a-Rb and of ARF-p53 senescence pathways will be presented more in detail now. 
Interestingly, these pathways begin either by p16INK4a or ARF activation, and it appeared that 
both these proteins are products of genes originating from the INK4a locus. Even though the 
p16Ink4a and p14Arf (p19ARF in mice) transcripts are initiated at different promoters, they share 
part of the same sequence, but in alternative reading frames (hence the name of Arf) (Figure 
5). The reason why these two tumour-suppressor genes are so intimately linked is not known, 
but it is suspected that this chromosomal link may have a utility for the cells. As both these 
proteins are involved in interpreting responses to hyperproliferative signals and in modulating 
the Rb and p53 pathways, this chromosomal link could have a utility for these proteins to 
respond to similar signals. However, despite their intimate linkage, the two genes are 
independently positively and negatively regulated (Sherr, 2004). So, it is still not understood 
what selective advantage this linkage might have, if it has any. In fact, it seems particularly 
intriguing why two tumor suppressors are located in the same locus. This particularity makes 
that since some deletions in the INK4a-ARF locus can simultaneously compromise the 
functions of two tumor suppressors. This may seem to be a disadvantage for the cell, but if 
evolution has adopted this very peculiar conformation of tumor suppressor genes, it is 
probably for a good, but still unknown, reason.  
 
 INK4a/ARF 
ARF 
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p14ARF
p16INK4a
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Figure 5. The INK4a/ARF locus. A The INK4a/ARF locus encodes two proteins : p16Ink4a and 
p14Arf (p19ARF in mice) by different promoters.  (A) Overview of the INK4a/ARF locus, with 
the different promoters (arrows), exons (1β, 1α, 2 and 3), splice donors (SD), and splice 
acceptors (SA). 1β and 1α are alternative exons of ARF and p16Ink4a, respectively. (B) ARF 
only. (C) INK4a only. The second exon of p16Ink4a is similar to the second exon of ARF, but 
in an alternative reading frame, so that ARF stop codon is not placed at the same position than 
that of INK4a. (D) (E) the resulting p14ARF and p16INK4a products. Figure adapted from 
(Collins and Sedivy, 2003; Hayward, 2003; Sharpless, 2004; Sherr, 2001). 
 
 
1.1.5 The p16INK4a-Rb pathway 
 
The INK4 family comprises p16INK4a, p15INK4b, p18INK4c, and p19INK4d (p19INK4d being distinct 
from murine p19ARF). All these proteins are cyclin-dependent kinase inhibitors (CDKIs). The 
CDKIs inhibit the cyclin-dependent kinases that phosphorylate the related proteins p107 and 
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p130, leading to their inactivation, and to inhibition of cell cycle progression (Classon and 
Harlow, 2002). Implication of these proteins in tumorigenesis has been noted, but in different 
extents (Figure 6) (Sherr, 2001). Nevertheless, only INK4a and ARF, and not their related cell 
cycle inhibitors of the INK4 family, seem to have a major role in senescence. Moreover, only 
the expression of p16INK4a and ARF is increased in aged organs, once this expression is 
compared with the one found in young organs (Krishnamurthy et al., 2004). 
 
 
Ink4a 
Ink4b 
Ink4c 
Ink4d D3 
D1 
D2 
CDK4 
CDK6 
Rb 
p130 
p107 
E2Fs 1-3 
E2Fs 4,5 
Figure 6. The ink4 family of CDKI. The four Ink4 proteins inhibit complexes of cyclins D1, 
D2 or D3 with either Cdk4 or Cdk6. These six cyclin D-dependent kinases complexes can 
inhibit the three Rb-family members that interact preferentially with different E2f subunits. 
Rb associates primarily with E2fs 1–3, and p107 and p130 preferentially forms complexes 
with E2fs 4 and 5. Yellow, pink and green shadings indicate the proteins that are often, less 
frequently or only rarely (if at all) involved in tumorigenesis. Figure redrawn from (Sherr, 
2001).  
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The fact that INK4a-deficient human diploid fibroblasts were shown to be resistant to RAS-
induced senescence, has led to the implication of  p16INK4a in senescence (Brookes et al., 
2002). Moreover, in mice, increased expression of p16INK4a by deficiency of the SNF2-like 
gene PASG was shown to cause premature aging (Sun et al., 2004). One further evidence 
suggesting that p16INK4a is implicated in senescence came from MEFs with a p16 binding 
deficient mutant of CDK4, that failed to senesce in culture (Rane et al., 2002). It was also 
shown that when rare human epithelial cells escape cell cycle arrest once placed in culture, 
they show epigenetic silencing of the INK4a gene (Drayton and Peters, 2002). However, it 
was also shown that this particular block could be avoided by alternate culture conditions. 
Indeed, co-culture of epithelial cells with feeder layers allowed them to behave more like 
fibroblasts (Ramirez et al., 2001).  
Telomere shortening or telomere structure dysfunction is correlated with increased p16INK4a 
expression in senescing human fibroblasts (Bodnar et al., 1998b; Smogorzewska and de 
Lange, 2002). Despite this evidence, the signaling pathway linking uncapped telomeres to 
p16INK4a has not been completely elucidated. Additional events seem to regulate p16INK4a 
accumulation, but they are less well understood than that of ARF. Nonetheless, it is known 
that p16INK4a can be induced by certain forms of oncogene activation, such as by the 
RAS→RAF→MEK→ERK→Ets1/2 pathway (Zhu et al., 1998). Repressors such as Ets11 
and Id are also known to attenuate p16INK4a expression (Alani et al., 2001; Huot et al., 2002; 
Ohtani et al., 2001). In the end, bmi-1, cbx-7 and tbx2 have also been reported to repress the 
transcription of p16INK4a, but also of ARF (reviewed by (Sharpless, 2004)) (Figure 7).  
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p16INK4a
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Cdk4/6 
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Figure 7. p16INK4a induction leads to cell cycle arrest. Telomere dysfunction or oncogenic 
stress can activate p16INK4a. This prevents CDK4,6/Cyclin D complexes to phosphorylate 
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pRB-family of proteins, and leads to cell cycle arrest by pRB-family of proteins inhibition of 
E2F. Figure adapted from (Sharpless, 2004; Sherr, 2001). 
 
The role of p16INK4a is to associate with CDK4/6 complexes, and to separate cyclin D from 
CDK4/6. Subsequently, Cyclin D is degraded and unactive CDK lead to pRb 
hypophophorylation and reactivation (Sherr, 2001). Normally, in late G1 of cycling cells, 
hyperphosphorylation of Rb disrupts its association with various E2F family members, which 
heterodimerize with DP proteins. This allows subsequent transcription of the E2F-DP target 
genes, which are necessary for DNA synthesis (Dyson, 1998; Nevins, 1998) (Figure 8). In the 
contrary, if there are high levels of p16INK4a in cells, hypophosphorylation of pRB leads to cell 
cycle arrest.  
Modulation of expression of genes downstream of p16INK4a can have an effect on senescence 
and cell cycle, independently of p16INK4a. For example, if E2F is overexpressed, it can lead 
quiescent cells into S phase (Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994). In 
the contrary, pRb overexpression can lead to senescence, even in human immortal tumor cells 
(Xu et al., 1997).  
Different factors can influence p16INK4a action on CDKs, such as the CDKIs p21Cip1 and 
p27Kip1. Their respective action is reviewed elsewhere (Sherr, 2001). 
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pRB-family of proteins  
active  
repression 
DP       E2F      
activator 
 
pRb-family 
Cdk4/6 Cyclin D 
DP      E2F      pRb-family 
Derepression and activated 
transcription of E2F target genes 
P P P 
p16INK4a
Cdk4/6 
Cyclin D 
p16INK4a
degraded 
 
Figure 8. Transcription of E2F genes after pRb-family phosphorylation. In non-cyling cells, 
pRB-family of proteins are hypophosphorylated and repress transcription of E2F-DP 
(Malumbres and Barbacid, 2001). Once phosphorylated by Cyclin D-CDK4/6, proteins of the 
pRB-family dissociate from E2F, and permit transcription of E2F-DP target genes. Figure 
adapted from (Dyson, 1998). 
 
1.1.6 The ARF-p53 pathway 
Whereas mice lacking Arf develop normally but are highly tumor prone, MEFs from ARF 
null mice do not senesce and continue to proliferate much like established cell lines (Kamijo 
et al., 1997). The role of Arf in senescence seems to monitor latent oncogenic signals (Zindy 
et al., 2003). Among them, v-abl, c-myc, E1a, E2F or loss of RB have been demonstrated to 
induce ARF and thereby stabilize p53. In the contrary, the oncogenic transcription factors 
bmi-1, cbx-7, tbx-2, Twist and AML-ETO have been shown to repress p14ARF (Sharpless, 
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2004). Among them, bmi-1, cbx-7 and tbx2 also regulate the transcription of p16INK4a (Figure 
9). 
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Figure 9. The ARF/p53 pathway. Under normal circumstances, the ubiquitin ligase MDM2 
blocks p53 activity by targeting it for proteasomal degradation, and by directly blocking its 
transcriptional activity. The functions of MDM2 are auto-regulated by a negative feedback, 
because MDM2 is a p53-target gene. In case of strong proliferative signals, such as oncogene 
activation, ARF is transcribed, and negatively regulates MDM2. This leads to increased p53 
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activity, and cell-cycle arrest or apoptosis. Ub, Ubiquitin. Figure adapted from (Hipfner and 
Cohen, 2004; Sharpless, 2004). 
 
ARF binds to and inhibits MDM2 (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 
1998; Zhang et al., 1998). In turn, MDM2 is an E3 ubiquitin ligase that can target p53 for 
proteasomal degradation. MDM2 is also able to inhibit p53-mediated transcription. The 
MDM2-mediated repression of p53 is regulated by a negative feedback loop because MDM2 
is a p53-target gene. 
In addition to its stabilizing role of p53 by inhibiting Mdm2, ARF has also been reported to 
inhibit cell growth independently of p53, MDM2 and p21 (Korgaonkar et al., 2002). Apart its 
binding to Mdm2, ARF has also been reported to bind to E2F-1, topoisomerase I, MdmX, 
HIF-1α, PXF/pex19p and nucleophosmin (NPM)/B23 (Sharpless, 2004). Some of these 
interactions may explain p53-independent functions of ARF, and may also connect ARF not 
only to cell proliferation (through p53), but also to growth (through NPM and ribosomal 
processing).  
The degradation of ARF has recently been shown to be Mdm2- and p53-independent, but 
depends on N-terminal polyubiquitination. Nevertheless, contrary to other ubiquitination 
processes, lysines are not required for ARF degradation (Kuo et al., 2004).  
 
 
Myc                          Arf                           Mdm2                        p53 
Figure 10. Multiple feedbacks in the Myc-Arf-Mdm2-p53 pathway. p53 negatively regulates 
Arf and Myc, but positively regulates Mdm2. ARF is an antagonist of Myc, but in a very 
specific manner on different target promoters. Only gene expression of Myc is impaired, but 
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not gene repression. This inhibits Myc’s pro-proliferative, but not its apoptotic, functions. 
Figure modified from (Cleveland and Sherr, 2004). 
Multiple regulations can affect the Arf-p53 pathway, and its activators. For example, 
evidences suggest that p53 negatively regulates Arf, by an unknown mechanism, and that p53 
and Arf can negatively regulate Myc (Figure 10). 
      
Figure 11. Link of p53 and pRb-family of proteins through p21. p53 induces p21, which 
inhibits different CDK complexes (Roninson, 2002). Figure modified from (Roninson, 2002; 
Sherr, 2004; Sherr and Roberts, 1999).  
 p53                         p21                        Cdk2    Cyclin E                     pRb-family             
Apoptosis                                                                                              Cell-cycle arrest 
 
The role of p21 is to provide a link between p53 and pRB (Figure 11). The expression of p21 
is high in senescent cells (Atadja et al., 1995; Itahana et al., 2001), and targeted disruption of 
p21 is sufficient to bypass senescence in human fibroblasts (Noda et al., 1994). Therefore, 
p21 may have a major role in induction of cellular senescence of human fibroblasts. In the 
contrary, MEFs from p21 null mice senesce normally (Pantoja and Serrano, 1999). This has 
led to the proposition that other factors downstream of the p19ARF-p53 pathway may limit the 
growth of MEFs. At the molecular level, p21 (WAF1/CIP1) acts as a CDKI, but contrary to 
the INK4 CDKIs, p21WAF1 does not dissociate cyclin-CDK complexes. p21 associates with 
different cyclin-CDK complexes, and arrests cells in both G1 and G2/M stages of the cell 
cycle. The particular association of p21 with cyclin E and CDK2 provides a link between p53 
and pRB. p21 is a p53 target, and through its association with Cyclin E and CDK2, it 
inactivates this complex, and maintains Rb in an hypophosphorylated form. This in turn 
permits the sequestration of E2F by Rb, and leads to cell cycle arrest, through activation of 
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E2F-DP target genes (Figure 12) (reviewed by (Roninson, 2002; Sherr, 2004; Sherr and 
Roberts, 1999)).  
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Figure 12. p21 can mediate cell cycle arrest. pRB can inhibit phosphorylation of pRB-family 
of proteins by interacting with cyclin/CDK complexes such as CDK2/Cyclin E, and this leads 
to cell cycle arrest. Figure adapted from (Dyson, 1998). 
New findings suggest that p21 may have other properties, which may not be linked to cell-
cycle. It may regulate apoptosis, and transcriptional activation (Andres, 2004). It has also 
been found recently that the involvement of p21 in senescence may be triggered by telomere 
shortening through a pathway involving ATM and p53, but not p16INK4a (Herbig et al., 2004).   
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1.1.7 Senescence, quiescence and apoptosis 
Two cell statuses resemble senescence: quiescence and apoptosis, and they are all cell cycle 
arrest.  
The major difference between senescence and quiescence is that the cell cycle arrest is 
irreversible (Beausejour et al., 2003; Dirac and Bernards, 2003; Gire and Wynford-Thomas, 
1998; Sage et al., 2003). Distinct morphologic alterations are also associated with senescence, 
such as cellular flattening. Moreover, senescent cells also differ from quiescent cells at the 
molecular level. They have increased adherence, a loss of c-fos induction to serum 
stimulation, an increased expression of plasminogen activator inhibitor (PAI), the expression 
of senescence-associated ß-galactosidase activity (Campisi, 2001), and an unusual form of 
heterochromatin present in discrete nuclear foci, known as senescence-associated 
heterochromatic foci (SAHF) (Narita et al., 2003).  
Apoptosis is more related to senescence than quiescence. For instance, different experiments 
have linked p53 not only to senescence, but also to apoptosis (Lowe et al., 1993; Yonish-
Rouach et al., 1991). A role for p16INK4a in inducing apoptosis has also been suggested 
(Ausserlechner et al., 2001; Lagresle et al., 2002; Plath et al., 2000; Tamm et al., 2002). 
Moreover, cancer-related stimuli such as oncogene activation, DNA damage, and telomere 
shortening can not only induce senescence, but also apoptosis (Lowe and Sherr, 2003). 
Nevertheless, the molecular events at the basis of the decision-making between apoptosis and 
senescence are incompletely understood. They appear to depend on many variables including 
cell type, genetic context, and proliferation state.  
 
1.1.8 Escape from senescence and crisis 
 
Immortalization of murine cells is possible if they bypass a block of senescence, but 
immortalization of human cells is possible is possible only if they bypass a second block, 
crisis (Figure 13).    
 
Time 
Growth 
Crisis  
(M2)
Senescence 
(M1) 
Long-term growth 
Escape 1: escape from the pRb/p53 pathway 
 
Escape 2: expression  
of a telomere length 
maintenance mechanism 
 
Figure 13. Immortalization and mortality stages. Normal cells have to bypass the two 
mortality stages M1 and M2 before to become immortal. Cells can escape the first mortality 
stage M1 called senescence if they bypass the pRb/p53 pathway by gene inactivation or by 
expression of an oncogene, and they can escape the second mortality stage M2 if they express 
a telomere length maintenance mechanism. 
 
In normal human cells, cell division triggers telomere attrition (Harley et al., 1990a; Hastie et 
al., 1990). Critical telomere shortening causes replicative senescence, via activation of the p53 
and pRb tumor suppressor pathways (Wright and Shay, 1992). Recent experiments suggest 
that replicative senescence is not determined by the shortest telomere, or by the mean length 
of all the telomeres, but rather by a specific group of chromosomes with the shortest 
telomeres (Zou et al., 2004). If the p53 and pRb pathways are inactivated by antisense 
mechanism (Hara et al., 1991) or by viral oncoproteins (Shay et al., 1991), cells can have 
increasing numbers of divisions before cell cycle arrest, but they finally enter into a crisis. 
This state is characterized by extensive telomere attrition that leads to chromosomal 
instability and finally to massive cell death (Counter et al., 1992a).  
Rare events in cells subjected to crisis (1 in 10 million cells) lead to immortal cells that have 
acquired the ability to proliferate indefinitely. These cells often possess a telomerase activity 
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(Counter et al., 1992c). It is also at very low frequencies that virally transformed human cells 
escape crisis (Shay et al., 1991). In the contrary, crisis can be readily bypassed by telomerase 
expression (Bodnar et al., 1998b; Vaziri and Benchimol, 1998b) or by one or more 
mechanisms referred to as alternative lengthening of telomeres (ALT) (Bryan et al., 1997). 
TERT can stabilize telomere length and can lead to extension of life span (Bodnar et al., 
1998b; Vaziri and Benchimol, 1998a). ALT is also a possible mechanism to maintain suitable 
chromosome lengths, but its mechanism of action is different from the hTERT mechanism. 
This mechanism is recombination-based in mammals (Roth et al., 1997). However,  different 
ALT mechanisms exist in other organisms, such as a the retrotransposon-based ALT of 
Drosophila melanogaster (Biessmann et al., 1992). Nevertheless, even though both ALT and 
telomerase can extend telomere lenghths, they do it at different extents. ALT mechanisms 
lead to large increase in average telomere length, whereas telomerase activation can lead 
either to normal or to short telomeres (Figure 14).  
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Figure 14. Telomere length maintenance and immortalization. When the telomere lengths of 
proliferating normal cells become too low, the cells undergo senescence. Cells can continue to 
proliferate by loss of function of key tumor suppressor genes, but the telomeres eventually 
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become critically short and the cells enter crisis. At this stage, activation of a telomere 
maintenance mechanism (telomerase or ALT) can permit cells bypass crisis and to become 
immortal. Telomerase activation often results in stably short telomeres, or in telomere 
lengthening and stabilization in the normal length range. In the contrary, ALT mechanisms 
result in a large increase in average telomere length, but there are very short and very long 
telomeres present within individual cells. Figure redrawn from (Reddel, 2003). 
 
In immortal and malignant cells, senescence has been bypassed, and telomeres are maintained 
at stable lengths (Counter et al., 1994). Even when these cells have become immortal, 
continued expression of a telomere maintenance mechanism is still important. This was 
shown by the expression of a catalytically inactive mutant of hTERT in telomerase positive 
human cancer cell lines, that finally led to the inhibition of telomerase activity, to telomeric 
shortening and to widespread apopotosis (Hahn et al., 1999c; Zhang et al., 1999).  
Nevertheless, in most cell types, upregulation of a telomerase maintenance mechanism is not 
sufficient to trigger immortalization. In fact, even though cells may harbor long telomeres, 
this is often not sufficient to trigger immortalization, except for some fibroblasts or for fetal 
hepatocytes (Blasco, 2002; Espejel and Blasco, 2002; Kiyono et al., 1998; Wege et al., 2003; 
Wei et al., 1999).  
All these evidences suggest that both the block of the pRb/p53 pathways and the activation of 
a mechanism for telomere length maintenance are required to bypass senescence and crisis. 
When this is ensured, immortal cells can be obtained, and they can be non-tumorigenic. 
Nevertheless, additional modifications can render these cells tumorigenic. For instance, if 
cells express not only hTERT, but also SV40 small and large T antigen, and activated Ras, 
they become transformed (Hahn et al., 1999a).  
 
 
1.1.9 Crisis and genetic instabilities 
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Figure 15. Genomic instabilities in cells bypassing senescence without activation of a 
telomere length maintenance mechanism. If cells bypass senescence without to express 
telomerase or ALT, telomeric shortenings lead to chromosomal instabilities. This source of 
mutations can permit to some rare cells (1 in 10 millions) (Radisky et al., 2002), to bypass 
crisis if they express a telomerase maintenance mechanism, such as telomerase or ALT. If 
cells express only at a late point a telomere length maintenance mechanism, they may be the 
subject of genome rearrangements, and this may lead to transformed phenotypes. 
 
Even if cancer cells may be immortal, they may still have to evolve to acquire a large number 
of mutations, which will allow the acquisition of new cancerous properties (Loeb, 2001). Two 
different types of mutations can lead either to “microsatellite instabilities neoplasias” (MIN) 
or to “chromosomal instabilities neoplasias” (CIN). MIN are characterized by mutations in 
repetitive sequences, whereas CIN are characterized by chromosomal instabilities such as 
chromosomal breakages, translocations, and aneuploidy. The vast majority of human cancers 
are of the CIN type, but the molecular basis of CIN is less clear than that of MIN. CIN-type of 
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cancers are related to defective DNA mismatch repair (Lengauer et al., 1998). In the contrary, 
MIN cancers stem from defects in the mitotic checkpoint, from nonhomologous end-joining, 
and from DNA replication, as well as from increased oxidative stress and from telomere 
dysfunction (Bohr and Dianov, 1999; Elledge, 1996; O'Driscoll et al., 2001; O'Hagan et al., 
2002; Shen et al., 2000). During crisis, it has been observed that telomere attrition leads to 
chromosomal instability and to massive cell death (Counter et al., 1992a). However, 1 in 10 
millions cells escape crisis (Radisky et al., 2002), and these cells have often acquired 
mutations that have allowed upregulation of telomerase or of ALT. At this point, cells often 
also display a mutation-prone phenotype and the additional mutations that are provided from 
this point on are thought to be necessary for the cells to acquire complex tumorigenic 
phenotypes.  
1.1.10 Somatic mutation theory of carcinogenesis 
Different theories have been proposed for the origin of cancer cells (Soto and Sonnenschein, 
2004). The prevailing theory for the last 50 years has been the somatic mutation theory of 
carcinogenesis (SMT). According to this theory, cancer cells are derived from a single 
somatic cell that has accumulated mutations over time. Two main evidences were supporting 
this theory. First, carcinogenic chemicals were mutagenic. Second, the oncogenes responsible 
for cancers were found to be mutated versions of the cellular proto-oncogenes. Another 
evidence supporting this theory was that DNA fragments from chemically transformed cells 
were able to transform recipient cells (Cooper, 1983).  
Accordingly, two types of mutations were described to participate to carcinogenesis.  They 
included the gain-of-functions of oncogenes, but also the loss-of-function of tumor 
suppressors. These gain- and loss-of-functions could define not only what events were 
necessary to transform cells, but also the new properties that cancer cells had to acquire 
before to become fully tumorigenic.  
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1.1.11 Properties of cancer cells  
 
Hanahan and Weinberg have identified six “hallmark features” of metastatic cancer cells:  
they generate their own mitogenic signals,  
they overcome the growth-inhibitory signals, 
they evade apoptosis, 
they proliferate without limit, 
they acquire vasculature, 
they invade tissues, 
they metastasize (Figure 15) (Hanahan and Weinberg, 2000).  
It is often assumed that all tumor cells finally acquire all these properties, in a more or less 
determined order. However, it should be noted that (in rare cases) death can occur before 
cancer cells metastasize, because, for example, an organ important for survival has been too 
severely damaged. Moreover, discussions exist to know if these cancerous properties should 
be acquired in a strict order. The path toward tumorigenesis can be different in histologically 
similar cancers, and can be still more different in different forms of cancers (Hanahan and 
Weinberg, 2000). Nonetheless, in some cases, it is not simply mutations, but also their order 
that may be important to determine the propensity for neoplasia (Kinzler and Vogelstein, 
1996).  
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Figure 16. Different properties of cancer cells. See text for details.  
 
 
1.1.12 How many mutations are required to trigger oncogenesis? 
Mutations or deregulations of oncogenes or of tumor suppressors can both contribute to the 
acquisition of neoplasic phenotypes (DePinho and Jacks, 2001; Hakem and Mak, 2001; 
Knudson, 2001). In fact, dominantly acting oncogenes and recessive tumor suppressors are 
often mutated or lose a large portion of their genetic sequences in tumorigenesis (Sager, 
1989). This implies that sequencing whole genomes of normal and cancer cells would permit 
the discovery of genes mutated in cancers, and would permit to know how many genes need 
to be mutated in cancers. Nevertheless, this method has two disadvantages. First, genome-
sequencing of mutated cells is not yet feasible. Second, even if this method would exist, it 
would not be able to find the genes that contribute to cancer, but only the genes that are 
mutated. However, in cancers, dysfunction of genes may not always be caused only by 
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mutations but also by aberrant expression. In fact, a lot of genes important for carcinogenesis 
have already been shown to be differentially regulated in an epigenetic manner. For instance, 
tumor-suppressors have CpG islands of nucleotides in their promoter sequences that may be 
methylated and that may contribute to the expression of these genes (Baylin and Bestor, 
2002). Usage of microarrays would be the tool of choice to determine the aberrantly 
functioning genes. Nevertheless, in this case, it may be difficult to find the genes relevant in 
carcinogenesis among a wide array of differentially expressed genes. For these reasons, the 
exact number of genes must be deregulated or mutated to induce tumorigenesis will probably 
not be defined soon, even though a lot of progress has already been done in this area. For the 
moment, it is assumed that at least four to six mutations might be required to reach 
tumorigenesis in humans, and fewer mutations seem to be required in mice (Hahn and 
Weinberg, 2002).  
 
1.1.13 Pathways leading to tumorigenesis  
 
Cancer cells have usually to become immortal, and then they often have to acquire additional 
features to become fully tumorigenic. Immortalization of human cells requires maintenance of 
a sufficient telomere length and inactivation of the retinoblastoma (pRB) and p53 tumor 
suppressor pathways. Maintenance of a sufficient telomere length is possible by activation of 
telomerase or of an alternative telomere length maintenance (ALT) mechanism. Inactivation 
of the pRB and p53 pathways is possible by large T antigen expression. At this stage, cells are 
immortal, but not yet tumorigenic. Until now, only few experiments were able to induce 
tumorigenesis of immortalized cells after addition of defined genetic elements. These 
experiments showed that if tumorigenesis was triggered, both the phosphatase 2A (PP2A) and 
the H-RAS pathways were perturbed. This was done by addition of small t antigen, and by H-
RAS overexpression (Zhao et al., 2004) (Figure 17).  
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Figure 17. Pathways thought to be implicated in human cell transformation. This figure was 
modified from (Hahn and Weinberg, 2002; Zhao et al., 2004).  More complicated pathways 
leading to tumorigenesis can be seen elsewhere (Hanahan and Weinberg, 2000). 
 
The tumor suppressor PP2A is as a serine/threonine-specific phosphatase that regulates 
different signal transduction pathways, cell cycle progression, DNA replication, gene 
transcription and protein translation  (Janssens et al., 2005). Its implication in tumorigenesis 
has been observed in various human cells where LT + ST + Ras + hTERT have been 
introduced. In such experiments, a mutant of ST unable to bind PP2A was also used. With 
this mutant, tumorigenesis was not observed (Hahn et al., 2002).  
Even though it is known that the Ras pathway may be implicated in tumorigenesis, the precise 
protein(s) that are implicated in this phenomenon are not yet known. However, the anchorage-
independence survival and growth of cancer cells seem to be mediated by PI3K, Stat3, and 
guanosine triphosphatases (GTPases) such as Cdc42 and Rac1 (Wang, 2004). Normally, cells 
have to adhere to their neighboring cells or to the extracellular matrix (ECM). If it is not the 
case, cells usually die or stop dividing. For instance, if epithelial cells lose their adhesion to 
their substratum, they undergo apoptosis. This phenomenon is known as “anoikis”. In the 
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contrary, if fibroblasts are deprived from their substratum adhesion, they only undergo cell 
cycle arrest. In any case, if cells can survive and grow, without to be anchorage-dependant, 
they have acquired one important property of cancers cells. The exact proteins allowing 
anchorange-independent growth are not known, but Rho and Cdc42 are candidates for 
obtention of this function. These proteins were initially known to regulate the formation of 
stress fibers and filopodia. Nevertheless, additional cellular functions have been subsequently 
discovered for these proteins, notably in cell growth, motility and transformation. This makes 
of these proteins interesting candidates for acquisition of properties related to anchorange-
independent growth (Wang, 2004).  
Other proteins have been involved not in the genesis of tumors such as the acquisition of 
anchorange-independent properties, but in metastasis tumor suppression. Then, it is not their 
induction that is thought to be important to induce tumorigenesis, as for Rho and Cdc42, but 
their downregulation. These proteins include KISS1, MKK4, BRMS1, CRSP3, TXNIP, 
Cadherins, SSeCKS, Nm23, KAI1 (CD82), TIMPs, RhoGDI2 and DRG-1. The roles that are 
currently proposed for these proteins in tumorigenesis are reviewed elsewhere (Shevde and 
Welch, 2003).  
Until now, we have described mutations or modifications in cells that may trigger 
immortalization, and even tumorigenesis. Nevertheless, mutations in one single cell might not 
be sufficient to explain all cancers, because it is known that tumors may be heterogeneous in 
cell types. This has led to two proposals. Either cancer cells may originate from stem cells, or 
cancer cells may modulate other cell types in their environment. 
 
1.1.14 Cancer, stem cells, and cancer stem cells  
 
Stem cells have the capacity to self-renew indefinitely, but also to differentiate into the mature 
cells of the organ in which they reside. Some articles have suggested that these stem cells also 
have the capacity to transdifferentiate into other tissues. However, more recent studies have 
shown that this plasticity is the result of a rare fusion event between stem cells (or progenitor 
cells) and a cell of another organ (Vassilopoulos et al., 2003; Wagers et al., 2002; Wang et al., 
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2003). The self-renewal capability of stem cells closely resembles the properties of at least 
some of the cancer cells, which are immortal. This similarity led to the proposal that at least 
some cancer cells might originate from stem cells. Cancer cells are nonetheless different from 
stem cells, because the proliferation of stem cells is tightly regulated (Morrison et al., 2002; 
Phillips et al., 2000; Phillips et al., 1992). Then, if cancer cells arise from stem cells, they 
would have to bypass these mechanisms of growth regulation. Further studies suggested that 
some cells in a cancer are derived from stem cells. For instance, only a minority of cancer 
cells have the capability to form a tumor once transplanted into another host, because only 
this subpopulation is able to proliferate extensively. This has been demonstrated with acute 
myelogenous leukaemia (AML), where only a minority of AML cells form tumors once 
transferred into NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice 
(Lapidot et al., 1994). The tumor-forming cells closely resemble to normal haematopoietic 
stem cells (HSCs) in their cell-surface markers, in their multipotency and in their hierarchical 
self-renewal properties. This experiment put forward the concept of cancer stem cells, and it 
was suggested that leukemia stem cells either derive from HSCs or from more differentiated 
cells through acquisition of HSC properties.  
In short, stem cells could be good candidates as cells of origin for cancer, because they 
already have the capacity for self-renewal and unlimited replication (Reya et al., 2001; 
Taipale and Beachy, 2001) that at least some cancer cells possess. The concept of cancer stem 
cells could also be interesting to explain why some cells can, once transplanted in NOD/SCID 
mice, reconstitute the heterogeneous surface markers that were present in the original cancer 
(Al-Hajj et al., 2003). Nevertheless, the general validity of the cancer stem cell concept has 
not been proven, and it is possible that cancers arise from other cells than stem cells. If cancer 
stem cells exist, they might also derive from more committed cells, and they might get stem 
cells properties by genetic or epigenetic changes that confer self-renewal ability (Passegue et 
al., 2003). This theory of cancer stem cells is interesting, that is why it has been presented 
here, but it is certainly not considered nowadays to be the main source of cancers. Moreover, 
now, experiments suggest that it is not only the genetic and epigenetic characteristic of a cell 
that counts for the explanation of its cancerous property, but also its context. This will be 
discussed now. 
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1.1.15 Context counts 
 
It is often considered that the default state of a cell is quiescence. Then, the events leading to 
cancers would be mostly activation of dominant oncogenes in one cell. This view is notably 
supported by studies with oncogenes from Oncoretroviruses that have dominant effects on 
cells, and transform them toward a cancerous phenotype. This has led to the formulation of 
the somatic mutation theory of carcinogenesis (SMT), which considers that accumulation of 
mutations in one single renegade cell is the cause of cancer. However, one might also 
consider that the default state of a cell might be proliferation (Sonnenschein and Soto, 2005). 
Indeed, the basics concepts of natural evolution suggest that it would favor dividing cells: if 
cells are in a suitable environment, and if they have enough nutrients, they should multiply 
(Harris, 2004). Considering this, if cells are in a clement environment, with adequate nutrient 
supply, and if they do not multiply, these cells are not in “resting”, they are repressed. This 
conceptual view has some implications. First, it may suggest that the events leading to cancers 
would be mostly inactivation of recessive tumor suppressors. Second, it may suggest that the 
environment is important for the cell status of a cell. This would imply that mutations in one 
single cell may not be sufficient for carcinogenesis, independently of its environment. For this 
reason, this view was called the tissue organization field theory of carcinogenesis and 
metastasis (TOFT). 
TOFT is verified in a large extent in heritable and acquired cancers, because they are mainly 
the results of gene inactivation, such as of Rb and p53. The context also seems to be 
important in other types of carcinogenesis, because, for example, teratocarcinoma cells can 
reverse their cancerous phenotype once placed into early embryos (Soto and Sonnenschein, 
2004). This view is still supported by a new publication, which shows the importance of the 
stroma in the establishment of a cancer phenotype (Barclay et al., 2005). In this article, the 
same cell line can be cancerous or not, depending on the stromal cells used. Moreover, the 
cancer phenotype can be reversible if a new "normal" stroma is provided.  
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1.1.16 The cellular environment 
 
Different signals from the environment of a cell can have an influence on its development in 
general, but also on the acquisition of carcinogenesis properties of this cell. For instance, 
stromal cells can affect the tumorigenesis of epithelial cells in a reciprocal way (Figure 18) 
(Radisky et al., 2001). More generally, environmental pressures, inflammation, immune 
activation, and acquired or inherited genetic mutations can influence tumorigenesis. 
Inflammation in general seems to trigger tumorigenesis, so that inhibition of cyclooxygenase-
2 (COX2), an enzyme that is involved in the synthesis of prostaglandins, has an 
antitumorigenic activity (Prescott and Fitzpatrick, 2000). Fibrotic tissues, such as breast scars, 
have also been shown to predispose to cancers (Jacobs et al., 1999b). Such discoveries have 
led to the emergence of new therapies of hepatocarcinoma, where not only conventional 
chemotherapies are used, but where fibrosis is also targeted. Inflammatory conditions can 
trigger stromal fibroblasts to upregulate enzymes such as matrix metaloproteases (MMPs). In 
general, changes in the composition of the extracellular matrix (ECM) can lead to changes in 
gene expression, which notably lead to changes in cell shape and behavior (Roskelley et al., 
1995). In fact, the differential composition of the basement membrane can lead not only to 
proliferation, but also to growth arrest and to apoptosis (Bissell and Radisky, 2001). Among 
the different changes that can affect the composition of the ECM, expression of stromelysin-1 
(SL-1, also known as MMP-3) has been shown to be sufficient to lead to preneoplastic or 
even to neoplastic phenotypes (Thomasset et al., 1998).  
 
 Activation of stromal cells by 
acquired or inherited genetic 
mutations, chronic inflammation, 
or environmental insults 
Activation of epithelial 
cells by acquired or 
inherited genetic mutations 
Initial 
activation
Tumorigenesis 
Reciprocal 
activation
Figure 18. Model of reciprocal activation between stromal and epithelial cells. Genetic 
modifications or external stimuli such as chronic inflammation or environmental insults can 
activate epithelial or stromal cells. In turn, the neighboring cells are activated, and this finally 
might lead to tumorigenesis. Figure modified from (Radisky et al., 2001). 
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It is not only the extracellular matrix, but also the links between cells, which can be important 
in tumorigenesis. As a result, loss or alteration of some components implicated in cell-
adhesion, such as E-cadherin, but not N-cadherin, can lead to tumorigenesis (Seidel et al., 
2004). Moreover, differential expression of β-catenin, α-catenin, connexin 32 (Cx32) and 
Cx43 have also been shown to be important during tumor progression (Bissell and Radisky, 
2001). Some myoepithelial proteins were even shown to suppress transformation of luminal 
epithelial cells in vivo. They include α-smooth muscle actin, Cytokeratin 5, α6-integrin, 
Caveolin-1, Connexin 43, Maspin, TIMP-1, Relaxin, and Activin (Bissell and Radisky, 2001). 
These proteins are produced by myoepithelial cells in the breast, and have been termed “class 
II tumor suppressors” (Sager, 1997) (Figure 19).  
Protein Function 
α-smooth muscle actin Cell structure 
Cytokeratin 5 Cell structure 
α6-integrin ECM receptor 
Caveolin-1 Cell-surface molecule 
Connexin 43 Gap-junction component 
Maspin Protease inhibitor 
TIMP-1 Protease inhibitor 
Relaxin Hormone 
Activin Hormone 
Figure 19. The myoepithelial proteins that were shown to have tumor-suppressor activities. 
Figure taken from (Bissell and Radisky, 2001).  
 
It has been proposed that reciprocal activation mechanisms occur between different cells in 
early tumors. As a result, this would activate some of the normal wound-healing responses, 
which might increase angiogenesis in a “vasculogenetic mimicry” (Bissell and Radisky, 
2001).  
Beside the importance of the ECM, of reciprocal activation of cells, and of wound healing 
responses in tumor formation, the immune system may also play role. Indeed, the immune 
system may not only limit tumor formation, but it may also be a tumor activator in some 
cases. For instance, NK cells can not only kill HLA-low cells, but it can also provide positive 
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signals for the progression of preneoplastic lesions, by producing MMPs, and degradation of 
ECM can further activates fibroblasts and angiogenesis (Bissell and Radisky, 2001).  
 
1.1.17 Escape from the immune system 
 
The immune system can to some extent limit or prevent tumor formation, and the T cells are 
main effectors for this immune surveillance. However, the innate immune system, which 
includes natural killer cells, macrophages, monocytes and mast cells, is also involved in 
immune response against tumors.  
Cancer cells, in their development, can be more or less susceptible to attacks of the innate 
immune response. During the early stages of carcinogenesis, tumor cells are poor stimulators, 
or become resistant to the immune response. Malignant cells can escape to the action of 
cytotoxic T lymphocytes (CTLs) that recognize processed cancer peptides on human 
leukocyte antigens (HLA) class I by downregulating their immunogenicity (Algarra et al., 
2004). Then, even though the primary tumor is HLA-positive, during development, HLA-low 
cells appear and are negatively immunoselected by T-lymphocyte antitumor responses. 
Nevertheless, the cells that escape to T lymphocytes harbor at their surface less HLA proteins, 
and this is recognized by killer cell inhibitory receptors (KIRs) of natural killer (NK) cells, 
which lead to NK-mediated killing of the HLA-low cells (Figure 20). However, the 
antitumorigenic killing of NK can also be escaped by cancer cells, for example if they 
upregulate only some HLA class I haplotypes, or if they lose the activatory NK receptors 
(Algarra et al., 2004).  
 
 Tumor cell  
Cytotoxic T 
Lymphocyte  
Negative 
Cytotoxicity  
Positive 
Cytotoxicity  
NK cell  
Antigen 
processing  
KIR  TCR  
HLA class I  
HLA class I  
Figure 20. HLA class I interactions with T-lymphocytes and NK cells. Cancer peptides are 
presented on HLA class I and are recognized by cytotoxic T lymphocytes, which kill the 
transformed cells. Cells can escape from cytotoxic T lymphocytes by downregulating HLA 
class I complexes, but then NK cells recognize the lack of HLA class I cells and kill the 
potentially transformed, HLA-low, cells. Figure redrawn from (Garcia-Lora et al., 2003).  
Tumors can evolve not only to escape the immune system; they can also modulate the 
immune system. For example, macrophage migration inhibitory factor (MIF) has been 
associated with tumor progression. It can be overexpressed in tumor cells, and might 
contribute not only to suppress immune surveillance, but also to suppress p53 function 
(Bissell and Radisky, 2001). At later stages, the tumors can impair the adaptive immune 
response by blocking the maturation and function of APCs. This leads to alteration of T-cell 
signal transduction and function (Rodriguez et al., 2003).  
1.1.18 Immune senescence  
 
Increase in cancer in elderly people may be explained by the multiple mutations that require 
tumorigenesis. However, with aging, there is also a decline in the T- and B-cell associated 
functions. This is termed immunosenescence (Hakim et al., 2004). These two phenomenons 
may both lead to increased tumorigenesis in the elderly, and they are difficult to dissociate 
 
59
 60
methodologically, but this topic has nevertheless become a new area of investigation. It has 
been shown that bone marrow stem cells renewal capacities decrease with age. Stem cells also 
mobilize less efficiently with age, and they commit less efficiently to lymphopoiesis. In the 
elder people, there is a decline in germinal center formation, diminished FDC function, 
diminished circulating memory B cells, lower T cell number, lower T cell functions, lower 
CD5+ B cells, and lower CD40 levels on B cells. Nevertheless, lower NK function is 
compensated by higher NK numbers, so that the total NK-cell toxicity remains stable. Despite 
this, both T-dependant and T-independent B-cell responses are diminished with aging. More 
importantly, there are alterations in T cell populations. There is a decline in naïve T cells, but 
there are also more memory cells and more effector cells with limited T-cell repertoire 
(Hakim et al., 2004).  
 
1.1.19 Tests of carcinogenesis  
 
Different in vitro and in vivo tests have been used to characterize and detect tumor cells.  
In vitro tests include focus formation and colony formation assays, which can discriminate if 
cells still possess respectively, contact inhibition properties, or anchorage-dependence growth 
(Jacobsen et al., 2002). 
For in vivo tests, different mouse strains have been used. The results of the tests for 
carcinogenesis largely depend on the genetic background of the mice used (Algarra et al., 
2004). For example, chemically induced sarcomas produced in nude and SCID mice are more 
immunogenic than similar sarcoma cells induced in congenic immunocompetent mice. The 
classical model used for tumorigenesis is the athymic nude mouse, which is deprived of T 
lymphocytes (Rolstad, 2001). These mice have nonetheless NK and dendritic cells, and they 
may contribute to immune responses in the absence of mature T cells. Particularly, KIR-
ligand mismatch in cell transplantation may trigger NK cell alloreactivity (Malmberg et al., 
2005).  
 
1.2 Genes used for immortalization 
 
It would be too long to review all the genes that could be used for immortalization. For this 
reason, it was chosen to review only the genes that are of particular interest for us. They 
include telomerase, ALT, Bmi-1, SV40 Early region genes, and Bcl-2. These genes have the 
property to inhibit different proteins involved in the pathway toward senescence (Figure 21), 
but they also have additional functions, which will also be discussed now.  
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Figure 21. The Pathways depending upon p16INK4a-Rb or ARF-p53, with various inhibitors of 
these pathways. Figure modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; 
Sharpless et al., 2004; Sherr, 2001; Sherr, 2004; Zhao et al., 2004).  
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1.2.1 Telomerase  
More than sixty years ago, Barbara McClintock predicted from experiments in maize that 
telomeres are able to protect chromosomes from end-to-end fusion. From then on, a lot of 
progress has been done in the elucidation of the telomeric structures. Telomeres are composed 
of repeats of the hexanucleotide sequence TTAGGG at each chromosome end (Moyzis et al., 
1988). The size of these repeated sequences is up to 15 kb of tandem repeats, but diminishes 
of 50-150 bp after each cell division (Harley et al., 1990a). The decrease in telomere may not 
always be constant for each cell division, depending on the environment of the cells. Stresses, 
and particularly hypoxia, induce increased shortenings of telomeres (von Zglinicki et al., 
1995). As discussed earlier, telomere length has been taken as a marker of ageing because 
life-span can be extended by overexpression of telomerase (Bodnar et al., 1998a; Vaziri and 
Benchimol, 1998b). Nevertheless, telomere length is not sufficient per se to define ageing, 
because it has been shown that cells can senesce even though they harbor long telomeric 
sequences (Gorbunova et al., 2002; Wei et al., 1999).  
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TTAGGGTTAGG 
CAAUCCCAAUC 
Telomerase RNA 
TERT Dyskerin 
Figure 22. The human telomerase ribonucleoprotein complex. Telomerase RNA (red) must 
interact with H/ACA proteins (including dyskerin, green) to accumulate in cells as stable, 
processed functional RNA. TERT (blue) has reverse transcriptase properties, but probably 
other proteins must join the ribonucleoprotein complex to form a fully functional telomerase. 
Figure redrawn from (Wong and Collins, 2003). 
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Telomerase is a ribonucleic complex (Greider and Blackburn, 1985) composed of an RNA 
molecule, referred to as TR or TER, and a catalytic subunit, TERT.  The RNA component of 
telomerase must interact with H/ACA proteins, like dyskerin, to be processed and to function 
properly (Figure 22). Telomerase is an enzyme that possesses reverse transcriptase activity, 
which can compensate the loss of telomeric sequences that occurs during DNA replication 
(Bryan and Cech, 1999).  
Telomeres must be capped, so that the ends of chromosomes are not recognized as DNA 
breaks. Otherwise, telomeres are recognized by the DNA-repair machinery (Blackburn, 2001; 
Chan and Blackburn, 2002; Goytisolo and Blasco, 2002), often leading to cell-cycle arrest 
and/or apoptosis (De Lange, 2002; Goytisolo and Blasco, 2002). However, a “repair” can 
occur, it is triggered by the standard DNA repair machinery. However, this repair is not 
suitable for telomeres. After the DNA-damage responses, end-to-end chromosomes fusions 
happen, and this leads to loss of genomic integrity. Ku86, the protein which is essential for 
non-homologous end-joining (NHEJ) of DNA double strand breaks (DSBs), has been shown 
to mediate both end-to-end chromosome fusions and apoptosis that is triggered by critically 
short telomeres. This indicated that NHEJ proteins detect and signal the presence of non-
capped telomeres (Espejel et al., 2002).  
The functionality of telomeres does not only depend on a sufficient telomere length. Telomere 
capping requires a minimum length of TTAGGG repeats, the integrity of the 3’-overhang and 
functional telomere-binding proteins (De Lange, 2002; Espejel et al., 2002; Goytisolo and 
Blasco, 2002).  
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Figure 23. The Pathways depending upon p16INK4a-Rb or ARF-p53, with telomerase or ALT 
actions. Figure modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; Sharpless et 
al., 2004; Sherr, 2001; Sherr, 2004; Zhao et al., 2004). 
 
In some circumstances, if telomerase is expressed at a sufficient level in cells, it can be a 
sufficient condition for them to be or to become immortal. Normal cells, such as germ cells 
and a sub-population of adult stem cells, have telomeres maintained at a constant length, and 
are immortal (Harley et al., 1990a; Reyes et al., 2001). Some normal non-immortal cells can 
also be immortalized if telomerase is activated (Counter et al., 1992b), or if there is presence 
of an ALT mechanism (Bryan et al., 1995). Concerning cancers, 85% of them are telomerase-
positive (Shay and Bacchetti, 1997), but additional features are also modified in these cells.  
Telomerase has already been overexpressed at non-physiological levels, as shown in the 
telomerase-transgenic mice (Gonzalez-Suarez et al., 2001). In such a situation, there is no 
abnormal telomere lengthening, probably reflecting the existence of a regulated structure (T-
loops) at the telomere (Blasco, 2002). If telomerase is upregulated in cells, the lengths of 
telomeres increase if they are too short, and survival signals from capping of telomeres are 
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triggered. This often allows the cells to become immortal, or to survive longer. In the 
contrary, if the regulation of the telomeres is inappropriate, such as in the case of NHEJ or 
TRF2 mutations, telomere fusions, cell cycle arrest and apoptosis can happen, even though 
the telomere length may be sufficient, and even though there may be telomerase activity 
(Blasco, 2002). 
Senescence can be bypassed by hTERT overexpression, even in some human cells (Bodnar et 
al., 1998a). However, it has been reported that hTERT-immortalized fibroblasts can gradually 
acquire features associated with a transformed phenotype, so that safety concerns should be 
raised before hTERT-immortalized cells can be used for cell therapy (Milyavsky et al., 2003). 
Even though hTERT-mediated immortalization can escape genomic instability, in some cases, 
hTERT expression was not sufficient to induce immortalization. This suggests that, often, 
other mechanisms may exist (in addition to telomere length measure) to avoid that cells 
become immortal (Drayton and Peters, 2002; Yaswen and Stampfer, 2002). In cases of 
telomere-independent induced senescence, accumulation of p16INK4a was observed. This 
suggested that p16INK4a might be a sensor for telomere-independent induced senescence. 
However,  p16INK4a accumulation was also suggested to be a result of inadequate growth 
conditions (Dickson et al., 2000; Herbert et al., 2002; Kiyono et al., 1998; Ramirez et al., 
2001; Yaswen and Stampfer, 2002).  
In addition to telomere maintenance, telomerase may have additional carcinogenesis 
properties (Blasco, 2002). Telomere shortening below a critical level results in end-to-end 
chromosome fusions, and dicentric chromosomes might generate the chromosome instability 
which seems to be important for the cancer cells. It may allow them to acquire new mutations 
that may induce in them new carcinogenetic properties (Artandi and DePinho, 2000; 
Gisselsson et al., 2001; Hackett et al., 2001). Moreover, telomerase might have pro-survival 
and anti-apoptotic activities to maintain cell survival and proliferation, independently of its 
telomerase enzymatic activity (Cao et al., 2002). It has already been observed that telomerase 
may contribute to tumorigenesis by a telomere length-independent mechanism, because the 
immortal ALT cell line GM847 could be transformed after the addition H-Ras and 
telomerase, but not after the expression of H-Ras alone (Stewart et al., 2002b). 
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Telomerase and telomere length has been implicated in different diseases, such as in HIV and 
in chronic hepatitis or liver cirrhoses (Wong and Collins, 2003). Telomere length implication 
in Duchenne’s Muscular Dystrophy is also discussed (Oexle and Kohlschutter, 2001). 
 
1.2.2 Alternative lengthening of telomeres (ALT) 
 
Some cells are immortalized, but they are telomerase-negative. In such a case, until now, their 
telomere length was shown to be maintained through one or more mechanisms referred to as 
alternative lengthening of telomeres (ALT) (Bryan et al., 1997). In humans, ALT uses some 
telomeric sequences (or extrachromosomal telomeric DNA) as a copy template to elongate 
one particular telomere. This mechanism was demonstrated by inserting a DNA tag into a 
telomere of ALT cells, and in this experimental setting, the tag was copied on to other 
telomeres (Reddel, 2003). As a result, telomere length maintenance by TERT or by ALT are 
functionally two different mechanisms. The first mechanism is using a template in the enzyme 
telomerase to add sequences to the telomeres, while the second uses telomeric sequences from 
one telomere as a template to elongate another one. Consistent with this, ALT expressing cells 
are insensitive to inhibition of the hTERT function by the dominant-negative enzyme (Hahn 
et al., 1999b). In the contrary of telomerase positive cells, ALT cells have extremely 
heterogeneous telomere lengths, ranging from very short to extremely long (Bryan et al., 
1997). This pattern of varying telomere sizes in one single cell is not seen in most normal 
human and murine cell types. Currently, no normal cell is known to express a normal 
counterpart of ALT, which would have the same activity as ALT in transformed or cancerous 
cells. It is only in telomerase-null mice that an ALT mechanism could be observed in some B 
cells (Herrera et al., 2000). Despite few human or murine cells seem to possess an ALT 
mechanism, some species of mammalian cells can have non-telomerase mechanisms for the 
conservation of their telomere length. For instance, mosquitoes (Anopheles gambiae) use a 
recombination-based ALT mechanism (Roth et al., 1997) and Drosophila melanogaster use a 
retrotransposon-based ALT (Biessmann et al., 1992) instead of telomerase.  
Based on a limited number of published evidences, it seems that the expression of an ALT 
mechanism is present more often in cell lines and tumors of mesenchymal origin than in those 
of epithelial origin (Henson et al., 2002).  
Some tumors have been shown to possess both ALT and telomerase activity (Bryan et al., 
1997). In vivo, it is not known if this is the result of two processes of carcinogenesis. If it was 
the case, however, this would explain why there is sometimes within a tumor heterogeneity of 
ALT+ and telomerse+ cancer cells. However, these mechanisms may not exclude each other 
in a cell. Indeed, it has been shown in vitro that these two telomere length mechanisms 
(TMM) can coexist within the same tumor cells (Cerone et al., 2001; Grobelny et al., 2001; 
Perrem et al., 2001; Stewart et al., 2002a).  
1.2.3 Bmi-1 
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Figure 24. The Pathways depending upon p16INK4a-Rb or ARF-p53, with Bmi-1 action on 
both pathways. Figure modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; 
Sharpless et al., 2004; Sherr, 2001; Sherr, 2004; Zhao et al., 2004). 
 
67
 68
Bmi-1 stands for B lymphoma Mo-MLV insertion region (van Lohuizen et al., 1991). The 
name of this gene derives from the manner it was discovered. It was observed that constitutive 
expression of the myc oncogene alone is not sufficient to cause B cell lymphoma. In an 
attempt to identify genes that cooperate with myc in B cell transformation, transgenic animals 
were used, in which the expression of myc was increased by placing an immunoglobulin 
heavy chain enhancer near myc (Eμ-myc). These animals were shown to develop 
lymphomagenesis only after a certain period of time, suggesting that other events are 
necessary to promote tumors (Adams et al., 1985; Cory and Adams, 1988). Nevertheless, 
these additional mutations are often small, and difficult to find in the genome, complicating 
the search for new genes cooperating in oncogenesis. In the contrary, retroviral insertion can 
permit to activate oncogenes, and this mutation can be easily found by classical inverse PCR 
methods.  In the case of B cell transformation, one day old Eμ-myc transgenic mice were 
infected by 105 infectious units of Mo-MLV. This infection led to a dramatic acceleration of 
lymphomagenesis, and permitted to discover that in 35% of tumors, proviruses were 
integrated in the bmi-1 gene (van Lohuizen et al., 1991).  
Bmi-1 is expressed in most organs, but higher levels can be detected in thymus, heart muscle, 
and brain. Relatively high levels of Bmi-1 were also found in testis, in embryonal stem cells, 
in placenta and in day 10.5 mouse embryos (van Lohuizen et al., 1991). This data pointed to a 
role of Bmi-1 in immortal cells, and indeed, Bmi-1 was subsequently shown to be necessary 
for self-renewing cell divisions of adult HSCs as well as adult peripheral and central nervous 
system neural stem cells (Molofsky et al., 2003; Park et al., 2003). It is also likely that Bmi-1 
regulates the self-renewal of other types of somatic stem cells, because there is a broad range 
of phenotypic changes observed in Bmi1-deficient mice, including posterior transformation 
and neurological abnormalities (van der Lugt et al., 1994). 
The main roles of Bmi-1 seem to be mediated mainly by its capacity to inhibit p16INK4a and 
p19ARF, the two open-reading frame products of the INK4A-ARF tumor suppressor locus 
(Sharpless, 2004). Overexpression of Bmi-1 is associated with increases in the probability of 
neoplastic proliferation in lymphocytes (Alkema et al., 1997; Haupt et al., 1993). Bmi-1 may 
also play a key role in some cancers, including in mantle cell lymphomas, in B-cell non-
Hodgkin lymphoma and in non-small cell lung cancer (Bea et al., 2001; van Kemenade et al., 
2001; Vonlanthen et al., 2001). Bmi-1 has different effects in mouse or human fibroblasts. On 
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the first hand, in normal mouse embryonic fibroblasts (MEFs), overexpression of Bmi-1 
resulted in a proliferative advantage and extended MEF lifespan. After a slow growth period, 
Bmi-1 overexpression even allowed immortalization of MEFs (Jacobs et al., 1999a). On the 
other hand, in WI-38 human fetal lung fibroblasts, Bmi-1 extended replicative lifespan but did 
not induce immortalization when overexpressed (Itahana et al., 2003). This discrepancy 
between human and rodent immortalization has often been explained by the fact that there is 
telomerase expression in most of the murine cells. Other data, in other systems, support the 
hypothesis that immortalization or infinite life span provided with Bmi-1 overexpression is 
more likely if there is also telomerase expression.  
There is evidence that Bmi-1 might upregulate telomerase expression in human mammary 
epithelial cells (MECs) and might play a role in the development of human breast cancer 
(Dimri et al., 2002). Mammary tissue can be explanted into tissue culture medium, and forms 
a heterogeneous population of MECs, termed preselection MECs. However, in vitro, only rare 
MECs are able to grow, they are termed postselection MECs. In these postselection MECs, 
the p16Ink4a gene is silenced, but the cells do not immortalize spontaneously, and they 
undergo replicative senescence though they have 30-40 additional doublings compared to 
preselection MECs (Brenner et al., 1998; Wong et al., 1999). In this system, postselection 
MECs but not preselection MECs can be immortalized by overexpression of either hTERT, 
human papillomavirus (HPV) E6, or Bmi-1. However, Bmi-1 immortalization of postselection 
MECs was associated with higher hTERT expression (Dimri et al., 2002).  
Bmi-1 does not only downregulate p16Ink4a and p19Arf, and microarrays experiments have 
shown that it also regulates stem cell–associated genes, survival genes, antiproliferative 
genes, and genes associated with stem cell fate decisions (Figure 25).  
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Figure 25. Postulated Bmi-1 targets. Self-renewal signals trigger stem cells to upregulate 
Bmi-1 levels. This inhibits p16Ink4a and p19Arf, but also Hox genes, chemokine orphan 
receptor 1 (RDC1) and tight junction protein (TJP). Bmi-1 also possibly activates, via indirect 
mechanisms, some genes including telomerase, apoptosis inhibitor-6 (Ai6), and platelet-
activating factor acetylhydrolase (PAF-AH ). These genes likely play a role in stem cell fate 
decisions including self-renewal and differentiation. Figure modified from (Park et al., 2004; 
Park et al., 2003).  
The particular role of Bmi-1 in senescence has made of this gene a new candidate for 
immortalizing cells (Dimri et al., 2002; Jacobs et al., 1999a; Milyavsky et al., 2003; Salmon 
et al., 2000; Vonlanthen et al., 2001; Zeisig et al., 2004). 
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1.2.4 SV40 large T antigen 
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Figure 26. Production of SV40 Large T (LT), small T (ST) and 17kT antigens by SV40 early region. LT, ST and 
17kT are produced by alternative splicings of the SV40 early region. All these proteins share the same 82 amino 
acids in their N-terminus, which has a DnaJ-related sequence. LT binds to the RB family members by its 
LXCXE sequence, and binds to p53 in two regions of its C-terminal part. ST binds to Phosphatase 2A (PP2A) by 
means of an intron in the LT-coding sequence. 17kT shares the amino-terminal part of LT, but a second splicing 
terminates this protein with three amino acids from an alternate reading frame (Boyapati et al., 2003). The 
resulting 17kT protein binds to RB, but not to p53 or PP2A (Rundell and Parakati, 2001). 
 
Simian virus 40 (SV40) can ultimately transform cells with three proteins: large T (TAg or 
LT), small T (tAg or ST), and 17 kT antigens. All these proteins are produced by alternative 
splicing of SV40 early region (Figure 26). However, in practice, a lot of authors may talk 
about TAg, when they are using in fact the complete SV40 early region. Then, they are using 
LT, ST, and 17kT antigens. For this reason, it is often only when we read in detail the 
“Materials and Methods” of an article that we know what genes were effectively used. 
Despite this problem of nomenclature, it has been noticed that most of the effects due to SV40 
early region are due to large T, but we are going to review the effects of all the proteins 
currently known in the SV40 early region. Already with the SV40 virus, the functions of the 
SV40 early regions are thought to be mainly accomplished with by large T antigen. In SV40, 
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the SV40 early region permits host cell transformation, higher cellular proliferation, and 
higher viral replication. This task is thought to be accomplished mainly by large T antigen, 
which disrupts the functions of both the Rb family members and of p53 (Figure 27).  
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Figure 27. The main functions of TAg : Disruption of pRB and p53 functions. Figure 
modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; Sharpless et al., 2004; 
Sherr, 2001; Sherr, 2004; Zhao et al., 2004). 
 
1.2.4.1 Large T domains  
 
Large T has three main domains implicated in transformation (Figure 25). It has a bipartite 
carboxy-terminal region (amino acids 351-450 and 533-626), which binds to the tumor 
suppressor p53 (Kierstead and Tevethia, 1993; Peden et al., 1989; Srinivasan et al., 1989; Zhu 
et al., 1992), but also to CBP, p300, and the related p400 (Eckner et al., 1996; Lill et al., 
1997). The 103-107 residues of Large T contain a LxCxE motif, which binds to the 
retinoblastoma proteins pRB, p107 and p130 (Peden et al., 1989; Srinivasan et al., 1989). 
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Finally, the J domain (residues 1-82) exhibits dnaJ domain function (Kelley and 
Georgopoulos, 1997) and binds to hsc70, a homologue of the heat shock protein hsp70 
(Kierstead and Tevethia, 1993; Zhu et al., 1992).  
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Figure 28. Domains of SV40 large T antigen. Three major domains are involved in 
transformation (green) : the J domain, the LxCxE motif, and the bipartite region. These 
domains respectively bind hsc70, Rb family members, or p53. Two regions may also 
contribute to full transformation of Tag : its DNA binding region, and its p300/CBP/p400 
binding region. The latter appears to be located in the C-terminus of Tag but there are 
indications that certain N-terminal residues may also play a role in this binding.  
 
Notably, the LxCxE motif of Large T has also been found in other oncoproteins such as 
adenovirus E1A, and the human papilloma virus (HPV) E7. In these viruses, this motif has 
also been found there to be important for binding to pRB and to pRB-related proteins p107 
and p130 (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1989).  
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1.2.4.2 TAg, p53 and pRB  
The function of TAg in transformation is achieved mainly by the binding of p53 and pRB 
family of proteins. In humans, disruption of both p53 and pRB pathways are thought to be 
important for immortalization, whereas in mice, and especially in MEFs, disruption of only 
the p53 pathway by TAg can suffice for immortalization (Stubdal et al., 1997; Thompson et 
al., 1990; Zhu et al., 1992).  
p53 was first discovered as a cellular protein associating with SV40 large T antigen. 
Additional experiments showed that p53 was a key protein in the mechanisms of cell cycle 
control (Friend et al., 1986; Ko and Prives, 1996). p53 acts at least in part as a transcription 
factor, and can lead to arrest in G1/S and G2 phases of the cell cycle. TAg can bind to p53 
DNA binding domain, and this results in preventing p53-mediated transcription (Jiang et al., 
1993; Mietz et al., 1992; Segawa et al., 1993). TAg can also increase the half-life and steady-
state levels of p53 (Oren et al., 1981; Sladek et al., 2000). This is probably achieved by TAg 
binding of mdm2 (Brown et al., 1993; Henning et al., 1997; Zalvide et al., 1998), which 
normally facilitates the ubiquitination-dependant degradation of p53 and inactivates the 
transcriptional activity of p53. It is not currently understood why TAg needs to prevent p53 
degradation by mdm2, since p53 sequestered by TAg is already transcriptionally inactive. 
TAg J domain can suppress the repression of E2F activity by p130 and pRB (Avantaggiati et 
al., 1996). With hsc70 and ATP, TAg can dissociate E2F-4 from p130 (Friend et al., 1986), 
and can promote p130 degradation (Qin et al., 1992). TAg has also an effect in hypo-
phosphorylating p107 and p130 (Hinds et al., 1992; Qin et al., 1992). All these effects lead to 
inactivations of the pRB proteins, and relieve their possible effect on blocks in G0/G1 or in S 
phase (Figure 29). Inactivations of p107 and p130 have been rarely found in human tumors, 
but these proteins may affect transformation, as seen in Rb-/- MEFs (Goodrich et al., 1991; 
Stiegler et al., 1998). 
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Figure 29. TAg interactions with RB family members. TAg leads to p130 elimination, 
possibly after p130 phosphorylation. This relieves E2F4 from p130 inhibition, and lead to 
transcription of G0/G1 phase genes. TAg can also interact with the hypophosphorylated form 
of Rb. This releases E2F1-4 transcription factor, which then transcribes S phase genes. Figure 
modified from (Ali and DeCaprio, 2001).  
1.2.4.3 Other functions of TAg 
TAg transformation capabilities are not only due to its binding to p53 and to pRb proteins. 
TAg contains a DNA-binding domain (residues 131-246), which is implicated in 
transcriptional transactivation, possibly of some cellular genes (DeCaprio et al., 1988). 
Moreover, TAg interacts with unphosphorylated form of p300 (Avantaggiati et al., 1996; 
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Eckner et al., 1996). This binding may have an effect in E2F-1-mediated transcription, 
because E2F1 transcriptional activity depends on its interaction with CBP (Trouche et al., 
1996). Alternatively, this binding may have an effect in the inhibition of p53 degradation 
(Figure 30). New binding partners of TAg have recently been identified. They include p400, a 
member of the p300/CBP family, and a 193 kD protein with a bcl-2 homology (Ali and 
DeCaprio, 2001). In the end, a new domain in residues 525-541 of TAg has been identified to 
have antiapoptotic activities (Conzen et al., 1997).  
 
p53 p21 
E2F1
mdm2
Cdk 4/6 
cyclinD 
TAg 
p300 / CBP  
Rb 
TAg 
Cdk 2 
cyclinE 
Figure 30. One model of TAg-mediated disruption of cell cycle checkpoints. TAg binds to 
p53, pRb and p300/CBP, and manipulates the activity of E2F1 through multiple routes. Figure 
modified from (Ali and DeCaprio, 2001).  
 
1.2.4.4 Small t 
Small t has the capability to bind to the catalytic core of protein phosphatase 2A (PP2A) and 
to inhibit its enzymatic activity toward most substrates (Yang et al., 1991). This interaction is 
important in small t-dependant transformation, including focus formation of HDF (Mungre et 
al., 1994; Porras et al., 1996). Small t presence, in addition with Large T, may be particularly 
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crucial for the transformation of quiescent cells, such as Chinese hamster lung cells, or murine 
lung and kidney cells (Choi et al., 1988; Cicala et al., 1992; Martin et al., 1979). These 
experiments and others have shown that the main purpose of small t is to transform the cells, 
in a c-myc dependent manner (Janssens et al., 2005). 
Small t interaction with PP2A activates not only the Myc pathway, but also the MAPK 
pathway (Sontag et al., 1993), the Creb pathway (Wheat et al., 1994), the Rac/Rho pathway, 
and the Akt pathway (Figure 31).  
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Figure 31. SV40 early regions (ER) proteins effects on cellular pathways. SV40 Large T 
antigen (LT) inactivates the pRB and p53 pathways, whereas small T antigen (ST) perturbs 
Phosphatase 2A (PP2A). This can lead some cell types to immortalization, and also to 
acquisition of tumorigenic phenotypes. Figure modified from (Zhao et al., 2004). 
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1.2.4.5 17kT 
Until now, very few studies have been published about 17kT. It was shown that this protein 
has weak transforming activities in rat cells (Zerrahn et al., 1993). Similarly to Large T, it can 
reduce levels of pRb and of p130, and stimulate cell-cycle progression of quiescent fibroblasts 
(Boyapati et al., 2003).  
 
1.2.4.6 Utility of TAg in immortalization 
 
SV40 Large T, alone or in combination with small T, has been extensively used in a large 
number of immortalizations, sometimes with telomerase (Hahn et al., 1999a; Hahn et al., 
2002; Rich et al., 2001; Yu et al., 2001).  
Nevertheless, despite its utility in immortalization of a large variety of cells, TAg has some 
drawbacks. TAg can induce chromosomal aberrations, including aneupoidy, and 
translocations. These chromosomal aberrations are induced by large T antigen, but not by 
small t (Stewart and Bacchetti, 1991).  
 
1.2.5 Bcl-2 
 
Apoptosis can play different roles, which are related to carcinogenesis prevention. First, 
different stress signals such as oncogenic activation can lead to increased p53 activity and cell 
cycle arrest or apoptosis (Figure 32) (Hipfner and Cohen, 2004). 
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Figure 32. The Pathways depending upon p16INK4a-Rb or ARF-p53, with Bcl-2 anti-apoptosis 
effects. Figure modified from (Drayton and Peters, 2002; Lowe and Sherr, 2003; Sharpless et 
al., 2004; Sherr, 2001; Sherr, 2004; Zhao et al., 2004). 
Second, apoptosis can be triggered if cells lose their attachment to their substratum, a 
phenomenon known as anoikis (Figure 33).  
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Figure 33. Speculative model for mammalian stress-induced apoptosis. Figure modified from 
(Cory et al., 2003; Heiser et al., 2004; Jacks and Weinberg, 2002).  
The ARF-MDM2-p53-apoptosis pathway is a response to activated oncogenes. ARF responds 
to proliferation signals, and binds to MDM2. This inhibits p53 transcriptional silencing and 
degradation by MDM2. p53 activates target genes that promote cell-cycle arrest or apoptosis 
in response to cellular stresses such as oncogene activation. Anoikis can also trigger 
apoptosis, by Bmf activation, which suppresses Bcl-2 anti-apoptotic activities.  
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Cellular transformation and tumor progression has been associated with activation of anti-
apoptotic pathways, both in vitro, and in some in vivo models (Jacks and Weinberg, 2002).  
 81
For all these reasons, Bcl-2 may be useful not only to immortalize cells, but also to induce 
transformation of cells.  
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1.3 Of the utility of cell lines 
In the laboratory, it is useful to use cell lines with an infinite life span. These cells are often 
easy to cultivate, so that sufficient amounts of them can be obtained for nearly any 
experiments, and they allow the reproducibility of experiments. They also allow different 
researchers around the world and in different times to work with the same material. This then 
permits the comparison of different researches.  
A lot of cell lines exist, for different cell types (e.g. for epithelial cells, hepathocytes, 
macrophages, T cells …). The first immortal cells to be obtained are called HeLa. These are 
human epithelial cells from a fatal cervical carcinoma transformed by Human Papilloma 
Virus 18 (HPV 18) (Gey et al., 1952; Scherer et al., 1953). These cells were obtained in 1951 
from a 31 years old black woman living in Baltimore, Henrietta Lacks, whose name is now 
famous because of the utility that HeLa cells have had in laboratories around the world. This 
is reflected in the PubMed searches, where the word “HeLa” could retrieve more than 47000 
entries in December 2005. However, despite the utility of HeLa cells as a cellular model, it 
has been shown that this cell line is considerably different from normal primary cells. 
Consistent with its cancerous origin, HeLa cells have different tumorigenic markers. They 
include a low level of p53, and an abnormal chromosome number (Belcher, 1971). Moreover, 
this cell line is tumorigenic in nude mice. Most of the cell lines also contain abnormal 
oncogenic and viral sequences when they are compared to the primary cells.  
The cancerous origins of cell lines may be useful for some studies of cancer because both 
these types of cells may have common characteristics. Nevertheless, the cells lines are easy to 
cultivate and cancer cells are usually very difficult to put in culture (Masters, 2000). This is an 
illustration that cell lines are different from cancer cells. Moreover, even if a cell line is 
derived from a cancer, it may be different from the cancer it comes from. Indeed, an 
individual cancer cell line can be representative of only some of the cancer cells at the time 
biopsy was taken and they can still be the subject to additional genotypic instability during the 
time that they are cultivated in vitro. Despite these limitations, it remains that cell lines 
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originating from cancers have been largely used to study cancer but they could also allow the 
discovery a lot of molecular events that take place in normal cells.  
Nevertheless, all cell lines do not originate from a cancer. Some of them were obtained in the 
laboratory, for instance with carcinogenic agents. The mutations caused by these agents can 
lead finally to immortalization of the cells. However, the cells obtained with this method can 
have an altered phenotype, once they are compared with the primary cells. This can be due 
either to unwanted mutations in genes which are unrelated to immortalization or this can be 
due to immortalization through a process resembling to tumorigenesis. However, when these 
cells are compared to cancer cells, they may have less tumorigenic properties. This may be the 
case, because the cell lines obtained in vitro did not have to escape from the immune system, 
and it is not the case for most of the cancer cell lines obtained in vivo.  
Anyway, the multiple mutations that take place in chemical mutagenesis can often not be 
revealed, and this is one thing that researchers often would like to know. In fact, researchers 
would like to know with what kind of material they are working with. This is why cell lines 
with defined genetic elements were produced (Hanahan and Weinberg, 2000). For this 
purpose, either viral or oncogenic genes can be introduced into the primary cells, and can lead 
or not to immortalization. Such cell lines are certainly the cell lines of the future, because they 
allow researchers to know exactly with what kind of material they are working with.  
The cell lines are largely used in biological research for a large number of studies. However, 
it is more and more envisaged that they could have other utilities, for example in gene therapy 
experiments. For instance, the mouse myoblast cell line C2C12 has already been genetically 
modified to release a therapeutic product, and this therapeutic cell line could then be 
encapsulated and implanted into a murine host (Cirone et al., 2004).  
In the present days, it is probably too early to generalize the usage of cell lines for therapeutic 
purposes. To this end, new cell lines should probably be established. These cells should be as 
near as possible to the primary cultures, without to have a tumorigenic or altered phenotype. 
Such cell lines would also be advantageous for in vitro studies, because they would resemble 
more to the primary cells that researchers want to study. Moreover, if such cells could be 
created with defined genetic elements, it would be an advantage for researchers, because they 
could know exactly in what they differ from the primary cells they are derived from. 
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1.4 Lentiviral immortalization 
We have presented until now the utility of cell lines, and the genes that could be useful to use 
for immortalization. However, we still need a vehicle to deliver the genes of interest into the 
genome of the host cells. For this purpose, we have chosen lentiviral vectors. These vectors 
have, first, the advantage to allow the successful delivery of genetic material into nondividing 
cells. Second, they have the advantage to allow high-level expression of the transgenes, 
because integration occurs in locations that are situated close to actively transcribed genes 
(Mitchell et al., 2004). Third, they permit the transfer of transgenes without transcription of 
viral proteins in host cells. Fourth, they allow the packaging of relatively long transgenes, 
which may cover most of the clinical applications. Fifth, and finally, progress in the design of 
lentiviral vectors have allowed the quasi-elimination of risks that replication-competent 
viruses may appear. All these properties have been illustrated in a number of studies (Naldini 
et al., 1996; Salmon et al., 2000; Zufferey et al., 1998; Zufferey et al., 1997). We are going 
now to review briefly the development of the lentiviral vectors, and we are going to describe 
the generation of lentiviral vectors that we have finally used.  
The lentiviral vectors originate from a modified Human Immunodeficiency Virus (HIV). In 
fact, it has been shown that it is possible to exploit the properties of HIV to insert genes (also 
called transgenes) into the genome of non-dividing cells, thereby producing a lentiviral vector 
(Naldini et al., 1996). For this purpose, deletions in the HIV sequence were done. This 
allowed the production of HIV-derived vectors that were not harboring the usually HIV-
related pathogenic effects. Different deletions were done in HIV, producing different 
generations of HIV-derived packaging systems.  
In the second generation packaging system, the lentiviral vectors are produced from HIV 
deprived of the accessory but pathologic proteins Nef, Vif, Vpr and Vpu, but also of the HIV 
envelope. The safety of this system is also ensured by impairing HIV replication. This was 
done by splitting the components of the vector in three plasmids: the Packaging, the 
Transgene and the Envelope plasmids (Figure 34). The Packaging plasmid contains the 
genetic informations that are necessary for the construction of the capsid of the vector. This 
plasmid also permits the productions of the proteins involved in the reverse transcription and 
integration processes. The Transgene plasmid provides the genetic material to be encapsidated 
into the vector. Finally, the Envelope plasmid provides the envelope that can give a host 
specificity of the vector. If the HIV envelope is replaced by Vesicular stomatitis virus G 
protein (VSV-G), the vector is called VSV-G-pseudotyped, and the type of the cells it can 
enter into (also called its tropism) considerably broadens (Naldini et al., 1996). In these 
plasmid constructs, only the Transgene plasmid was designed to contain the two determinants 
that could allow to its genetic information to be incorporated into the host genome. These two 
integration-related elements contained in the Transgene plasmid are Ψ, and the R U5 
sequences. Ψ is the packaging signal that can permit incorporation of Transgene RNA into 
viral particles, and the R U5 sequence allows successful reverse transcription of the template 
RNA in the host. Further HIV deletions can be done in the Packaging plasmid. They include 
the deletions of Tat, Rev and of the rev responsive element (RRE), but removal of these 
sequences lead to lower vector titers (Gasmi et al., 1999; Pacchia et al., 2001).  
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Figure 34. Plasmids used in transfections for production of lentivectors. Co-transfection of 
three plasmids are able to produce lentiviral vectors: packaging, transgene and envelope 
plasmids. See text for explanations. CMV: human cytomegalovirus immediate early 
promoter. Figure modified from (Zufferey et al., 1997). 
 
The properties of the second generation lentiviral vectors were used to immortalize cells, with 
slight modifications (Salmon et al., 2000). For this purpose, a LoxP sequence was added in 
the R sequence at the 3’ end of the transgene sequence. This allowed the insertion into the 
host genome of LoxP sites surrounding the transgene, and excision of the transgene cassette 
after Cre expression (Figure 35). At the same occasion, part of the HIV U3 sequence in the 3’ 
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part of the Transgene plasmid was deleted, leading to a self inactivating lentiviral vector 
(SIN), which has the property not to give a functional viral promoter post reverse transcription 
(Dull et al., 1998; Miyoshi et al., 1998; Zufferey et al., 1998). After the immortalizing agent, 
an internal ribosomal entry site of the encephalomyocarditis virus (IRES) sequence was also 
inserted, with a following sequence from the thymidine kinase of herpes simplex virus type 1 
(HSV1-TK). This ensured that the cells that would escape Cre-mediated excision could still 
be selectively killed after Acyclovir or Gancyclovir treatment (Salmon et al., 2000).  
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Figure 35. The lentiviral vector, the integrated transgene, and its excision. (1) Plasmids are 
transfected into 293T cells and lead to RNA species without the U3 part of the LTR. (2) RRE 
permits successful exit of the nucleus of non-spliced transcripts, while Ψ permits 
encapsidation of the transgenes into lentiviruses. (3) Once in the target cell, reverse 
transcription and integration lead to integration of the transgene in the genome, flanked by 
LoxP sites. (4) After expression of Cre, only the LoxP sites remain integrated in the genome, 
and R U5. Figure modified from (Salmon et al., 2000). 
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1.5 Why to immortalize human myoblasts? 
Different cells can be immortalized for therapeutic purposes or for in vitro studies. We have 
chosen to immortalize myoblasts for two major reasons. First, before our work, no human cell 
line was reflecting the biology of real human myblasts. Second, we chose myoblasts as targets 
for immortalization because this cell type allows easily to study if resulting cells can still fully 
differentiate after immortalization, and immortalized cells were often reported to have 
problems of differentiation.  
Numerous attempts have been done to immortalize human myoblasts (Corti et al., 2001; Di 
Donna et al., 2003; Miranda et al., 1983; Pincon-Raymond et al., 1991; Seigneurin-Venin et 
al., 2000; Simon et al., 1996; Tedesco et al., 1995; Webster et al., 1988). However, the 
resulting cell lines were often reported to behave very differently from the normal primary 
myoblasts. They often had tumorigenic properties or difficulties to differentiate. If 
immortalization was coupled with these properties, it was probably due to the methods of 
immortalization used in these articles, involving strong oncogenes or viral-derived genes.  
 
Immortalizations with Ras were often reported to be coupled with induction of tumorigenesis 
(Hahn et al., 1999a; Kusakari et al., 2003) but also to modifications of cell cycle (Rajalingam 
et al., 2005). However, it is thought that only a tightly regulated cell cycle would allow the 
differentiation of a cell, even though this topic is still the subject of debate (Brown et al., 
2003). At least, it is known that Ras and Bcl-2 may perturb the differentiation of memory B 
cells to antibody-producing B cells (Takahashi et al., 2005).  
 
Viral genes can also, like oncogenes, lead to modifications of phenotypes and not only to 
immortalization. In fact, the purpose of the viral genes is not to give to researchers a good 
immortalized cell line but to modify the cells in a manner that the viruses they are encoded by 
can grow easier. We have previously discussed the immortalizations with Large T Antigen, 
which often led to aberrant karyotypes. In the specific case of myoblast immortalization, some 
viral proteins were already shown to perturb differentiation. For instance, Adenovirus E1A 
and T-Ag was shown to suppress myogenic differentiation of mouse myoblasts (Webster et 
al., 1988). Moreover, T-Ag led to loss of contact inhibition, to anchorage-independent growth 
(Miranda et al., 1983), and to a strong tendency to apoptosis (Corti et al., 2001).  
 
As, until now, most of the attempts to immortalize myoblasts were only half-successful, 
practically no human myoblast cell line with the basic properties of human primary myoblasts 
are used in laboratories. This means that human myoblasts have to be isolated from 
orthopedic surgery or diagnostic biopsies for different in vitro studies. Such primary cells 
have a limited replication potential, and repeated isolations of myoblasts must be performed. 
The satellite cells obtained from Duchenne patients are known to have even shorter lifespans 
and they can also be less easily obtained than normal primary myoblasts. Considering these 
facts, we wanted to attempt to immortalize human primary myoblasts, in such a way that these 
cells would keep their myogenic capacities after immortalization. We have done this, not only 
to obtain a human myoblast cell line which would be similar to primary cells, but also 
because myoblasts permit to study easily if the differentiation phenotype of these cells is the 
same after immortalization (Figure 36). For this purpose, we have used genes that might still 
allow differentiation of myoblasts after immortalization. They include bmi-1, telomerase, and 
bcl-2. We have already discussed previously the properties that these genes may have in 
immortalization processes. Now, we are going to talk more about myoblasts.  
 
 
Immortalization ? 
         and phenotypes = ? 
                    and differentiation = ? 
Bmi-1 
hTERT 
TAg 
Bcl-2 Primary cell 
Figure 36. What happens after addition of oncogenes into primary cells? Are they 
immortalized? And what are their resulting phenotypes, also during differentiation? 
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1.6 Muscles and satellite cells: an overview 
A number of specific reviews exist about the muscle, and because we can not discuss all the 
muscle-related issues, we will make an overview of the muscle physiology, particularly in our 
interest to immortalize control myoblasts, and myoblasts originating from patients suffering 
of Duchenne Muscular Dystrophy.  
Muscles are derived from the mesodermal cells that are themselves derived from the somites. 
The myogenic precursor cells express the transcription factor Pax-3, the tyrosine kinase 
receptor c-Met, the transcriptional repressor msx1, and the transcription factor Lbx 1 but these 
precursors lack expression of the myogenic regulatory factors of the MyoD family (Hawke 
and Garry, 2001). Precursor cells are committed positively to the myogenic lineage by 
Noggin, Wnts, and Shh, while BMP4 has a negative effect (Figure 37). The committed cells 
finally upregulate MyoD and/or Myf5, the basic helix-loop-helix transcriptional activators of 
the myogenic regulatory factor family (MRF) and then can be termed myoblasts  (Chargé and 
Rudnicki, 2004).  
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MT 
SC 
NT 
NC 
Pax3 
LP 
E 
DM 
NT
MyoD 
Myf5 
Noggin 
Wnts 
Shh 
Shh 
BMP4 
BMP4 
Noggin 
Wnt11 
Wnt7a 
Figure 37. Signaling factors involved in embryonic skeletal muscle formation. Wnts, Sonic 
hedgehog (Shh) and Noggin induce (and BMP4 inhibits) the expression of the primary MRFs 
(Myf5 and MyoD) and commit the mesodermal somitic cells located in the dorsal part of the 
somite [dermomyotome (DM)] to the myogenic lineage. Commited myoblasts migrate 
laterally to form the myotome (MT), which eventually forms the skeletal musculature. Pax3 
promotes myogenesis in the lateral myotome. E, ectoderm; LP, lateral plate; SC, sclerotome; 
NC, notochord; NT, neural tube. Figure modified from (Chargé and Rudnicki, 2004). 
 
Proliferating myoblasts withdraw from the cell cycle to become terminally differentiated 
myocytes that express the “late” MRFs, Myogenin and MRF4. These cells finally fuse to form 
a multinucleated syncytium, and mature into contracting muscle fibers. Only a subpopulation 
of myoblasts do not differentiate, and remain associated with the surface of the myofiber. 
They are the quiescent muscle satellite cells (Figure 38) (Chargé and Rudnicki, 2004). It is 
well established that the myogenic precursors derive from the multipotent mesodermal cells 
of the somite, but the origin of satellite cells is less well understood. It is currently proposed 
that satellite cells may originate from somitic or from endothelial cells. Nonetheless, it is 
known that Pax7 is responsible for the specification of progenitor cells to the satellite cell 
lineage. Quiescent and activated satellite cells both express in vivo Pax7 (Seale et al., 2000). 
Pax7 is closely related to Pax3, which is a key regulator of somatic myogenesis (Maroto et al., 
1997; Tajbakhsh et al., 1997). 
 
Pax3 
Pax7 
Mesodermal  
somitic cells  
Myoblasts 
MyoD/Myf5 
Myocytes 
Myogenin/MRF4 
Pax7 
Satellite cells 
Somitic cells ? 
Endothelial cells ?  
Myofibers and 
satellite cells 
? 
Pax7 
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Figure 38. Pax3 expression in the lateral myotome promotes myogenesis. Pax3 expression in 
precursor cells contributes to myogenic cell expansion. Induction of MyoD and/or Myf5 
commits cells to the myogenic lineage. After cell divisions, cells become quiescent myocytes, 
and upregulate the secondary MRFs (myogenin and MRF4). Finally, myocytes fuse and give 
rise to multinucleated myofibers. At a later embryogenic stage, some satellite cells give rise to 
myoblasts and promote fiber growth, while others remain associated with the myofibers in a 
quiescent undifferentiated state. It is known that Pax7 promotes the specification/expansion of 
the satellite cell population. The embryonic origin of the satellite cells still remains to be 
determined. Figure modified from (Chargé and Rudnicki, 2004). 
 
The muscles are composed of a network of different myofibers, blood vessels, motor neuron, 
and extracellular tissue matrix. Muscle contraction is the result of a the sliding of a myosin-
rich thick filament over an actin-rich thin filament after neuronal activation. Myofibers types 
can be either slow-contracting/fatigue resistant or fast-contracting/non-fatigue-resistant. The 
fast-contracting fibres are needed for movement, and the slow fibres are required for posture 
maintenance. The relative amount of slow type I myosin heavy chain isoform determines the 
type of muscle (Figure 39). If a muscle is rich in myofibers expressing the slow type I myosin 
heavy chain isoform, the muscle is defined as a slow contracting muscle (Kameda et al., 
1993).  
 
Skeletal muscle  
Epimysium 
Myofiber 
bundle 
Perimysium 
Myofiber 
A B 
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Figure 39. The muscle, the myofiber, and satellite cells. A. Schematic view of a skeletal 
muscle. A skeletal muscle is composed of myofibers, which are multinucleated syncitia with 
post-mitotic nuclei placed at the periphery. Here, a slow contracting (e.g. soleus and not 
plantaris) muscle is shown. This muscle is rich in myofibers expressing the slow type I 
myosin heavy chain isoform (green). Myofibers not expressing the slow type I myosin heavy 
chain isoform are shown in yellow. B. One satellite cell on a myofiber bundle. The schema of 
the skeletal muscle was modified from (Chargé and Rudnicki, 2004). The picture of the 
satellite cell placed on a myofiber was given by Laurent Bernheim.  
The satellite cells are defined by their characteristic position surrounding individual fibers 
(hence their name). They are located close to the myofibers, between the sarcolemma and the 
basal lamina. These quiescent cells do not express myogenic regulatory factors of the MyoD 
or MEF2 families or other known markers of terminal differentiation. Satellite cells can be 
found on all muscles. Nonetheless, higher numbers of satellite cells are found surrounding the 
slow muscle fibers if they are compared with the fast fibers within the same muscle. Ageing is 
associated with decreases in satellite cell numbers in rodents, but not in humans (Jejurikar and 
Kuzon, 2003). 
 
1.6.1 Fusion of myoblasts 
 
Satellite cells can be activated for post-natal growth, for repair of skeletal muscle, or in 
reaction to hypertrophic stimuli.  In such circumstances, these cells will proliferate, will 
express the myogenic markers MyoD and/or Myf5 and can be termed myoblasts (Figure 38) 
(Black and Olson, 1998; Chargé and Rudnicki, 2004). Myogenic cells differentiate and can 
fuse to existing damaged fibers for repair. This has been demonstrating by radiolabeling 
experiments of satellite cells. Once activated, satellite cells become myoblasts, which can fuse 
to one another to form new myofibers. This process is very similar as muscular 
embryogenesis. The fusion event is a process that follows an ordered set of cellular events: 
recognition, adhesion, alignment, and membrane union. Then, myoblast fusion is a highly 
ordered process. This is to avoid that myoblasts do not fuse without proper activation, but also 
to avoir that myoblasts would fuse with any cell type, wich would be disastrous for an 
organism. This is why if myoblasts are able to fuse between them to form multinucleated 
syncitia, they do not fuse with other cell types (Okazaki and Holtzer, 1965). 
Different molecules regulate mammalian myoblast fusion. They are membrane proteins, 
extracellular secreted factors, or intracellular proteins (Figure 40). Until now, the events of 
fusion have been mainly studied in vitro, and relatively little is known about the process of 
myoblast fusion in vivo. This is largely due to the difficulties encountered when studying 
fusion in animals. 
Recent experiments suggest that Kir2.1 channel activation is a required key early event that 
initiates myogenesis by turning on myogenin and MEF2 transcription factors via a 
hyperpolarization-activated Ca2+-dependent pathway (Konig et al., 2004).  
Calcium, calmodulin and PGF2  act upstream of NFAT to induce skeletal muscle growth 
(Horsley and Pavlath, 2004). IL-4 is a crucial factor in muscle growth and controls the fusion 
of myoblasts with nascent myotubes in a pathway downstream of NFATC2 (Horsley et al., 
2003). 
Cell surface proteins have also been identified to be important for myoblast fusion. 
Particularly, myoblast fusion can be inhibited when myoblasts are treated with trypsin 
(Knudsen and Horwitz, 1977). Monoclonal antibodies can also be raised against fusing 
myoblasts (Greve and Gottlieb, 1982). Further studies have identified integrins as important 
cell surface proteins for fusion. They may influence alignment or fusion of secondary 
myoblasts with primary myotube, as seen with antibodies raised against the integrin VLA-4 or 
its counterreceptor VCAM-1 that inhibit myoblast fusion (Rosen et al., 1992).  
Other molecules have been implicated in fusion. They include GRP94, ADAM12, calpain and 
caveolin-3. However, their role still remains unclear (Horsley and Pavlath, 2004). Among 
them, calpain likely leads to destabilization of the plasma membrane before membrane fusion 
(Horsley and Pavlath, 2004).   
 
 
 
93
Molecule                           Proposed function/activity 
 
Membrane proteins  
ADAM12 (meltrin α)    Metalloprotease 
Caveolin-3   
VLA-4 (α4 integrin)    Alignment via interaction with VCAM-1 
VCAM-1     Alignment via interaction with VLA-4 
β1 integrin    Extracellular matrix receptor 
Inward rectifying K+ channels   Induction of intracellular Ca++ elevations 
T-type Ca++ channels     Induction of Ca++ influx 
GRP94     Interactions on the cell surface 
 
Extracellular/secreted factors 
Ca++     Regulation of extracellular protein activity 
Cathepsin B    Protease 
IL-4     Recruitement of myoblast fusion 
PGE1 
PGF2α     Activation of NFATC2 pathway 
 
Intracellular proteins 
Calmodulin    Cytoskelettal rearrangements, activation of signaling pathways 
Calpain     Protease destabilisation of sarcolemma 
FKHR     Regulation of gene expression 
Calpastatin    Inhibition of calpain 
NFATC2     Regulation of gene expression in nascent myotube 
 
Figure 40. Molecules that regulate mammalian myoblast fusion. FKHR: Forkhead in human 
rhabdomyosarcoma, VCAM: vascular cell adhesion molecule, VLA: very late antigen. Figure 
taken from (Horsley and Pavlath, 2004).  
The early events differentiation events lead to activation of myoblasts transcription factors 
myogenin and MEF2, and myoblast terminal differentiation is characterized by upregulation 
of  MRF4 (Figure 41) (Black and Olson, 1998; Chargé and Rudnicki, 2004; Cornelison and 
Wold, 1997).  
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Figure 41. Myoblast differentiation. Activated satellite cells are called myoblasts. They 
express MEF2A, and MyoD and/or Myf5. Differentiation and fusion leads to MEF2C and 
myogenin expression. Finally, muscle fibers express MRF4 and MEF2C, but also the muscle-
specific proteins, such as Troponin T and MyHC. Figure elaborated with (Black and Olson, 
1998; Chargé and Rudnicki, 2004; Cornelison and Wold, 1997). 
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1.6.2 Satellite cell markers and heterogeneity 
 
Satellite cells are not only defined by their specific location on the myofibers. They also 
possess small heterochromatic nuclei compared to those of adjacent myofibers, and different 
markers, whose expression may vary during activation of the cell (Figure 42). 
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  Satellite Cell Expression   
Molecular Markers  
 
Quiescent Proliferating  Experimental Protocol  
 
Cell surface     
    M-cadherin  +/-  +  In vivo/in vitro  
    Syndecan-3  +  +  In vivo/in vitro  
    Syndecan-4  +  +  In vivo/in vitro  
    c-met  +  +  In vivo/in vitro  
    VCAM-1  +  +  In vivo  
    NCAM  +  +  In vivo  
    Glycoprotein Leu-19  +  +  In vivo/in vitro  
    CD34  +/-  +/-  In vitro  
Cytoskeletal     
    Desmin  -  +  In vivo/in vitro  
Transcription factors     
    Pax7  +  +  In vivo/in vitro  
    Myf5  +/-  +  In vivo/in vitro  
    MyoD  -  +  In vivo/in vitro  
    MNF  +  +  In vivo/in vitro  
    MSTN  +  -/+  In vitro/in vivo  
    IRF-2  +  +  In vivo  
    Msx1  
 
+  
 
-  
 
In vitro  
 
 
Figure 42. satellite cell markers. MSTN, myostatin; VCAM-1, vascular cell adhesion 
molecule-1; NCAM, neural cell adhesion molecule; MNF, myocyte nuclear factor; IRF-2, 
interferon regulatory factor-2. Figure taken from (Chargé and Rudnicki, 2004). 
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Analysis of satellite cell markers is complicated by the fact that these markers may vary 
during different phases of cell activation, and from cell to cell. Indeed, single-cell analyses of 
myogenic markers in satellite cells by multiplex RT-PCR have shown heterogeneities in this 
population (Cornelison and Wold, 1997). In this study, during the early time point of satellite 
cell activation, it was shown that either MyoD or myf5 were expressed. Then, myoblasts 
expressed both myf-5 and MyoD simultaneously. After cell cycle arrest, myogenin was 
expressed with MyoD and myf5. Ultimately, many cells expressed all four MRFs 
simultaneously (Figure 43). It has been suggested that MyoD and myogenin may be located in 
fast-twitch and slow-twitch adult myofibers, respectively, but a RT-PCR study on these fibers 
was not able to show such biases (Cornelison and Wold, 1997; Hawke and Garry, 2001).  
 
 
c-met 
myogenin 
c-met 
myf5 
c-met 
MyoD 
c-met 
myf5 
MyoD 
c-met 
myf5 
MyoD 
myogenin 
c-met 
myf5 
MyoD 
myogenin 
MRF4 
c-met 
c-met 
myogenin 
MRF4 
Quiescent 
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cell 
Myoblast 
Cell cycle arrest 
Myotubes 
Fusion Intermediate 
phenotypes 
Differentiation 
Figure 43. Model of MRF coexpression during satellite cell activation. Figure redrawn from 
(Cornelison and Wold, 1997).  
 
As seen with their differential expression of markers, different populations of satellite cells 
may exist. Differences in satellite cell population may also stem from their differential origin. 
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Discussions exist to know if satellite cells may derive from somitic or from endothelial cells 
(Chargé and Rudnicki, 2004). It has also been suggested that satellite cells might also derive 
in some circumstances from mesoangioblasts, which are vessel-associated stem cells, from 
neural stem cells, and from bone marrow cells (Chen and Goldhamer, 2003). Even in 
uninjured skeletal muscle, some satellite cells express the hematopoietic marker CD45. This 
specific subset of satellite cells have been shown to be poorly myogenic compared to CD45-
negative cells. In the contrary, the CD45-positive subpopulation of cells has been shown to 
contribute to neo-vascularization in regenerating muscle, and the CD45-negative population 
does not seem to have this property (Chen and Goldhamer, 2003).  
Some experiments also suggest that some myotubes might dedifferentiate to become satellite 
cells when placed in special circumstances. At least, it has been shown that terminally 
differentiated myotubes from C2C12 cells are capable to dedifferentiate and to form 
myoblasts when exposed to the urodele homeobox-containing transcriptional repressor Msx1 
(Odelberg et al., 2000).  
A subpopulation of satellite cells, termed side population (SP) cells can be identified using the 
DNA-binding dye Hoechst 33342 and dual-wavelength flow cytometric analysis (Hawke and 
Garry, 2001). These cells have the differential ability to export the Hoechst dye, and can 
adopt alternative fates in permissive environments. Only 100 SP cells are sufficient to 
reconstitute the entire bone marrow of a lethally irradiated mouse (Jackson et al., 1999). SP 
cells can also be isolated from the bone marrow of a normal mouse, and transplanted into an 
irradiated mdx mouse bone marrow. In such experiments, these cells have been shown to be 
able to reconstitute the bone marrow of mdx mice, but they could also be recruited from the 
bone marrow and participate in muscle repair (Gussoni et al., 1999). Some satellite cells can 
also differentiate into hematopoietic cells, adipocytes, chondrocytes, cardiomyocytes, and 
smooth muscle cells (Peng and Huard, 2004).  
It is not only SP cells from the muscle that can contribute to the bone marrow reconstitution. 
Some experiments also suggest that bone marrow cells can also transdifferentiate to muscle 
cells, albeit at a low rate. In the murine bone marrow side population (mSP), most cells (92%) 
express Sca-1, whereas only 16% express CD45 consisting of both Sca-1+ (9.2%) and Sca-1– 
(6.8%). Both CD45+ and CD45– mSP cells can undergo myogenic conversion when 
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cocultured with myoblasts, but the myogenic potential of CD45- muscle-derived cells is 
higher after intramuscular injection (McKinney-Freeman et al., 2002). 
However, even though circulating stem cells can regenerate skeletal muscle, some evidences 
indicate that resident stem cells are the cells primarily responsible for the regeneration or 
repair of local tissues (Polesskaya et al., 2003).  
The satellite cell population is not only heterogenous. It has also been shown that satellite 
cells follow asymmetric division in vitro. For instance, Numb, a plasma membrane-associated 
cytoplasmic protein, is asymmetrically segregated within dividing satellite cells (Conboy and 
Rando, 2002). The asymmetric division of satellite cells has been mainly shown in vitro but it 
may be also important in vivo to ensure that a significant number of muscle stem cells remain 
on myofibers, even after some satellite cells have fused for the repair of muscles (Baroffio et 
al., 1996). Despite these properties, there is a decrease in satellite cell numbers in rodents with 
ageing. In the contrary, human satellite celle numbers do not decrease with age (Jejurikar and 
Kuzon, 2003). 
 
1.6.3 Factors modulating satellite cell activity 
 
Different factors can modulate satellite cell activity. These factors have been extensively 
studied either alone or in combination, with satellite cells isolated from animals. For this 
purpose, satellite cells have often been isoltated from young animals, because satellite cells 
are about 6 times more abundant in young animals (Hawke and Garry, 2001). However, these 
studies are to be put in the perspective that older satellite cells do not react as younger ones 
(Tatsumi et al., 1998). These factors can be grouped into two main subcategories: the growth-
factors molecules and the cytokines. The growth-factors molecules include FGF, HGF, IGF-I, 
IGF-II, TGF-β, PDGFAA/AB, PDGFBB and EGF. The cytokines are IL-6 and LIF. All these 
molecules often have chemotactic properties, and positive effects on proliferation, but their 
effect on differentiation may vary (Figure 44). However, this list of factors playing a role in 
satellite cell activity is not exhaustive. For instance, testosterone and nitric oxide (NO) may 
also play a role in satellite cell activity, as well as crushed muscle or platelet-derived extract 
(Hawke and Garry, 2001).  
 
 
 
Factors affecting satellite cell activity 
 
Growth factor Chemotactic Ability    Proliferation Differentiation 
 
FGF    ↑/NE   ↑   ↓ 
HGF    ↑   ↑   ↓ 
IGF-I       ↑   ↑  
IGF-II       ↑    
TGF-β    ↑   ↓/↑   ↓/↑   
PDGFAA/AB   NE   NE 
PDGFBB   ↑/NE   ↑ 
EGF    NE   ↑* 
LIF    ↑   ↑/NE    
IL-6       ↑    
Figure 44. Factors affecting satellite cell activity. A number of factors affect satellite cell 
proliferation, differentiation, and chemotaxis. NE, no effect. FBF, HGF, IGF, TGF, PDGF, 
and EGF, fibroblast, hepatocyte, insulin-like, transforming, platelet-derived, and endothelial 
growth factor, respectively. LIF, leukemia-inhibitory factor. * Stimulation of satellite cell 
proliferation in the presence of serum but no effect in serum-free medium. ↑ and ↓, Increase 
or decrease in effect, respectively. Figure taken from (Hawke and Garry, 2001). 
 
In vivo, it is thought that the activity of a satellite cell can be modulated in response to 
myotraumatic events, but also by the vasculature, the immune responses, the motor neurons, 
the surrounding satellite cells, and by growth factors, cytokines, hormones and autocrine 
factors (Figure 45).  
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Figure 45. Extracellular factors affecting satellite cell activity. Figure redrawn from (Hawke 
and Garry, 2001).  
1.6.4 Muscle regeneration  
 
A large variety of mouse strains exist to study muscle regeneration. However, regeneration 
differs between the varying mice strains that can be used (Figure 46). Even though these 
differences are not well understood, it seems that the genetic background may play a role. The 
differential expression of Pax7 isoforms, MyoD and FGF have been particularly correlated 
with efficiency of repair (Grounds, 1987; Grounds and McGeachie, 1989; Irintchev and 
Wernig, 1987; Mitchell et al., 1992; Roberts et al., 1997). However, targeted mutations of 
additional muscle genes have also been shown to be able to affect muscle regeneration in 
mice (Figure 46). They are reviewed elsewhere (Chargé and Rudnicki, 2004). One specific 
mutation is more interesting for us; it is mutations in the Dystrophin gene, causing Duchenne 
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Muscular Dystrophies in humans. We are going now to talk more in detail about this disease, 
among the other muscular dystrophies.  
Targeted 
Mutation  
 
Adult Muscle Phenotype  
Muscle 
Regeneration 
Phenotype  
Satellite Cell 
Phenotype (In 
Vitro)  
 
 Transcription factors   
MyoD-/-  Minor alterations  Impaired  Increased proliferation  
Delayed differentiation  
Pax7-/-  Growth deficit, satellite cells 
absent  
Deficient  No satellite cell  
Slug-/-  Fairly normal  Impaired  ND  
MNF-/-  Growth deficit  Impaired  Decreased proliferation  
Normal differentiation  
 DGC components   
MCK (Cre)-
dystroglycan 
(LoxP)  
Increased degeneration without 
fibrosis or fat replacement, muscle 
mass increase  
Efficient  ND  
Dystrophin-/- (mdx)  Increased degeneration with 
fibrosis and fat replacement  
Impaired in older mice  Normal proliferation  
-Sarcoglycan-/-  Increased degeneration with 
fibrosis and fat replacement  
Impaired in older mice  ND  
 Growth factors   
FGF-6-/-  Fairly normal  Normal or Impaired ND  
LIF-/-  Normal  Impaired  ND  
MSTN-/-  Muscle mass increase (hyperplasia 
and hypertrophy)  
Improved  ND  
 Others   
M-cadherin-/-  Normal  Normal  ND  
Desmin-/-  
 
Some degeneration  Delayed  ND  
 
Figure 46. Targeted germline mutations in mice affecting muscle degeneration/regeneration 
process. MNF, myocyte nuclear factor; MCK, muscle creatine kinase; FGF, fibroblast growth 
factor; LIF, leukemia inhibitory factor; MSTN, myostatin; ND, not determined. Figure taken 
from (Chargé and Rudnicki, 2004).  
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1.7 Muscular dystrophies 
1.7.1 General definition of muscular dystrophies  
Muscular dystrophy describes a group of severe and progressive muscle-wasting diseases of 
genetic origin. These diseases are classified clinically in six groups by the distributions of 
muscle weaknesses (Figure 47) (Emery, 2002). However, similar locations of muscle 
weaknesses do not always reflect the same gene being affected. Gene mapping experiments 
have led to the identification of a number of genes being implicated in a particular clinically-
defined muscle dystrophy. Although clinically similar diseases may be found, the mutated 
genes that are associated with these diseases may be located on different chromosomes 
(Figure 48) (Dalkilic and Kunkel, 2003; Emery, 2000). Particularly, limb-girdle muscular 
dystrophy is extremely heterogeneous in the genes that can be implicated (Laval and Bushby, 
2004).  
 
A                                   B                                 C                                  D                                  E                                  F 
Figure 47. Distribution of predominant muscle weakness in different types of dystrophy, A, 
Duchenne-type and Becker-type; B, Emery-Dreifuss; C, limb-girdle; D, facioscapulohumeral; 
E, distal, F, oculopharyngeal. Shaded=affected areas. (Reproduced from BMJ 1998; 317: 
991–95).  
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Taken together, the muscular dystrophies are mapped until now to 29 different loci and they 
can give rise to 34 distinct disorders. Their mode of inheritance can also differ: they can be 
recessively X-linked, autosomal dominant, or autosomal recessive (Figure 48) (Dalkilic and 
Kunkel, 2003; Emery, 2000).  
 
 
Disease     Mode of inheritance  Gene locus  Gene product 
 
Duchenne/Becker muscular dystrophy  XR   Xp21   Dystrophin 
 
Emery-Dreifuss muscular dystrophy   XR   Xq28   Emerin 
Emery-Dreifuss muscular dystrophy   AD/AR   1q11  Lamin A/C 
 
Limb-girdle muscular dystrophy 
LGMD 1A     AD   5q22–q34 Myotilin 
LGMD 1B     AD   1q11–21  Lamin A/C 
LGMD 1C     AD   3p25   Caveolin-3 
LGMD 1D     AD   6q22 
LGMD 1E     AD   7q 
LGMD 2A     AR   15q15   Calpain-3 
LGMD 2B     AR   2p13   Dysferlin 
LGMD 2C     AR   13q12   γ-Sarcoglycan 
LGMD 2D     AR   17q12–q21  α-Sarcoglycan 
LGMD 2E     AR   4q12   β-Sarcoglycan 
LGMD 2F     AR   5q33–q34  δ-Sarcoglycan 
LGMD 2G     AR   17q11–q12  Telethonin (TCAP) 
LGMD 2H     AR   9q3–q34  TRIM32 
LGMD 2I     AR  19q13.3  Fukutin-related protein 
LGMD 2J     AR  2q  Titin 
 
 
Congenital muscular dystrophy (CMD) 
CMD 1A      AR   6q22   Lamimin α2 
CMD 1B     AR  1q   
CMD 1C     AR  19q  Fukutin related protein 
Fukuyama CMD     AR   9q31–q33  Fukutin 
α7 integrin congenital myopathy   AR   12q13 a7  Integrin 
Muscle-eye–brain (MEB) disease   AR   1p32–p34 O-mannose β -1,2-N-acetyl- 
glucosaminyl transferase 
Walker-Warburg syndrome   AR  9q  O-mannosyltransferase 1 
Rigid spine CMD     AR   1p35–36  Selenoprotein N1 
Bethlem myopathy/Ullrich syndrome   AD   21q22   Collagen VI α1 
AD   21q22   Collagen VI α2 
AD   2q37   Collagen VI α3 
 
Distal muscular dystrophy 
Miyoshi myopathy     AR   2p13   Dysferlin 
Tibial MD     AD  2q  Titin 
     AD  14q 
 
 
Facioscapulohumeral muscular dystrophy  AD   4q35 
 
Oculopharyngeal muscular dystrophy  AD   14q11.2–q13 Poly A binding protein 2 
 
 
Figure 48. Muscular dystrophies and gene locations.*AD, autosomal dominant; AR, 
autosomal recessive; LGMD, limb-girdle musclar dystrophy; XD, X-linked dominant; XR, X-
linked recessive. *This table includes disorders which have been mapped to a chromosome. 
Figure modified from (Dalkilic and Kunkel, 2003; Emery, 2000). 
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Despite all the heterogeneities mentioned, most of these diseases seem to have one common 
determinant: they seem to be caused by loss of proteins involved in the structure of muscles. 
These structural proteins can be part of the linkage between the extracellular matrix and the 
actin cytoskeleton, or they can be located in the sarcomeric and in the nuclear structures 
(Figure 49) (Dalkilic and Kunkel, 2003; Emery, 2000). These structures may also be 
connected between them (Blake and Martin-Rendon, 2002).  
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Figure 49. Schematic view of the location of the proteins currently known to be involved in 
muscular dystrophies. Figure inspired from (Dalkilic and Kunkel, 2003; Emery, 2000). 
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We have mentioned the existence of a large number of muscular dystrophies discovered until 
now, but we will not talk extensively about all them. They are reviewed elsewhere (Dalkilic 
and Kunkel, 2003; Emery, 2000). We are going now to talk more in detail about one of these 
dystrophies, Duchenne muscular dystrophy, its animal models, and the therapeutic strategies 
currently aimed at the correction or at the improvement of the clinical features observed in 
this disease.  
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1.7.2. Duchenne Muscular Dystrophy (DMD) 
 
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder affecting 1 in 3.500 
live males at birth. About a third of cases occur as de novo mutations, in the dystrophin gene. 
Dystrophin is encoded by a 2.5 Mbp gene, which represents 0.1% of the genome, but only 
about 1% of this gene codes for the 86 exons of the Dystrophin protein (Muntoni et al., 2003). 
The fully processed transcript is only 14 kbp, and produces a 427 kDa protein, composed of 
3685 amino acid residues. The large size of this gene contributes significantly to its high rates 
of mutations. Most dys mutations in DMD patients are large deletions or insertions that result 
in downstream codon reading frameshifts (58%) or small frameshift rearragements or point 
mutations (41%), and the remaining mutations are the results of duplication events. DMD is 
usually diagnosed at 4-5 years of age, on the basis of gait abnormalities. DMD patients 
experience severe and progressive loss of muscle mass and function. Typically, wheelchair 
use is necessary by the age of 8-10. When they are teenagers, patients are wheelchair bound. 
In the late teens or early twenties, the DMD patients usually die, because muscle degeneration 
occurs to such an extent that it finally leads to respiratory or cardiac failure. Nevertheless, 
with some specific mutations, some patients can have milder phenotypes of disease and can 
live longer. Then, these patients are often referred as to suffer from the milder Becker 
muscular dystrophy (BMD) (Muntoni et al., 2003). Mutations in the dystrophin can also cause 
another disease. It consists of the cardiomyopathy seen in DMD and in BMD, but without 
significant muscle disease. Then, this myopathy is referred to as X-linked dilated 
cardiomyopathy (XLDCM) (Lapidos et al., 2004). 
 
1.7.3 Dystrophin  
Dystrophin is a major component of the dystrophin-glycoprotein complex (DGC). Its function 
is to link the myofiber cytoskeleton to the extracellular matrix. Once this complex is 
disrupted, injury occurs during muscular contractions, and sarcolemmal damage finally leads 
to myofiber necrosis. Dystrophin has 4 domains: the N-terminal and parts of the helical-rod 
domain bind to actin whereas the C-terminal and a cysteine-rich domain distal to the rod 
domain form complexes with syntrophin and beta-dystroglycan, respectively (Figure 50) 
(Dalkilic and Kunkel, 2003; Emery, 2000). In myogenic cells, Dystrophin provides a crucial 
structural link between the extracellular matrix and the intracellular cytoskeleton. Dystrophin 
mutations occur in DMD and BMD, and cause in both diseases sarcolemmal instability, 
which leads to destabilization of the sarcolemmal dystrophin-associated complex, but a wide 
range of severity phenotypes are possible both in DMD and BMD. The genetic mutations that 
cause DMD or BMD are not fully understood, but it seems that the correct expression of the 
C-terminal part of dystrophin, and particularly the cysteine-rich domain (that binds β-
dystroglycan), often allowed by exon skipping or by non frame-shift mutations, is often 
leading to a partially functional dystrophin protein and to milder symptoms (Muntoni et al., 
2003; Tidball and Wehling-Henricks, 2004). Nevertheless, exceptions exist to this rule 
(Muntoni et al., 2003). Some rare dystrophin mutations can also cause neither DMD nor 
BMD, but an almost exclusive cardiac disease in X-linked dilated cardiomyopathy. This rare 
disorder is caused by a cluster of mutations towards the 5′ end of the gene, or by missense 
mutations that disrupt dystophin preferentially or exclusively in the cardiac muscle (Muntoni 
et al., 2003). Patients with mutations in the dystrophin gene have not only muscle problems, 
their mutations were also associated with lower IQ results (mean IQ of 82) and retina 
problems (reduction of the b-wave amplitude in the scotopic electroretinography) (Muntoni et 
al., 2003).  
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Figure 50. Schematic regions of dystrophin gene. 3 different promoters permit the expression 
of the 14-kb cDNA dystrophin in cardiac muscle, skeletal muscle, and the brain. This full-
length 427 kDa form of Dystrophin includes a classical actin binding domain (ABD) at its N-
terminus, and rod region composed of 24 spectrin repeats (blue square). The rod regions are 
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separated by 4 regions (ovals) to create flexible hinge regions in the rod. A second actin 
binding domain has been characterized in the rod region in spectrin repeats 11 through 17. 
The carboxy-terminus of dystrophin includes a cysteine-rich (CR) and carboxy-terminal (CT) 
domains that interact with the remainder of the DGC. Thre is existence of 4 promoters within 
the dystophin gene, which drive the expression of dystrophin short forms. These forms are 
devoid of the actin binding domain, and are differentially expressed. Dp260 is highly 
expressed in the retina, whereas Dp140 are expressed in the nervous system, and Dp71 is 
widely expressed in nearly all cell types.  
 
1.7.4 Dystrophin deficiency and muscle degeneration 
 
Skeletal muscle regeneration in adults is thought to occur thank to the myogenic satellite cells 
that are located in close association with mature muscle fibers. Under normal circumstances, 
satellite cells are quiescent, but in response to stress, they are activated, prompting multiple 
rounds of proliferation. Some satellite cells fuse with one another to form myotubes, whereas 
others serve as bridges between myofibers, aiding in their regeneration (Chargé and Rudnicki, 
2004). In normal human muscles, the number of quiescent satellite cells essentially remains 
stable within adults over multiple cycles of injury and regeneration. However, the absolute 
number of satellite cells can decrease in case of pathologic situations, such as with Duchenne 
muscular dystrophy and with chronic muscle denervation, but also at the onset of advanced 
age or after atrophy secondary to deconditioning or immobilization. In dystrophic muscles, 
loss of dystrophin results in a mechanically weaker membrane that is more easily damaged 
during muscle contraction. In such a situation, there is probably an extensive satellite cell 
activation to repair damaged muscle, as seen with the rate of telomere loss in DMD patients 
that is 14 times greater than that observed in controls. Consequently, the proliferative 
potential of satellite cells decrease with age. For instance, it has been shown that a 9-year-old 
dystrophic patient has a satellite cell proliferative potential of one-third of age-matched 
controls (Jejurikar and Kuzon, 2003). After different cycles of degeneration-regeneration, 
regeneration gradually fails. This leads to degeneration of skeletal muscle fibers and 
connective tissue replacement. Degeneration is probably due in part to satellite cell depletion 
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and their impaired proliferation, which lowers their ability to form new myofibers, or repair 
existing ones. As a result, in the individual, skeletal muscle contraction significantly worsens. 
It is currently not fully understood why there is satellite cell depletion and why they have 
diminished proliferation potential. However, it is assumed that senescence and apoptosis may 
play a role to explain this fact. (Jejurikar and Kuzon, 2003). Particularly, the host environment 
within dystrophic skeletal muscle may contribute to the impaired proliferative potential of 
satellite cells. In dystrophic patients, IGF may not be available to satellite cells because 
fibroblasts release increasing amounts of IGF binding proteins, and this may lead to 
senescence. Moreover, apoptosis may play a role in diminishing satellite cell numbers 
because DNA fragmentation has been seen in mdx mice, before senescence is observed 
(Jejurikar and Kuzon, 2003).  
 
1.7.5 Therapeutic strategies for DMD 
 
Gene correction of DMD muscles is probably a method of choice to correct DMD, as well as 
transplatations of stem cells or muscle precursor cells, but these approaches currently raise 
several issues.  
Gene correction can be done either by introducing a functional dystrophin gene into the 
muscles of DMD patients, or by correcting the existing gene. Dystrophin can be added into 
muscles by viraly derived vectors, but its large size (14 kb) has hampered the introduction of 
the full gene into small viral capsids. Large adenoviral capsids can be used, but then the 
vectors are too large to cross the extracellular matrix that surrounds mature myofibres (van 
Deutekom and van Ommen, 2003). To circumvent this problem, it is only recently that special 
viral constructs have been designed to carry the full dystrophin cDNA (Goncalves et al., 
2005). Nevertheless, it has been shown that dystrophin size can be shrunk and can still lead to 
a functional protein (Scott et al., 2002). Such engineered proteins have been put into viral 
vectors and have been able to correct some of the mdx-associated phenotypes (Harper et al., 
2002). Others have attempted to correct dystrophin by overexpressing utrophin, which is a 
shorter homolog. In fact, utrophin is 80% identical to dystrophin in its cysteine-rich and C-
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terminal domains, and these domains are knowon to bind to the dystrophin associated protein 
complex (DAPC), including the dystroglycans and syntrophins (Perkins and Davies, 2002). 
Replacement of dystrophin by utrophin can be interesting, because it has the benefit of not 
eliciting an immune response against a foreign gene. In this respect, it is better to replace 
dystrophin deficiency by utrophin than to try to correct DMD by adjunction of dystrophin, 
because this method has the risk that Dystrophin would be recognized as a foreign protein by 
the immune system of the patient. Other approaches have been attempted to correct muscular 
dystrophies, such as oligonucleotide-mediated therapy (Rando, 2002). In this case, the 
dystrophin gene is corrected by chimeric RNA/DNA oligonucleotides ("chimeraplasts") that 
repair point mutations.  
All these approaches are nonetheless problematic to use in patients, because it is difficult for a 
viral vector to target all the muscles that can be afflicted in DMD patients. For this reason, 
other approaches have been used. For instance, stem or precursor cells isolated from DMD 
patients can be corrected ex vivo and transplanted back into DMD patients (Gregorevic and 
Chamberlain, 2003). Nevertheless, also with such a method, it is not a small task to allow 
correction of all muscles associated with DMD disease. Indeed, it has been shown that cell 
transplantation experiments often led to poor survival of the myoblasts immediately post 
transplantation (van Deutekom and van Ommen, 2003). 
The use of viral vectors either in in vivo or ex vivo approaches should consider the integration 
of the foreign DNA. Particularly, the integration site of the transgene should not induce 
bystanding harmful proto-oncogenes, and for that, careful choice of viral vector should be 
made (Check, 2005).  
Considering all the potential problems that are still associated with gene therapy of DMD, 
until now, only conventional drug treatments are clinically done with DMD patients. Such 
treatments do not correct the cause of DMD, but they attempt only to correct some of the 
different negative effects associated with this disease, and they are often associated with 
severe side-effects, as it will be discussed now.  
Anabolic steroids are one of classes of drugs that have been used in hope to have a beneficial 
effect in the muscle mass of DMD patients. Nevertheless, their use was found to produce only 
minimal improvements in muscle functions, and was accompanied by androgenic side-effects 
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(they include priapism, acne, and growth of pubic hair). However, more recent studies have 
identified oxandrolone as an anabolic steroid candidate for DMD treatment, because it may 
protect muscle mass with minor androgenic side-effects (Tidball and Wehling-Henricks, 
2004).  
Growth hormones (GH) were used in the objective to maintain muscle mass and function of 
DMD patients, but they often produced opposite catabolic effects. These results suggested 
that GH inhibitors may reduced pathology of DMD, but the clinical trials that have been done 
subsequently have produced only slight improvements in muscle function (Cittadini et al., 
2003). Nonetheless, Insulin-like Growth Factor-I (IGF-I) could be a candidate to protect 
DMD muscles, because it has been shown to be a potent anabolic agent that can increase 
muscle mass (Gregorevic et al., 2002). In mdx mice, this agent was also shown to reduce 
exercise-induced weakness (De Luca et al., 2003). However, despite these advantages, IGF-1 
should be used with caution, because it has been shown to increase the proliferation and 
metastasis of cancer cells (Chan et al., 1998).  
Beneficial effects could be produced by leukemia inhibitory factor (LIF). LIF is a potent 
mitogen, especially for undifferentiated cells, such as embryonic stem cells, hematopoietic 
stem cells and germ cells, but also for muscle cells (Barnard et al., 1994). Consequently, LIF 
treatment has therapeutic potential, but before this treatment is applied, side-effects of this 
drug should be better known. 
Inhibition of calcium-dependent proteases has been suggested after it was noted that there was 
an influx of extracellular calcium into dystrophin-deficient muscles. β2-adrenergic agonists 
can increase calpastatin expression, which is an inhibitor of the calcium-dependent calpain 
proteases. These agonists were used in DMD boys and were shown to improve muscle 
function, but no significant difference was seen in muscle function tests, such as in the ability 
to climb stairs (Spencer et al., 1997). 
The inhibition of the ubiquitin/proteasome system using MG-132 protease inhibitor has been 
shown to diminish pathology in mdx mice. This inhibitor has been shown to increase 
localization of the N-terminal portion of the Dystrophin protein at the membrane, by a 
mechanism that is still not completely understood (Bonuccelli et al., 2003). 
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Decreasing the inflammatory responses has also been attempted in DMD, because it has been 
shown that depletions of CD4+ or CD8+ T cells or macrophages significantly reduced the 
pathology in mdx mice (Spencer et al., 2001). Accordingly, immunosuppressants such as the 
glucocorticoid prednisone were shown to maintain muscle strength and function, and delayed 
disease progression (Yilmaz et al., 2004). However, prednisone was accompanied with side-
effects such as weight gain, suppression of growth, bone demineralization, cushingoid 
appearance, hirsutism, and behavioral changes that often prompted cessation of treatment. 
Nondaily dosing may reduce these adverse side-effects. However, additional research is 
needed to demonstrate the mode of action of prednisone. Indeed, even though prednisone is 
known as an immunosupressive drug, its benefic action in DMD may not be related to 
immunosuppressive effects. This is suggested by the fact the immunosuppressant azathioprine 
has not been shown to have the similar effects on DMD patients (Griggs et al., 1993). 
However, it is true that azathioprine is not an immunosuppressant per se. In fact, it is a purine 
analog that inhibits DNA synthesis. Therefore, the beneficial mode of action of prednisone in 
DMD may still be related to immunosuppressive effects. Nevertheless, it is known that 
prednisone has additional effects beneficial effects on DMD muscles, including the 
modulations of calcium homeostasis (Metzinger et al., 1995), of protein metabolism (Rifai et 
al., 1995), and of cell survival (Sklar and Brown, 1991).   
Chinese herbal medecine has a beneficial effect in DMD therapy, and dhis effet is probably 
glucorticoid-dependent (Courdier-Fruh et al., 2003). However, such medecine may be 
potentially harmful in some cases, particularly if the glucocorticoid content is not measured in 
different herbal preparations.  
For the treatment of DMD, modulation of the immune system has also been attempted with 
TNF-α or with nitric oxide. The rationale to treat DMD patients with NO stems from the fact 
DMD muscle release neuronal-type NO synthase (nNOS), the protein responsible to 
synthesize NO in skeletal muscle (Brenman et al., 1995). However, even though 
normalization of nitric oxide (NO) production in mdx muscles had benefic effects (Wehling et 
al., 2001), this approach has the risk of adverse side-effects, because NO plays a role in 
different physiologic systems that are unrelated to its function in muscles.  
Myostatin, a negative regulator of muscle mass, could be a possibility to try to cure DMD. 
Indeed, anti-myostatin injections have already been shown to produce desirable effects in mdx 
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muscles (Bogdanovich et al., 2002). Nevertheless, further experiments are required in this 
field before clinical trials are attempted in humans.  
Consequently, currently, no efficient treatment (either by gene therapy by chemicals) exists 
for DMD, and there is still need of a lot of research on this disease and on putative therapies.  
1.7.6 A dual high capacity hybrid Adeno/AAV vector 
Recently, an interesting new vector has been designed for the transduction of dual expression 
units for the full-length form of dystrophin (Goncalves et al., 2005). It is a dual high capacity 
hybrid Adeno/AAV (hcAd/AAV) vector. This vector has the advantage to combine the 
capacity of AAV to integrate into the AAVS1 locus, and the Adeno property to package large 
genes. It is constituted of the the Adeno capsids and packaging signal, but also of the AAV 
sequence required for integration in the AAVS1 locus. A further addition in such vectors of the 
AAV ITR in the 3’ of their sequence also allowed the formation of dual genomes with tail-to-
tail organization (Goncalves et al., 2005).  
The resulting vectors are constituted of the 5’Ad ITR, the 3’AAV ITR, and of the p5IEE 
(AAV integration efficiency element), which is necessary for integration in the AAVS1 locus 
(Philpott et al., 2002a; Philpott et al., 2002b). All these elements can be located in a plasmid, 
and production of dual hcAd/AAV hybrid vectros can be done if this plasmid is transfected in 
producer cells, with a Helper Adeno virus (Ad.floxedψ). With two plox sites around the 
Adeno packaging signal ψ, the encapsidation of the helper Adenovirus Ad.floxedψ can be 
largely prevented, if their producer cells express Cre. In the contrary, dual Ad/AAV genomes 
can be packaged into Adenovirus capsids, because they contain the Adeno packaging signal ψ 
in their 5’AdenoITR.  
The figure 51 summarizes the production of dual hcAd/AAV vectors, after transfection of 
Mss I-digested transgene plasmid in Cre-expressing cells, and after Helper Ad.floxedψ 
infection.  
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Figure 51. Production of dual hcAd/AAV. Figure adapted from manuscript of (Goncalves et 
al., 2005). 
 
The resulting vectors can integrate in chromosome 19 if Rep proteins are expressed in 
transduced cells (Goncalves et al., 2005). For this purpose, the AAV Rep78 and Rep68 
proteins are able to interact with the p5IEE elements of incoming vectors and with the AAV1 
sequence of the host, and finally trigger integration in the AAV1 locus (Chiorini et al., 1994; 
McCarty et al., 1994).  
Two dystrophin cDNAs have already been introduced with CAG promoter into Adeno 
capsids, in a so-called dual high capacity adenovirus (hcAd) vectors. This allowed the highest 
expression until now of the full-length dystrophin in mdx mice (Gilbert et al., 2003; Gilbert et 
al., 2002). This is why our collaborators also used the same method. Another interst in 
making expression units composed of two dystrophin cDNAs is their hability to be packaged 
in a good manner. Indeed, the maximal size of packaging of Adeno genome is ~36 kb but 
packaging of small fragments of DNA are not efficient and lead to genomic rearrangement. 
Experiments have concluded that genomes with 75% of the Adeno size (27.7 kb) are 
efficiently packaged (Parks and Graham, 1997). As said earlier, such expression units have 
allowed the transduction results of Dystrophin expression in fibers up to now. In fact, it 
allowed transduction of up to 42% of fibers in the tibialis anterior of mdx neonatal mice 
(Gilbert et al., 2003).  
The hcAd/AAV vectors package dual tail-to-tail expression units. This is done by using one 
of the properties of AAV replication, which can result in tail-to-tail tandems, and not head-to-
head dimers (Figure 52). 
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Figure 52. Model of AAV DNA replication. The 3’ITR of can form a hairpin structure and 
primes the synthesis of a complementary strand, leading to a ds monomer. If there is no cut at 
the terminal resolution site (trs), the 3’ITR AAV can once again form a hairpin structure, and 
prime synthesis, leading to a ds dimer, but also even to longer intermediates. Alternatively, if 
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is cut at the trs position, repair synthesis can occur, leading to a unit-length monomer duplex. 
Figure modified from (Hong et al., 1994).  
The property of AAV to form long intermediates has been exploited in hcAd/AAV vectors, 
because they contain not only the 5’ Ad ITR, but also the 3’AAV ITR. After transfrection of 
the shuttle plasmid, there is formation of dsmonomers. Then, two pathways have been 
postulated to lead to the formation of dual genomes in hcAd/AAV vectors (Figure 53). 
The first pathway postulates that Holliday-like structures of AAV ITR are resolved by Rep78 
and Rep68 or by cellular proteins to lead to dimer molecules that can be then propagated by 
replication from their Ad ITR.  
The second pathway postulates that the 3’AAV ITR hairpin structure allows the priming for 
the formation of dimers, after strand displacement. Then, the 5’ Ad ITR provides an origin of 
replication for the Ad DNA polymerase complex.  
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Figure 53. Tail-to-tail packaging of dual hcAd/AAV hybrid vectors. See text for details. 
Figure taken from (Goncalves et al., 2005).  
 
1.7.7 Models of DMD, and their limitations  
Different animal models of Duchenne Muscular Dystrophy already exist. Among them, there 
are notably mice models, dog models, feline models, but also non-mammalian models, such 
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as the zebrafish model and the C. elegans model. Despite the utility of animal models, the 
extent to which these models reproduce the DMD pathology seen in humans is variable. 
The mdx mouse model of dystrophin deficiency is one of the most used models, because it has 
a small size and it is genetically and biochemically similar to human DMD. Nevertheless, in 
mice, null mutation of dystrophin causes a progressive pathology that begins at an old age, so 
that dystrophin-deficient mice live a nearly normal lifespan. On the contrary, in humans, null 
mutations produce a disease in early life, and evolution of pathology greatly reduces life 
expectancy. 
The mild phenotype of dystrophin deficiency in mice has been attributed to expression in 
these animals of the homologous protein utrophin. For this reason, mice which are null for 
both dystrophin and utrophin (mdx/utrn-/-) have been generated. These mice have a more 
severe phenotype, comparable to DMD. Particularly, in contrast to mdx, mdx/utrn-/- mice 
exhibit growth retardation, weight loss, spinal curvature and joint contractures, weight loss, 
spinal curvature and joint contractures, early diaphragmatic pathology and premature death 
(Collins and Morgan, 2003). However, these mdx/utrn-/- mice are still not similar with DMD 
pathology seen in humans, mainly because of their size, and because the regulation of satellite 
cell number and activity is different in mice. For instance, rodent muscles have decreasing 
satellite cell population with increasing age, but not human skeletal muscles (Jejurikar and 
Kuzon, 2003). To circumvent these problems, other models have been used.  
Spontaneous mutations of dystrophin, leading to X-linked muscular dystrophy, have been 
detected in several breeds of the domestic dog, including the Golden Retrivever, the 
Rottweiler, the German short-haired pointer, and a beagle model. Among these models, the 
golden retriever dystrophic (GRMD) dog model has been most extensively studied and best 
characterized. This model seems to be one of the nearest pathological counterpart of human 
DMD. Nevertheless, this model is not the most used one, because dogs are not ideal 
laboratory animals. Colonies of dogs are difficult to maintain, their genome is not 
manipulable, and they are highly sentient and emotive. In the cat model, dystrophin 
deficiency produces hypertrophic feline muscular dystrophy (HFMD), rather than atrophy and 
fibrosis seen in both DMD and GRMD. For this reason, this model is not widely used. 
However, this model has additional disadvantages, particularly because researchers do not 
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wish to practice experiments on a large, sentient and emotive animal, for economic and ethic 
reasons.  
Both Zebrafish and C. elegans express a dystrophin homologue that interacts with other DGC 
proteins. Both these models have been also used, because they have a low complexity, and 
because they harbor less individual-related variations. C. elegans has also the property to be 
easily genetically manipulable. Nevertheless, the biology of these animals and their size, that 
are not similar than that of humans, have prevented their large use in study of DMD. 
Nevertheless, these models may be valuable tools for specific experiments. 
Currently, in vitro models of DMD consist mainly of cells isolated from mdx mice, even 
though we have already discussed that the mdx cells do not completely reflect the biology of 
humans. No in vitro human model of DMD is largely used, because they do not exist, or 
because the few existing ones are thought not to be similar to DMD.  
In an attempt to create such an in vitro human model for DMD, we have attempted to 
immortalize human myoblasts, either normal or of DMD origin.  
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CHAPTER 2: FIRST STUDY:                                   
Lentiviral Immortalization of Myoblasts 
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2.1 GENERAL INTRODUCTION FOR THE FIRST 
STUDY
“Lentivector-Mediated Transfer of Bmi-1 and Telomerase in Muscle 
Satellite Cells Yields a Duchenne Myoblast Cell Line with Long-
Term Genotypic and Phenotypic Stability” 
HUMAN GENE THERAPY 14:1525–1533 (November 1, 2003) 
 
 
Here, we are going to summarize the most important facts of this introduction in regard to our 
particular task of immortalization of myoblast. We are going also to discuss here why we 
have chosen to immortalize myoblasts, and why we have used some particular methods to 
reach this goal.  
Normal primary cells do not have an infinite lifespan. Usually, they can divide about 30-50 
times and they finally die after a crisis phase where they usually stop proliferating. Only rare 
cells (~1 in 10 million) can escape crisis and become immortal, but they often are associated 
with aberrant phenotypes. These facts imply that for getting large amounts of cells of a 
particular cell type, multiple isolations of primary cells have to be done, often from different 
donnors. However, for some goals, isolation of cells derived from different donors is not 
possible. This is the case if we want to work with a specific individual or to work with a 
specific genetic background. Then, cell lines have to be created, so that they should be as 
close as possible to their corresponding primary cells.  
The human cellular models are more sought than murine ones, because researchers often want 
to pursue fundamental biological human studies and medical studies of human cells. 
Nevertheless, there are still very few human cell lines, whose properties are similar to primary 
cells. It is for such reasons that we have aimed to create a human cell line.  
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Until now, a lot of the existing cell lines are derived from murine cells because murine cells 
are more easily immortalized than human cells. Nevertheless, these murine cell lines have 
often been reported to be genetically and phenotypically distinct from the normal primary 
cells, particularly from human primary cells. However, biomedical research often needs to 
work with models that are as close as possible to normal human cells. Fundamental 
researchers often like to get cells that are genetically and phenotypically as similar as possible 
to primary human cells. Because most cell human or murine lines have cancerous origin, they 
may not be in some circumstances the most relevant models. Indeed, these cancerous cell 
lines often have poorly known biochemical and genetic alterations, and they may therefore in 
some circumstances not be similar with some of the properties of the related primary cells. 
This is why we aimed to create a cell line with defined genetic elements, which would be able 
to trigger immortalization, but not tumorigenesis, of human cells.  
At this point, we could have immortalized different human cell types. We have chosen to 
immortalize human primary myoblasts, for two major reasons. First, Duchenne Muscular 
Dystrophy (DMD) is one of the most devastating diseases: it touches 1 out of 3500 boys. A 
lot of basic research is still probably needed to find a cure to this neuromuscular disease, and 
having a proper human cellular model would be useful for this task. The second reason why 
we have chosen to immortalize myoblast was because we wanted to know if the immortalized 
cells could still differentiate. Indeed, after immortalization of different cell types, the resulting 
cells are often said to be very similar to their primary counterparts because they possess the 
same surface markers. Nevertheless, presence of some surface markers on a cell does not 
always mean that this cell is completely similar to primary cells. It does not mean, either, that 
this cell is still able to follow the specific tasks of a primary cell. This has been particularly 
obvious with cells that can differentiate: even if these cells were immortalized and were 
thought to be normal, they often had lowered or impaired differentiation properties. Among 
the cell types that can differentiate, myoblasts have a phenotype of differentiation that is easy 
to observe: they have the ability to fuse between them and to form multinucleated myotubes. 
With such visible phenomenon of differentiation, myoblasts become an interesting paradigm 
to test in a simple manner if immortalization still allows differentiation. Indeed, even if 
immortalization of myoblasts has already been attempted, their authors often recognized that 
the resulting cells had lower fusogenic properties compared to primary myoblasts.  
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If immortalized myoblasts were often reported to have low fusogenic properties, it was 
certainly due to the use of virus-derived immortalizing genes, because the functions of such 
genes are known to lead to immortalization but also to alter cellular functions, and to have 
mutagenic properties. For instance, TAg is known to perturb different pathways, but also to 
alter karyotypes, leading to translocations, and aneuploidy, with chromosome numbers often 
in the diploid range. TAg is a protein of the SV40 virus whose properties are to act in 
different pathways, especially with its two major different splicings referred to as Large T and 
small t. In this respect, Large T was reported to inhibit at least the p53 and RB pathways, 
whereas small t was reported to act on Phosphatase 2A. The action of these proteins on these 
anti-tumorigenic mechanisms has already been reported to allow immortalization of numerous 
cell types. Other non-viral methods have been used for immortalization, with strong 
oncogenes, or with chemical mutagenesis. However, these alternatives often led to massive 
genetic changes, which could even often not be mapped.  
To circumvent these problems, we have used another approach. More precisely, we have 
attempted to find a method to immortalize myoblasts with defined and minimal genetic 
elements. This alternative way of immortalization would allow uncovering precisely what 
genes are useful for immortalization of myoblasts. This method would also be more 
appropriate to lead to cells with minor genetic and biochemical modifications.  
For this purpose, what have used Telomerase, Bcl-2 and Bmi-1. These proteins were chosen, 
because they were already suspected to play a role in immortalization. In fact, they had 
already been described to have either anti-senescence or anti-apoptosis effects. We are going 
now to summarize briefly their known function(s).  
First, Telomerase (hTERT) is the catalytic component of the human telomerase. This enzyme 
is able to replace the chromosome end repeats, which are eroded after multiple rounds of 
cellular divisions. Second, Bcl-2 has anti-apoptotic properties. Third, Bmi-1 is an oncogene 
regulating the tumor suppressors p16INK4a and p19ARF. Both these tumor suppressors originate 
from the same chromosomal locus, and they have been implicated in the senescence process.  
At this point, we still had to define what vector we should use to deliver the immortalizing 
genes. We have chosen here to use the HIV-derived lentiviral vectors, because they have 
sufficiently large capacities to carry the genes of interest, but also because they can easily 
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transduce a small number of cells. This property was important in our case because some 
myoblasts with altered phenotypes are present only in small amounts. Another reason to use 
lentivectors was because of their integrational properties. Indeed, lentiviral vectors allow their 
transgenes to be inserted in the genome of host cells in open chromatin regions. This allows 
high level expression of the transgenes, in our case of the genes used for immortalization. All 
transgenes inserted into myoblasts were surrounded with plox sequences, so that these 
sequences could be removed after expression of Cre recombinase.  
We would like to mention some of the previous attempts to immortalize human myoblasts. In 
the past, TAg has already been used together with telomerase, for the immortalization of 
human myoblasts. Nevertheless, as mentioned earlier, TAg immortalizations are known to be 
highly mutagenic, and to lead to karyotypes in the diploid range. Shortly before the 
publication of our results, it was also shown that telomerase alone was not sufficient to 
immortalize human myoblasts. We have confirmed these results, and we could demonstrate 
an alternative possibility for the immortalization of myoblasts. Here, we could show that Bmi-
1 + Telomerase also allow immortalization of myoblasts. This finally led to a Duchenne 
immortalized cell line, with normal phenotypic and fusogenic properties. We are going now to 
present these results, which were published in the journal Human Gene Therapy.  
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2.2 RESULTS OF THE FIRST STUDY :  
Cudré-Mauroux et al. 2003 Hum. Gene Ther. 14 :1525-1533 
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ABSTRACT 
Conditionally immortalized human cells are valuable substrates for basic biological studies, as 
well as for the production of specific proteins and for the creation of bioartificial organs. We 
previously demonstrated that the lentivector-mediated transduction of immortalizing genes 
into human primary cells is an efficient method for obtaining such cell lines. Here, we used 
human muscle satellite cells as model targets to examine the impact of the transduced genes 
on the genotypic and phenotypic characteristics of the immortalized cells. The most 
commonly used immortalizing gene, the SV40 large T antigen (T-Ag), was extremely 
efficient at inducing the continuous growth of primary myoblasts, but the resulting cells 
rapidly accumulated major chromosomal aberrations and exhibited profound phenotypic 
changes. In contrast, the constitutive expression of telomerase and Bmi-1 in satellite cells 
from a control individual and from a patient suffering from Duchenne muscular dystrophy 
yielded cell lines that remained diploid and conserved their growth factor-dependence for 
proliferation. Furthermore, the Duchenne-derived cell line exhibited all the phenotypic 
characteristics of its primary parent, including an ability to differentiate fully into myotubes 
when placed in proper culture conditions. It should constitute a useful reagent for a wide 
range of studies aimed at this disease. 
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OVERVIEW SUMMARY  
The aim of this study was to generate conditionally immortalized human muscle cell lines. 
For this, we transduced satellite cells with lentiviral vectors expressing various immortalizing 
genes. We found that T-Ag is extremely efficient at immortalizing muscle cells, but induces a 
high degree of genetic instability that rapidly leads to chromosomal aberrations and profound 
phenotypic changes. In contrast, the constitutive expression of telomerase and Bmi-1 yielded 
myoblast cell lines with long term genotypic and phenotypic stability. A Duchenne cell line 
was obtained, which fully conserved the fusogenic ability of primary myoblasts. This cell line 
will be a useful cellular model for studies focusing on this form of muscular dystrophy. More 
broadly, this work provides important information on approaches aimed at generating 
phenotypically relevant cell lines from primary human tissue. 
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INTRODUCTION 
The controllable expansion of human primary cells, be they early progenitors or differentiated 
effectors, represents an attractive means of producing large quantities of cells for 
experimental or therapeutic purposes. Through a process known as ex vivo immortalization, 
primary cells can be induced to grow indefinitely in vitro by genetic manipulation. Cell lines 
thereby obtained can be expanded, cloned, extensively characterized both in their 
immortalized and “de-immortalized” (i.e. after removal / silencing of the immortalizing 
genes) states, and used for analyses that range from basic physiology to proteomics, for the 
production of specific proteins and, in selected cases, for transplantation.  
Classically, genes encoding for at least two types of proteins have been used to immortalize 
human cells. First, proteins that trigger entry into the cell cycle, e.g. growth promoters or cell 
cycle inducers. Prototypes of this category are the SV40 large T antigen, which acts through 
the binding of Rb and p53 (Ali and DeCaprio, 2001), and Bmi-1, which downregulates the 
p16 and p19Arf tumor suppressor genes encoded by the ink4a locus (Jacobs et al., 1999). 
Second, anti-senescence factors such as telomerase (Greider and Blackburn, 1987), which 
prevents the progressive shortening of telomeres that occurs as the number of cell divisions 
augments. 
We previously demonstrated that lentiviral vectors are convenient tools to introduce 
immortalizing genes into human primary cells, owing to their ability to mediate the stable 
integration and long term expression of transgenes in a wide variety of targets irrespective of 
their proliferative status (Salmon et al., 2000). Furthermore, lentiviral vectors containing loxP 
sites into the vector long terminal repeats (LTR) allow for the Cre recombinase-mediated 
excision of the provirus, hence for the efficient de-immortalization of the expanded cell 
populations (Salmon et al., 2000).  
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Here, we applied this technique to the immortalization of human primary myoblasts from 
either a control individual or a patient suffering from Duchenne muscular dystrophy (DMD). 
This disease results from mutations in the gene coding for dystrophin, a component of the 
dystrophin-glycoprotein multimolecular complex (DGC), which connects the cytoskeletal 
actin with the transmembrane protein β-dystroglycan and thereby plays an essential role in the 
function of skeletal muscles (Spence et al., 2002). Molecularly, the muscular dystrophies are a 
heterogeneous group of disorders, some of which result from abnormalities in various 
components of the DGC. DMD is the most common type of muscular dystrophy affecting 
approximately 1 out of 3500 males. Patients with DMD present with a childhood onset 
progressive loss of muscle function and generally die by their early twenties as a result of 
either respiratory or cardiac failure (Emery, 2002).  
Although naturally occurring or genetically engineered mouse models can be used for 
studying some aspects of the muscular dystrophies, there is a shortage of reagents for 
molecular analyses conducted at the cellular level, in areas ranging from physiology to gene 
therapy (Allamand and Campbell, 2000).  
Myoblasts were previously immortalized by expressing proteins derived from adenovirus or 
polyomavirus SV40. However, immortalization often coincided with differentiation defects or 
other anomalies. Adenovirus E1A and SV40 large T antigen (T-Ag) suppressed myogenic 
differentiation of mouse myoblasts (Webster et al., 1988). Moreover, T-Ag led to loss of 
contact inhibition, to anchorage independent growth (Miranda et al., 1983), and to a strong 
tendency to apoptosis (Corti et al., 2001). To circumvent these problems, T-Ag expression 
was restricted to undifferentiated cells (Pincon-Raymond et al., 1991; Corti et al., 2001) or 
used in mutated versions. Expression of a cytoplasmic form of T-Ag was reported to be fully 
compatible with the terminal differentiation of C2 cells, despite enabling their growth in 
semisolid medium (Tedesco et al., 1995). The continuous growth of normal and Duchenne 
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human muscle cells was obtained with a temperature sensitive Large T antigen (Simon et al., 
1996), and Duchenne myoblasts were immortalized by co-expressing SV40 Large T and 
telomerase (Seigneurin-Venin et al., 2000). The long-term genotypic and phenotypic stability 
of these cells, however, remains unestablished. 
The present study tested different combinations of genes to immortalize primary human 
myoblasts. Our results indicate that, while T-Ag is extremely efficient at achieving this goal, 
it induces a high degree of genetic instability, which rapidly leads to chromosomal aberrations 
and profound phenotypic changes. In contrast, the constitutive expression of telomerase and 
Bmi-1 yielded myoblast cell lines devoid of these problems. Furthermore, a Duchenne muscle 
cell line was obtained, which fully and stably conserved the phenotypic characteristics of 
primary myoblasts. 
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MATERIALS AND METHODS 
Lentiviral vector production. LoxP-containing HIV-derived lentiviral vectors expressing the 
enhanced green fluorescent protein (GFP), SV 40 T-Ag, Bmi-1, human telomerase (hTERT), 
Bcl-2 and a nuclear localization signal-tagged form of the Cre recombinase (nls-Cre) from an 
internal human cytomegalovirus (CMV) immediate early promoter were previously described 
(Salmon et al., 2000). Vector stocks were produced by transient transfection of 293T cells 
(Zufferey et al., 1997), concentrated by ultracentrifugation and resuspended in X-VIVO 
medium (BioWhittaker). The GFP and nls-Cre vectors were titered on HeLa and HeLa-4.5 
cells, respectively. HeLa-4.5 is a HeLa-derived clone that contains a single copy of a loxP-
flanked, GFP-expressing lentivector provirus. Stocks of vectors expressing the immortalizing 
transgenes were evaluated by reverse transcriptase (RT) assay (Aiken and Trono, 1995).  
Culture and transduction of primary myoblasts. Samples of human skeletal muscle were 
obtained during corrective orthopedic surgery or diagnostic biopsies, in accordance with the 
guidelines of the ethical commitee of Geneva University Hospital. Myoblast clonal cultures 
were prepared from satellite cells following dissociation of the muscle biopsies by manual 
cloning using a micropipette under a microscope. Cells were seeded individually in growth 
medium consisting of Ham’s F10 (Gibco) supplemented with 15% fetal calf serum, bovine 
serum albumin (0.5 mg/ml), fetuin (0.5 mg/ml), EGF (10 ng/ml), dexamethasone (0.39 
µg/ml), insulin (0.18 mg/ml), creatine (1 mM), pyruvate (100 µg/ml) and uridine (50 µg/ml) 
(Baroffio et al., 1995). Differentiation medium consisted of DMEM (Gibco) supplemented 
with bovine serum albumin (0.5 mg/ml), EGF (10 ng/ml), creatine (1mM), pyruvate (100 
ng/ml) and uridine (50 µg/ml) (Baroffio et al., 1995). For transduction, 30% confluent 
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cultures of myoblasts were exposed to lentiviral vectors at a multiplicity of infection (MOI) of 
0.5 to 1 (as determined on HeLa cells) for the GFP vector, and of 0.5 to 3 (as determined on 
HeLa-4.5 cells) for the nls-Cre vector. For the immortalizing vectors, amounts of particles 
with an RT content equal to that of an MOI 1 of GFP vector were used. 
Protein analyses. Cells were either directly harvested in lysis buffer (1% triton X-100, 1mM 
aprotinin and phenylmethylsulphonyl –PMSF- in PBS) before pelleting nuclei by 
centrifugaion, or resuspended in one volume of TNE buffer (Tris pH 7.5 50 mM, NaCl 150 
mM, EDTA 1 mM) and one volume of Laemmli Sample Buffer (BIORAD) before boiling for 
3 min. Extracts containing 10 µg of protein (as determined with the BCA Protein assay, 
Pierce) were subjected to SDS-PAGE before transfer to PVDF transfer membranes 
(Polyscreen ; NEN Life Science). Membranes were blocked with T-TBS containing 5% non-
fat milk and hybridized with the following primary antibodies: mouse monoclonal antibodies 
against SV40 large T antigen (Santa Cruz), Myogenin (clone F5D obtained from W.E. 
Wright), Desmin (clone D33, DAKO) or α-Tubulin (clone DM1A, Sigma), and rabbit 
polyclonal antibodies against human p16, MEF2 or Myf5 (Santa Cruz). After incubation for 
one hour with HRP-conjugated goat anti-mouse or rabbit antibodies (BIORAD), blots were 
extensively washed with T-TBS, and processed using ECL reagents and MP Hyperfilms 
(Amersham Pharmacia Biotech). 
PCR amplifications. DNA was extracted using the DNeasy kit (Qiagen) and PCR 
amplifications were performed with the primers fwdCMV (5’-
ATTTCCAAGTCTCCACCCCATT-3’) and with revHBCL2 (5’-
GCGGGATGCGGCTGGAT-3’) or with the primers  
fwdCMV and revBMI1 (5’-TAGGACAATACTTGCTGGTCTCCA-3’).  
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Karyotypic analyses. Cells plated at 1/3 confluence 72 hours before analysis were processed 
with the Synchroset kit according to the manufacturer’s instructions. For each of the 12 
karyotypes analyzed, at least 3 different metaphase spreads were examined. 
Fusion assays. For assaying the fusogenic ability of primary myoblasts and cells 
immortalized with Bmi-1 and hTERT, differentiation medium was substituted to growth 
medium at confluence. For T-Ag-expressing cells (which kept proliferating in differentiation 
medium), various levels of confluence (from 20 to 80%) were tested, and in some cases 0.3 
mM aphidicolin (Sigma) was added to arrest the cells. At the time of analysis, nuclei were 
stained with 1 µg/ml Hoechst 33342 for 10 min, cells were washed twice with PBS, and 
examined with a CCD camera mounted on an inverted microscope (Nikon Eclipse TE 30). 
The fusion index was determined every 8 hrs according to the following formula: F.I. = 
number of nuclei in fused myoblasts / total number of nuclei. For each time point, a mean of 
about 300 nuclei in three randomly chosen fields were counted. 
Measurements of cell growth kinetics. The number of population doublings at each passage 
was defined as log N/log 2, where N is the number of cells harvested at confluence divided by 
the number of cells initially seeded. For analyzing growth in differentitiation medium, cells 
were periodically detached with Trypsin, counted, and replated using the trypsin inhibitor 
type I-S from Soybean (Sigma) to permit re-attachment in the absence of serum.  
Cell cycle analyses. Cells were plated so as to be 50% confluent 3 days later at the time of 
analysis. Hoechst 33342 dye was added into the medium at a concentration of 1 µg/ml, the 
cells were incubated at 37° C for 5 to 10 min, washed with PBS, detached with trypsin, fixed 
with paraformaldehyde 3.7%, and examined by FACS, using the CellQuest program for data 
analysis. For cell cycle analysis in DM, subconfluent cells were placed in DM, detached with 
trypsin, incubated in a buffer containing 0.03% saponin (Sigma), and stained with 20 µM 7-
amino-actinomycin D (7AAD) (Sigma). The cells were incubated at room temperature for 30 
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min, fixed with paraformaldehyde 3.7%, and examined by FACS, using the CellQuest 
program for data analysis. 
Immunofluorescence. After 3 days in differentiation medium, cells were washed with PBS, 
fixed for 10 min with MeOH at –20 °C, washed 5 times with PBS, and incubated in PBS 
containing 1% BSA for 40 min at room temparature. Dystrophin-specific antibodies NCL-
Dys1, NCL-Dys2, NCL-Dys3 (Novocastra, obtained from G. Pizzolato) were added at a 
dilution of 1:2, 1:100 and 1:40, respectively. After 40 min, cells were washed and anti-IgG 
Alexa-conjugated antibody was added at a dilution of 1:400 in PBS BSA 1% at room 
temperature; 30 min later, cells were washed and examineed with a Zeiss Axiocam 
epifluorescence microscope. 
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RESULTS   
Lentivector-mediated conditional immortalization of human myoblasts. When satellite 
cells isolated from human muscle biopsies were exposed to a lentiviral vector expressing the 
green fluorescent protein (GFP) from the CMV promoter at a MOI of 1, levels of transduction 
of about 80% were observed, indicating a degree of sensitivity slightly higher than that of the 
HeLa cell standard (not illustrated). DNAs encoding the SV40 T-Ag, Bmi-1, telomerase 
(hTERT) or Bcl-2 were then introduced by lentivector-mediated transduction into satellite 
cells obtained from a 13 year-old boy, either alone or in combinations. Only cells engineered 
to express T-Ag, T-Ag + hTERT, Bmi-1 + hTERT, or T-Ag + Bmi-1 + hTERT + Bcl-2 
escaped the crisis that occurred in control myoblasts at about 45 population doublings after 
transduction, corresponding to approximately 65 population doublings after initial isolation 
(Fig. 1). These cells have now been maintained in culture for more than two years, or more 
than 250 passages, and can thus be considered as immortalized. When examined by light 
microscopy, T-Ag-containing cells exhibited a rounder shape and a lower tendency to align 
regularly on the plate, compared to control or Bmi-1/hTERT immortalized myoblasts (Fig. 
2).The lentiviral vectors used in these experiments results in integrants flanked by loxP sites, 
and as previously described for similarly immortalized liver endothelial cells  (Salmon et al., 
2000), addition of Cre recombinase led to the rapid growth arrest of these cells (not 
illustrated). This demonstrated that their continuous proliferation was strictly dependent upon 
the presence of the immortalizing transgenes. From each population, at least 2 clones were 
randomly selected for further study. Expression of the appropriate exogenous proteins was 
verified by Western blotting with antibodies against T-Ag, p16 (a protein downregulated by 
Bmi-1), or by TRAP assay (which measures telomerase activity) (Fig. 3 and data not shown). 
Surprisingly, the highest TRAP score was found in cells tranduced with a vector expressing 
 139
T-Ag but in which no exogenous hTERT had been introduced. Although it explained the 
robust and long-term growth of these cells, it suggested that some intercurrent event had 
occurred following T-Ag transduction.  
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Karyotypic analyses. Six months after transduction, karyotypic analyses were performed on 
randomly chosen clones. Seven out of seven T-Ag-containing clones (2 T-Ag only, 3 T-Ag + 
hTERT, 2 T-Ag + hTERT + Bmi-1 + Bcl-2) exhibited major karyotypic anomalies, including 
aneuploidy as well as chromosomal translocations and fragmentations, often in a near-triploid 
or -tetraploid background. One of these clones was analyzed twice, at six and seven months 
post-immortalization. While marked chromosomal aberrations were already detected the first 
time, numerous additional karyotypic changes had accumulated a month later. In contrast, five 
out of five clones immortalized with Bmi-1 and telomerase stably conserved the diploidy of 
control primary cells (Fig. 4).  
Cell cycle analyses. T-Ag expression was associated with an increased proportion of the cells 
residing in the G2/M phase of the cycle (Fig. 5). When Bmi-1/hTERT immortalized myoblasts 
were placed in growth factor-depleted differentiation medium, they stopped dividing and 
accumulated in the G0/G1 phase of the cycle like non-immortalized primary myoblasts. Once 
re-incubated in growth medium, they immediately resumed their proliferation (Fig. 6). In 
contrast, T-Ag-containing cells still underwent a few divisions in differentiation medium, 
before exhibiting a high rate of death (not illustrated). 
In vivo tumorigenicity. The subcutaneous injection of 106 cells from two randomly chosen 
clones from each of the immortalized myoblasts populations did not lead to tumor 
development in nude mice after 11 weeks, while mice injected in parallel with HeLa cervical 
carcinoma cells exhibited prominent tumors in less than 4 weeks. The myoblast cell lines 
were thus not tumorigenic in this model, even when containing marked chromosomal 
abnormalities. 
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Immortalization of DMD myoblasts. Satellite cells purified from a muscle biopsy obtained 
from a seven year-old patient with Duchenne muscular dystrophy were transduced with 
lentiviral vectors expressing Bmi-1 or telomerase, alone or in combination. Only cells having 
received both vectors became immortalized, consistent with the results obtained with normal 
myoblasts. One clone was selected for further studies. The presence of the Bmi-1 and TERT 
transgenes was verified, and the karyotypic analyses revealed no abnormality (not illustrated). 
A light microscopic study of these cells demonstrated morphological features very close to 
that of control myoblasts, while indirect immunofluorescence confirmed their lack of 
dystrophin expression (Fig. 7).  
Differentiation ability of immortalized myoblasts. Control, non-immortalized myoblasts 
rapidly fused and formed myotubes when exposed to differentiation medium. Similarly, the 
DMD myoblast cell line also stopped growing and exhibited extensive fusion activity in 
differentiation medium, albeit with kinetics that were slightly slower (Fig. 8). This correlated 
with a pattern of gene expression typical of myotube differentiation, with a downregulation of 
Myf5, and an upregulation of Mef2, Myogenin, and desmin (Fig. 9). In contrast, little fusion 
and no significant switch in the expression of muscle-specific genes were observed when 
clones obtained from wild-type muscle were placed in differentiation medium. This 
differentiation block was present irrespectively of the immortalizing cocktail used, and 
whether or not the cells were “de-immortalized” with Cre (Fig. 9).  
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DISCUSSION 
In this study, the lentivector-mediated expression of SV-40 T-Ag, with or without TERT, and 
Bmi-1 + TERT in human muscle satellite cells yielded continuously growing human muscle 
cell lines. In contrast, TERT or Bcl-2, either alone or in combination, or Bmi-1 alone, were 
not sufficient to immortalize human myoblasts. T-Ag-containing or the Bmi-1/TERT 
immortalizing regimens had remarkably distinct genotypic and phenotypic consequences. 
Most strikingly, the introduction of SV40 large T into human muscle satellite cells led, over 
time, to a great degree of chromosomal instability. This correlated with the acquisition of 
novel phenotypic characteristics such as cell rounding, increased rates of progression into the 
G2/M phase of the cycle, and serum- and growth factor-independent proliferation. We have 
noted a similar degree of phenotypic drift in human keratinocytes, retinal epithelial cells and 
endothelial cells transduced with T-Ag-expressing lentiviral vectors (unpublished results), 
suggesting that this viral protein can induce genetic instability in a wide variety of targets. 
Here, the high levels of activity exhibited by T-Ag-expressing cells in the TRAP assay in the 
absence of exogenous TERT likely reflected the T-Ag-mediated induction of endogenous 
telomerase (Foddis et al., 2002; Yuan et al., 2002).  
The immortalizing capacity of T-Ag is generally attributed to its inhibitory association with 
p53, which relieves the cell cycle G1 checkpoint (Zhu et al., 1991). However, p53 also 
controls DNA repair and recombination in several ways, for instance by interfering with the 
RAD51 pathway (Saintigny and Lopez, 2002) and by associating with 53BP1, a 
transcriptional co-activator that participates in the formation of nuclear foci accumulating at 
the sites of double strand breaks (Schultz et al., 2000). Relatedly, DNA repair by the 
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MRE11/RAD50/nibrin pathway is disturbed in the presence of T-Ag, which may lead to 
increased mutation rates (Lanson et al., 2000; Digweed et al., 2002). Noteworthy, in the 
present work, T-Ag-induced chromosomal changes were not prevented by co-expression of 
the catalytic subunit of telomerase, suggesting that this genetic instability was not simply a 
response to telomere attrition (Maser and DePinho, 2002).  
In sharp contrast, we found that cells immortalized by expression of Bmi-1 and telomerase did 
not exhibit such chromosomal instability. Bmi-1 is a polycomb-group oncoprotein that acts as 
a negative regulator of the ink4a-ARF locus, which encodes the tumor suppressors p16 and 
p19arf (Jacobs et al., 1999). p16 blocks cell cycle progression by inhibiting cyclin D-
dependent kinases and thereby prevents the phosphorylation of Rb (Serrano et al., 1993), 
whereas p19arf prevents the degradation and inactivation of p53 by binding to Mdm2 
(Pomerantz et al., 1998; Weber et al., 1999). bmi-1 -/- mice suffer from severe proliferation 
defects in both the hematopoietic system and brain, while Bmi-1 overproduction leads to 
lymphomas (Alkema et al., 1997). In vitro, overexpression of Bmi-1 in MEFs was found to 
delay senescence and facilitate immortalization (Jacobs et al., 1999).  
Here, Bmi-1 alone could not immortalize human myoblasts, but in conjunction with 
temolerase it yielded continuously growing cell lines that exhibited three interesting 
properties. First, these cells displayed morphological features very close to those of primary 
myoblasts. Second, they were devoid of visible chromosomal aberrations and their genome 
apparently remained stable over a long period of time, suggesting that, in contrast to T-Ag, 
Bmi-1 is not by itself highly mutagenic. Third, the proliferation and arrest of Bmi-1/hTERT-
immortalized cells remained fully controllable by addition or withdrawal of growth factors.  
Using the Bmi-1/TERT immortalizing cocktail, we obtained a Duchenne myoblast cell line 
that conserved many characteristics of primary muscle satellite cells, in particular a full ability 
to differentiate into myotubes. In contrast, the wild-type myoblast immortalized clones 
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obtained in this study exhibited minimal differentiation ability, even though the starting 
material, a satellite cell clone isolated from the muscle biopsy of a 13 year old boy, could be 
induced to differentiate normally. The reasons for this limitation are unknown. Expression of 
Bmi-1 or TERT per se could not account for the differentiation block, since immortalized 
DMD cells expressing these genes readily formed myotubes. Furthermore, the fusogenic 
potential of the wild-type immortalized cells was not recovered after Cre-mediated excision of 
the immortalizing genes. It could therefore be that subtle mutations may have occurred in 
these cells, inactivating some critical master regulator of differentiation. Alternatively, muscle 
satellite cells may be heterogeneous in their ability to yield fusogenic myoblasts, and 
precursors with low fusion ability may be easier to immortalize. Future studies should address 
these possibilities, in particular by generating muscle satellite cell lines from a larger number 
of clones and from different donors. This will help determine whether the hereby-described 
immortalization protocol could be used broadly to obtain muscle cell lines from individuals 
suffering from other types of genetic disorders. 
It remains that the hereby described DMD myoblast cell line will facilitate a wide range of 
studies directed at muscular dystrophy, whether they focus on the physiopathology of this 
disease, on the testing of drugs to improve the function or survival of dystrophin-defective 
muscle cells, or on the evaluation of genetic approaches for the treatment of this devastating 
illness.  
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FIGURE LEGENDS 
 
FIG. 1. Proliferation curves of control and lentivector-transduced myoblasts.  
Satellite cells isolated from a human muscle biopsy were transduced with the indicated 
lentiviral vectors and their growth was monitored by measuring population doublings. The 
four regimens indicated on the upper left side yielded immortalized cell lines.  
 
FIG. 2. Phase contrast microscopy:  
Cells immortalized with Bmi-1 + hTERT are elongated and regularly aligned, whereas T-Ag-
containing cells are rounder and grow in disorderly fashion. Magnification 40x. Results are 
representative of more than ten clones from each population. 
 
FIG. 3. Detection of immortalizing agents. 
(A) Western blotting of T-Ag and of p16 (downregulated by Bmi-1). Two representative 
clones are shown from each immortalized cell population.  
(B) PCR assays to detect Bcl-2 and Bmi-1 transgenes in the clones containing T-Ag + 
Bmi-1 + Bcl-2 + hTERT. 
(C) TRAP assay to detect telomerase activity.  
Numbers correspond to cell clones indicated in lower right part.  
MB = myoblasts; H.I. = heat inactivated. 
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FIG. 4. Karyotypic analyses.  
While control primary myoblasts and (Bmi-1 + hTERT)-immortalized cells exhibit similarly 
diploid genomes, T-Ag-containing cells accumulate chromosomal abnormalities. The 
karyotype of cells immortalized with Bmi-1 + T-Ag + hTERT + Bcl-2 was similarly 
perturbed (not shown).  
 
FIG. 5. Cell cycle analyses. 
The DNA content of cells was determined by Hoechst staining and FACS analysis. The 
percentages indicate the fraction of cells in G2/M for each population. The Go/G1 peak was set 
at the same value for all clones, even though T-Ag-containing clones had higher ploidies. 
Results are representative of more than three clones from each population. 
 
FIG. 6. Proliferation in differentiation medium. 
(A) Proliferation of (Bmi-1 + hTERT)-immortalized clones is externally controllable. 
Cultures were consecutively incubated in growth and differentiation medium (GM and 
DM, respectively) as indicated, and cell numbers determined by counting. Results 
representative of more than 10 individual clones tested. 
(B) Cell cycle status of cells incubated for 7 days in differentiation medium, evaluated by 
staining their DNA with 7AAD followed by FACS analysis. The Go/G1 peak was set 
at the same value for all clones, even though T-Ag clones had higher ploidies. The 
percentages indicate the fraction of cells in G2/M for each population.  
 
 FIG. 7. Dystrophin expression in control but not in the DMD immortalized myoblasts. Phase 
contrast microscopy (A-C, G-I) and indirect immunofluorescence (D-F, J-L) of control 
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primary myoblasts (A-F) and (Bmi-1 + TERT)-immortalized DMD muscle cells (G-L), using 
antibodies binding to the rod domain (Dys1), the N-terminus (Dys2) or the C-terminus (Dys3) 
of human dystrophin.  
 
FIG. 8. Fusogenic potential of control and immortalized DMD myoblasts.  
Differentiation medium was substituted to growth medium when cells reached confluence. 
Fusion indexes were calculated in three randomly chosen microscopic fields by dividing the 
number of nuclei in fused cells by the total number of nuclei.  
 
FIG. 9. Differentiation-associated gene expression in myoblast cell lines.  
Extracts from Duchenne (left) or wild-type (middle and right) myoblasts clones immortalized 
with indicated cocktails were subjected to Western blotting with indicated antibodies after 
incubation in growth medium (GM), in differentiation medium for 4 days without (DM) or 
with (Cre) prior de-immortalization with an adeno-Cre vector. Only the Duchenne clone 
exhibits the downregulation of Myf5 and induction of Mef2, Myogenin and Desmin that are 
typical of myotube differentiation.  
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2.3 CONCLUSION OF THE FIRST STUDY 
In this article, we have demonstrated the feasability of lentiviral immortalization of myoblasts 
with bmi-1 and hTERT. This finally resulted in a new human cell line originating from a 
Duchenne patient, with long-term normal genotypic and phenotypic properties.  
We have used combinations of lentivectors coding for TAg, Bmi-1, hTERT and Bcl-2 for the 
immortalization of human primary myoblasts. Different combinations of transgenes allowed 
immortalization of human primary myoblasts. They include bmi-1 + hTERT, TAg, TAg + 
hTERT and bmi-1 + TAg + Bcl-2 + hTERT. Thus, the minimal cocktails of transgenes leading 
to immortalization were either TAg alone, or bmi-1 + hTERT. Nonetheless, the 
immortalization with Bmi-1 and hTERT were shown to be respectful of the phenotype of 
primary cells than TAg-containing immortalization.  Indeed, cells immortalized with TAg or 
TAg + hTERT or with Bmi-1 + TAg + Bcl-2 + hTERT had larger cell shape, increased cell 
proliferation, unusual growth in differentiation medium, and altered differentiation in 
differentiation medium, once these cells were compared to the normal primary cells. This was 
not the case for cells immortalized with Bmi-1 and hTERT, which were shown to have 
normal cell shape and proliferation in growth medium and also normal growth arrest and 
differentiation when placed in differentiation medium. Moreover, and in the contrary to TAg-
containing cells, the cells immortalized with Bmi-1 and hTERT are karyotipically stable. All 
the cell lines that were tested here were non-tumorigenic after subcutaneous injection into 
nude mice. Even the TAg-immortalized cells were non-tumorigenic, although ongoing genetic 
and phenotypic changes were shown to occur in these cells. Nevertheless, it is probable that 
the karyotipic instability of TAg-immortalized cells might trigger sufficient mutations to lead 
to tumorigenesis, particularly if the cells are placed in a propper selective environment.  
All these results suggest that the cells immortalized with Bmi-1 + hTERT may be used as cell 
lines, or for encapsidation purposes, because they are very similar to the primary cells.  
However, most of the immortalized myoblasts were shown to have low and decreasing 
fusogenic capacities with time. We found also the evidence that both fusing and non-fusing 
clones existed. Even though this may seem intriguing, this fact might be explained from the 
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choice of the satellite cells we have been picked up in the beginning or our experiments, but 
also by the differentiation that these cells may have in vitro.  
The satellite cell pool in Duchenne patients may be very different than the satellite cell pools 
in normal patients. Then, we may have picked in Duchenne patient the rare satellite cells that 
can be immortalized and can still retain long-term fusogenic properties. Different long-term 
fusogenic properties might also be derived from the heterogeneity of satellite cell population. 
Indeed, it is know that satellite cells are a heterogeneous population of cells, differing notably 
in their surface markers. This population is notably composed of side-populations cells and 
stem cells, and they may differ in their proliferative and differerentiation capacities, both in 
vitro and in vivo (Bachrach et al., 2004; Jankowski and Huard, 2004).  
The in vivo differences of the satellite cell population still not reflect the extent of 
differentiation properties of this cell population. Indeed, it has been noticed that a single clone 
of satellite cells can lead in vitro to different myoblast types. For instance, it is well known 
that the clonal culture of one single satellite cell can lead in vitro to a heterogeneous 
population of cells, with 70% of differentiation-prone cells. Among the non-fusing myoblasts, 
some small cells can resume proliferation and can lead once again to fusing and non-fusing 
myoblasts. This notably suggests that there is in vitro the presence of stem cells among the 
population of non-fusing myoblasts (Baroffio et al., 1996). 
The pre-cited evidences show that there is not only heterogenity of satellite cell pool, but also 
heterogenity of cells obtained from one single satellite cell. This may explain why we did not 
obtain a clone of normal myobasts immortalized with Bmi-1 and hTERT with long-term 
fusogenic properties. Then, probably that a large number of isolation procedures of satellite 
cells from normal donnors and different immortalizations procedures may help in the 
obtention of a normal clone of myoblast. However, this clone would not be isogenic 
compared to our obtained Duchenne clone.  
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A Duchenne cell line could be obtained in this study. It was shown to be phenotypically very 
similar to the normal primary myoblasts. Particularly, it has normal cell shape and 
proliferation properties compared to normal primary myoblasts. This cell line is also able to 
stop proliferating, to align, and to fuse, once placed in differentiation medium. Moreover, the 
fusion index of this cell line is about 70%, which is similar to the one found in normal 
primary cells. After more than one year in culture, the fusion index did not decrease, and the 
cells were not observed to acquire aberrant properties, in contrary to the TAg-immortalized 
cells. It was also verified that this cell line was not expressing Dystrophin. The obtained cell 
line was further analysed for expression of surface markers. It was shown that this cell line 
was expressing Myf5, one marker associated with normal myoblasts. These cells was also 
able to upregulate the differentiation markers that are associated with differentiation, 
including Mef2, Desmin and Myogenin. Only one difference could be noted between this cell 
line and normal primary myobasts: a slightly delayed speed of differentiation. Indeed, wheras 
normal maximum fusion was reached after 48 hours of differentiation, similar differentiaion 
of the Duchenne cell line was only observed after 64 hours. Delayed differentiation might be 
attributed either to the Duchenne phenotype, or to the immortalization itself. We believe it 
might be associated with the Duchenne phenotype, but only a control cell line with the same 
genetic background could prove this point. For this, a new cell line with normal genetic 
background had to be generated.  
For in vitro studies, the obtention of a new cell line containing dystrophin, and isogenic 
compared to our Duchenne cell is interesting. This is why, in the next article, the introduction 
into our Duchenne cell line of Dystrophin was pursued. The purpose of this work was not 
only to obtain a control for our Duchenne cell line, but also to find one method to correct 
Dystrophin deficiency in these cells. This was done as one of the first steps before thinking to 
correct Dystophin deficiency in Duchenne patients.  
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CHAPTER 3: SECOND STUDY:            
Complementation of Duchenne Muscular Dystrophy 
Muscle Cells by Dual High-Capacity Hybrid Viral 
Vectors 
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3.1 GENERAL INTRODUCTION FOR THE SECOND 
STUDY
 
After obtention of a new human Duchenne cell line, it was possible to study the correction of 
the human Duchenne Muscular Dystrophy in vitro. So, we aimed to generate dystrophin-
positive cell lines, with the same genetic background as our previously described human 
Duchenne cell line.  
Three main limitations have to be overcome to allow gene therapy in muscles. First, a 
convenient vehicle has to be chosen to carry the transgene. Second, the genetic material has to 
enter into muscle-derived cells. Finally, the transgene has to be able to be expressed in the 
long-term.  
Different methods of delivery of dystrophin cDNA have been used in attempts to correct 
DMD. For instance, injection of plasmids has already been attempted even in one clinical trial 
(Romero et al., 2004). However, such method is thought to be difficult to use for gene therapy 
purposes throughout a whole body. Indeed, it might be difficult for a genetic material to be 
directed to all the muscles that might suffer from DMD. This is why gene therapy of DMD is 
often attempted on precursor cells, which then may divide and fuse with existing fibers. 
However, it is not sufficient to be able to target such cells. For instance, Adeno vectors can 
transduce both dividing and non-dividing cells, but they do not allow integration into the host 
genome, and usually remain episomal, like most plasmids. This was not convenient for 
correction of progenitor muscular cells, because the episomal transgene is not duplicated after 
serial divisions of these cells, and becomes probably diluted in the resulting population of 
cells (Moisset et al., 1998). In fact, only the vectors that can integrate transgenes are thought 
to be successful candidates for attempts of DMD therapy. For this purpose, the vectors 
derived from the Adeno Associated Virus, but also the lentiviral vectors, have been methods 
of choice.  
AAV and Lentiviruses have the property to insert genes into the genome of cells, which is 
thought to be important for the long-term expression of a gene in dividing cells, specially in 
immunocompetent animals (Greelish et al., 1999; Harper et al., 2002). However, these two 
viruses have different integration methods. Lentiviruses integrate in gene-rich regions of the 
host genome, and AAVs integrate into the chromosome 19. Lentiviral integration in gene-rich 
regions allows high level expression of a transgene. In the contrary, AAV is also is able to 
insert its genome into a specified locus of chromosome 19, AAVS1 (Kotin et al., 1991). This 
feature would be particularly interesting to express a transgene without eventuality to cause 
severe damage to the host genome.  
 
hcAd/AAV 
Adenoviruses 
Integration in AAVS1 locus, 
in chromosome 19 
Integration in  
gene-rich regions 
Lentiviruses 
Packaging of ~36 kb 
AAV 
Figure 54 “Advantages” of different viruses, and fabrication of the hybrid vector hcAd/AAV.  
 
Despite its property to integrate in a very specific location, AAV has a limited packaging 
capacity. This is also the case for lentiviruses, but not for Adenoviruses. Nevertheless, for 
correction of DMD, a sufficient packaging size is needed. Dystrophin is the largest gene 
known in nature, spanning over 2.4 Mb in the human genome. Its cDNA measures 14 kb, and 
very few viral-derived vehicles allow the delivery of such a large size of genetic informations. 
For instance, despite their utility in other protocols lentiviral vectors do not allow the 
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packaging of large cDNAs. This is why only truncated versions of the dytrophin cDNA 
(called microdystrophins) can be packaged into lentiviral vectors (Bachrach et al., 2004). 
However, it is suspected that the microdystrophins are not able to restore muscle strength, 
even though they may stop ongoing muscle injury (Harper et al., 2002). To circumvent these 
problems, a hybrid vector was designed, with the property of AAV to integrate in AAVS1, and 
the property of Adenovirus to have high packaging capacities (Figure 54). This vector was 
also designed to have the capacity to package two dystrophin expression units. The resulting 
hybdid vector was named dual high capacity Adenovirus/Adeno-Associated Virus (dual 
hcAd/AAV) vector. In target cells, additional expression of Rep proteins was shown to lead to 
insertion of the expression units of this vector into the AAV1 locus of chromosome 19 
(Goncalves et al., 2005). In the following article, a further modification has been done in the 
fiber used by this vector, to permit better entry into muscular cells. For this purpose, the 
vector was modified to harbor part of the Ad 50 fibers, and not the conventional Ad5 fibers. 
This finally allowed complementation of our Duchenne cell line with dystrophin cDNA and 
led to correction of the DMD phenotype in vitro, as shown by restoration of the Dystrophin-
associated β-Dystroglycan Complex.  
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3.2 RESULTS OF THE SECOND STUDY  
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Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disease, is caused by 
mutations in the dystrophin gene, making it amenable to gene- or cell-based therapies. 
Another possible treatment entails the combination of both principles by transplantation of 
autologous myogenic cells after their genetic complementation. This approach requires 
efficient and stable transduction of these cells with recombinant dystrophin genes. Recently, 
we generated a dual high-capacity (hc) adenovirus (Ad)–adeno-associated virus (AAV) 
hybrid vector that can be used to deliver two full-length human dystrophin-encoding modules 
into target cells. Furthermore, we showed that hybrid vector transduction of human cells 
containing AAV Rep proteins leads to the insertion of foreign DNA into the AAVS1 locus on 
chromosome 19. Here, we focused on improving hybrid vector entry into muscle cells from 
DMD patients. After having verified that these cells barely express the Coxsackie B and Ad 
receptor (CAR), which constitutes the primary attachment molecule for Ad serotype 5 (Ad5) 
fibers, we equipped dual hcAd/AAV hybrid vector particles with Ad serotype 50 fiber 
domains to achieve CAR-independent uptake. These retargeted vectors much more efficiently 
complemented the genetic defect of dystrophin-defective myoblasts and myotubes than their 
isogenic counterparts with conventional Ad5 fibers. Importantly, the accumulation of β-
dystroglycan along the membranes of vector-treated DMD myotubes pointed to the proper 
assembly of dystrophin-associated glycoprotein complexes. 
 
 
Key words: high-capacity; hybrid vector; adenovirus; adeno-associated virus; 
retargeting; human muscle cells; duchenne muscular dystrophy; full-length dystrophin; 
CAR; CD46 
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INTRODUCTION 
Duchenne muscular dystrophy (DMD) is a recessive genetic disorder caused by mutations in 
the circa 2.5-megabase X-linked dystrophin gene. Knowledge about the precise roles of the 
various proteins encoded by dystrophin is incomplete. However, it is recognized that the 
3,685-amino acid isoform of the dystrophin protein (Dp427m) plays a key structural function 
in muscle fibers by connecting the intracellular cytoskeleton to the extracellular matrix via its 
association with a cluster of proteins in the sarcolemma called the dystrophin-associated 
glycoprotein complex (DGC) (Blake et al., 2002 [1]). In dystrophin-defective muscle tissue 
the absence of this linkage leads to sarcolemmal disruption followed by necrosis of muscle 
fibers. The damaged multinucleated fibers of DMD patients are initially repaired by fusion of 
myoblasts derived from resident muscle-committed progenitor cells called satellite cells. After 
exhaustion of these progenitors, functional muscle is substituted by adipose and connective 
tissues. This muscle wasting process is irreversible and inevitably ends in early death. 
Although the development of a therapy for DMD is fiercely pursued, there is currently no 
efficacious treatment available to prevent the disease or halt its progression. 
A possible route to DMD therapy consists of combining gene- and cell-based 
approaches via the ex vivo introduction of corrective genetic information into dystrophin-
defective myogenic cells followed by their autologous transplantation. The application of the 
patient’s own cells will reduce the risk of implant rejection and may preclude the need for 
stringent immune suppression regimens. Experiments aiming at stable phenotypic rescue of 
dystrophin-defective myogenic cells ex vivo used herpes simplex virus amplicon vectors in 
combination with fluorescence-activated cell sorting and G418 selection of transduced mouse 
myoblasts (Bujold et al., 2002 [2]) or lentivirus vectors to insert foreign DNA in so-called 
side population cells isolated from murine muscle (Bachrach et al., 2004 [3]). This resulted in 
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stable transduction of target cells, most likely through non-targeted host cell DNA integration, 
with a fully functional full-length dystrophin-coding sequence (Bujold et al., 2002 [2]) or with 
a truncated version of it (Bachrach et al., 2004 [3]). A non-viral procedure based on 
electroporation of myogenic cells with plasmids encoding a dystrophin fusion protein and the 
φC31 integrase followed by G418 selection has also been explored (Quenneville et al., 2004 
[4]). Although in the latter study site-specific chromosomal insertion of the full-length 
dystrophin-coding sequence was demonstrated, the cell mortality was high and the absolute 
transduction efficiency was low. Further improvements in gene delivery systems are 
warranted to achieve, simultaneously, efficient transduction of myogenic cells and targeted 
chromosomal integration of the full-length dystrophin-coding sequence to reduce the risk of 
insertional oncogenesis. Accordingly, we are developing a so-called dual high-capacity (hc) 
adenovirus (Ad)–adeno-associated virus (AAV) hybrid vector that can deliver two full-length 
human dystrophin-encoding expression units and can achieve maintenance of the foreign 
genetic information in the host cell by targeted integration into its chromosomal DNA 
(Gonçalves et al., 2005 [5]). 
In this study, we sought to increase the efficiency of dual hcAd/AAV hybrid vector 
entry into muscle cells from DMD patients to improve the extent of phenotypic correction. 
We found that the primary cellular attachment molecule for Ad serotype 5 (Ad5), the 
Coxsackie B and Ad receptor (CAR) (Bergelson et al., 1997 [6]; Tomko et al., 1997 [7]), is 
barely detectable on the surface of DMD myoblasts, whereas CD46, recently shown to be a 
receptor for the CAR-independent species B Ads (Segerman et al., 2003 [8]; Gaggar et al., 
2003 [9]), is abundantly expressed at the plasma membrane of these cells. Moreover, the cell 
surface amounts of CAR and CD46 in DMD myoblasts correlated very well with the 
transducibility of these cells by early region 1 (E1)-deleted Ad5 vectors carrying either Ad5 
fibers or chimeric fibers with shaft and knob domains from the species B Ad serotype 50 
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(Ad50). These results provided a strong rationale to endow dual hcAd/AAV hybrid vectors 
encoding full-length human dystrophin with the same fiber chimeras. Hence, a new helper 
Ad5 vector encoding fibers consisting of basal shaft sequences from Ad5 and distal shaft and 
knob motifs from Ad50 was constructed. This new recombinant helper Ad was subsequently 
used to generate dual hcAd/AAV hybrid vector particles carrying the chimeric fibers. The 
rescue and propagation of these dual hcAd/AAV hybrid vector particles was as good as that of 
isogenic particles displaying conventional Ad5 fibers. Importantly, the tropism-modified dual 
hcAd/AAV hybrid vectors were far more efficient at complementing the genetic defect in 
DMD muscle cells than their isogenic, Ad5 fiber-bearing counterparts. Transduction of DMD 
muscle cells with retargeted dual hcAd/AAV hybrid vectors encoding full-length human 
dystrophin caused redistribution of β-dystroglycan, a key component of the DGC, to its 
normal location along the plasma membrane. 
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RESULTS 
Surface Expression Levels of CAR and CD46 on DMD Myoblasts 
For mice it has been shown that CAR expression is down regulated in the course of skeletal 
muscle cell maturation (Nalbantoglu et al., 1999 [10]). This phenomenon may, at least 
partially, explain the inefficient Ad5-mediated gene transfer into adult muscle cells both in 
vitro and in vivo. Indeed, Ad5 vectors much more efficiently transduced mature skeletal 
muscle fibers of CAR transgenic mice than those of non-transgenic control animals 
(Nalbantoglu et al., 2001 [11]). Ad vectors containing fiber motifs that bind receptors other 
than CAR have the potential to effectively by-pass the CAR-dependent entry route. Ad 
serotypes from species B do not bind CAR but, alternatively, can utilize CD46 as a receptor 
(Segerman et al., 2003 [8]; Gaggar et al., 2003 [9]). Therefore, cells that express CD46 on 
their surface can be regarded as potential targets for genetic modification by Ad5 vectors 
carrying fiber domains from species B Ads. 
To evaluate plasma membrane expression of CAR and CD46 in myoblasts isolated 
from DMD patients, primary and TERT- and Bmi-1-immortalized cells (Cudré-Mauroux et al., 
2003 [12]) were labeled with CAR- and CD46-specific monoclonal antibodies (MAbs) and 
subjected to flow cytometrical analyses. Human epithelial cervical carcinoma cells (HeLa) 
served as positive controls for anti-CAR and anti-CD46 immunoreactivity. The results 
depicted in Fig. 1 clearly reveal that CAR is barely detectable on the surface of dystrophin-
defective human myoblasts as shown by the virtually complete overlap of the histograms of 
cell cultures incubated with the CAR-specific MAb and of cells labeled with the control MAb. 
On the contrary, DMD myoblasts incubated with the anti-CD46 MAb yielded histograms with 
a strong rightward shift as compared to those corresponding to control cultures, demonstrating 
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that the large majority of these cells have significant amounts of CD46 on their surface (Fig. 
1). 
Gene Transfer to DMD Muscle Cells by Replication-Defective Ad5 Vectors 
Displaying Ad50 Fiber Domains is Superior to that by Conventional Ad5 Vectors 
Subsequently, we investigated whether a direct correlation exists between CAR and CD46 
surface levels and the permissiveness of DMD myoblasts to E1-deleted Ad5 vectors carrying 
fiber shaft and knob domains from either CAR-dependent (i.e., Ad5) or CAR–independent 
(i.e., Ad50) serotypes. To this end, these cells were transduced with the unmodified Ad5 
vector or with the fiber-modified Ad5F50 vector at different multiplicities of infection 
(MOIs). Both vector types harbored the same EGFP expression unit to monitor and accurately 
quantify relative gene transfer activities. Both direct fluorescence microscopy (Fig. 2A) and 
flow cytometry (Fig. 2B) were performed. Fluorescence microscopy revealed that gene 
delivery into DMD myoblasts by the fiber-modified Ad5F50 vectors is much more efficient 
than that achieved by conventional Ad5 vectors (Fig. 2A). Flow cytometry data are presented 
both as the frequency of transgene-expressing cells (Fig. 2B, upper graph) and as the average 
amount of EGFP per cell (Fig. 2B, lower graph). The latter parameter is expressed in terms of 
mean fluorescence intensity (MFI) values. The flow cytometrical analyses showed that at 10 
infectious units (IU) per cell of Ad5F50 vector, virtually all cells expressed the transgene 
(Fig. 2B, upper graph). When the same vector was applied at 1 and 3 IU per cell circa 40 and 
80% of the myoblasts became EGFP-positive, respectively. Approximately 30-fold higher 
dosages were necessary to achieve similar frequencies of EGFP-expressing cells with the 
control Ad5 vector (Fig. 2B, upper graph). Moreover, at every MOI, the loads of reporter 
protein per cell were consistently higher in cells infected with Ad5F50 than those in Ad5 
vector-transduced cells. In fact, there was a clear vector dose-related increase in MFI values 
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in cells incubated with Ad5F50 but much less so in cells exposed to the Ad5 vector (Fig. 2B, 
lower graph). This indicates that few DNA copies of the latter vector reached the nuclei of 
DMD myoblasts and suggests that Ad5 vector particles enter these cells through low-affinity 
interactions with non-specific attachment molecules. Finally, the chimeric fiber-bearing 
Ad5F50 vector also clearly outperformed the Ad5 vector in inducing foreign DNA expression 
in differentiated DMD myotubes (Fig. 2C, compare the second with the fourth row). These 
data are in accordance with previous human myoblast transduction experiments using a 
luciferase-encoding E1-deleted Ad vector carrying Ad50 fiber domains (Havenga et al., 2002 
[13]). In addition, they demonstrate for the first time the superiority of this type of vectors 
over unmodified Ad5 vectors in transducing differentiated human myotubes. 
 
Generation of Dual hcAd/AAV Hybrid Vectors Displaying Ad50 Fiber Domains 
is as Efficient as that of Ad5 Fiber-Bearing Dual hcAd/AAV Hybrid Vectors 
The previous data provided a strong rationale to alter the tropism of full-length human 
dystrophin-encoding dual hcAd/AAV hybrid vectors by exchanging the Ad5 fiber domains 
for those of Ad50. To this end, we constructed the E1-deleted Ad helper vector 
Ad.floxedΨ.F50 to produce dual hcAd/AAV hybrid vectors with Ad50 fiber domains (dual 
hcAd/AAV.F50 vectors) instead of conventional Ad5 fibers (Fig. 3A). Three types of hybrid 
vector shuttle plasmids were used in combination with either Ad.floxedΨ.F50 or the standard 
E1-deleted helper Ad vector Ad.floxedΨ according to the scheme shown in Fig. 3B. The 
pAd/AAV.EGFP shuttle construct (Fig. 3B) was used to monitor and compare the rescue and 
propagation profiles of hybrid vector particles using each type of helper Ad vector. 
Preparations of the EGFP-encoding dual hcAd/AAV.F50 and dual hcAd/AAV vectors had, 
after four passages, titres of 1.2 × 109 and 1.6 × 109 HeLa cell-transducing units (HTU) per ml, 
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respectively, as determined by endpoint titration using flow cytometry as readout. We thus 
conclude that dual hcAd/AAV.F50 hybrid vectors can be produced with similar efficiencies as 
their isogenic counterparts carrying Ad5 fibers. 
Structure of Genomes Packaged in Conventional and Fiber-Modified Dual 
hcAd/AAV Hybrid Vector Particles 
Previous experiments showed that dual hcAd/AAV hybrid vector genomes consist of tail-to-
tail dimers. Experimental evidence pointed to a dimerization process that involves the 
progression of the Ad DNA replication complex through the AAV inverted terminal repeat 
(ITR) hairpin structure as opposed to intermolecular recombination between two hybrid 
vector monomers at the AAV ITRs (Gonçalves et al., 2005 [5]). The use of Ad.floxedΨ.F50 
as helper was expected to change neither this process nor the structure of the packaged hybrid 
vector DNA. Nonetheless, we decided to confirm this postulate and to investigate the stability 
of dual hcAd/AAV.F50 hybrid vector genomes upon serial propagation. To this end, producer 
cells were transfected with the hybrid vector shuttle plasmid pAd/AAV.eDYS and 
subsequently infected with either Ad.floxedΨ.F50 or Ad.floxedΨ according to the scheme 
depicted in Fig. 3A. After four rounds of propagation, DNA was extracted from purified 
hybrid vector particles, digested with HincII and subjected to Southern blot analysis with a 
mixture of two vector-specific probes. The autoradiograph shown in Fig. 4A demonstrates 
that, regardless of the recombinant helper Ad used, packaged hybrid vector DNA consists of 
tail-to-tail dimers (Fig. 4B). This structural organization together with the absence of any 
other DNA forms confirm previous experiments (Gonçalves et al., 2005 [5]) and show that 
hybrid vector genomes propagated with the aid of Ad.floxedΨ.F50 are as stable as those 
amplified with the support of Ad.floxedΨ. 
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Transfer of the Full-Length Human Dystrophin-Coding Sequence into DMD 
Myoblasts by Dual hcAd/AAV Hybrid Vectors Displaying Ad50 Fiber Domains is 
Superior to that by Conventional Dual hcAd/AAV Hybrid Vectors 
Next, we evaluated the gene transfer levels in DMD myoblasts transduced with unmodified or 
fiber-modified dual hcAd/AAV.F50 hybrid vectors. To this end, we made use of hybrid 
vectors encoding a fusion product between EGFP and the full-length human dystrophin 
protein (eDYS). This combination allowed straightforward and accurate quantification of 
recombinant dystrophin transfer and expression in target cells. At 1, 3 and 10 HTU per cell, 
the average percentages of dystrophin-positive DMD myoblasts were 112-, 54- and 18-fold 
higher for the tropism-modified vectors than for the control vectors (Fig. 5). These results 
show that the highly efficient transduction of human myoblasts by fiber-modified E1-deleted 
Ad vectors carrying reporter genes can be extended to dual hcAd/AAV.F50 hybrid vectors 
encoding therapeutic proteins. 
 
Genetic Complementation of DMD Muscle Cells by Dual hcAd/AAV Hybrid 
Vectors Displaying Ad50 Fiber Domains 
To test the capacity of dual hcAd/AAV.F50 hybrid vectors to deliver to and express in DMD 
muscle cells the full-length human dystrophin-coding sequence, two stocks of dual 
hcAd/AAV.F50 hybrid vectors encoding both DsRed and the human dystrophin protein were 
generated with the aid of Ad.floxedΨ.F50 (Fig. 3A). These vector preparations had titers of 
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1.4 × 109 and 3.2 × 109 HTU per ml as determined by limiting dilution assays and DsRed-
based flow cytometry performed 48 h post-infection. Fiber-modified hybrid vectors 
expressing two different transgenes can thus be produced equally well as those encoding a 
single gene product. 
Next, DMD myoblasts were incubated with the two-gene-containing fiber-modified hybrid 
vector particles at an MOI of 30 HTU per cell. Mock-transduced cultures served as a control 
in these experiments. The DMD myoblasts were either kept under growth conditions or were 
induced to differentiate into myotubes. Direct fluorescence microscopy and 
immunofluorescence staining of mock-infected myoblasts (Figs. 6A, B and C) and myotubes 
(Figs. 6G, H and I) showed neither DsRed- nor dystrophin-specific signals, respectively. The 
same assays applied to cells exposed to the dual hcAd/AAV.F50 hybrid vector revealed 
robust and widespread synthesis of DsRed and dystrophin proteins in myotubes (Figs. 6K, L, 
M, N, O and P) as well as in their precursor cells (Figs. 6D, E and F). Although in the 
majority of cells and syncytia both signals could be simultaneously detected, their 
intracellular distribution differed (Figs. 6F, M and P). DsRed permeated the nuclei and was 
more homogeneously distributed throughout the cytoplasm than dystrophin. In fact, 
accumulation of dystrophy along the plasma membrane of DMD myotubes was observed 
indicating correct localization of the protein (see arrowheads in Figs. 6N, O and P and in the 
corresponding insets). Importantly, neither the vector itself nor the encoded products blocked 
myotube differentiation since both mock- and vector-transduced DMD myoblasts could form 
large multinucleated myotubes as evidenced by staining with the nuclear dye Hoechst 33342 
and a skeletal myosin heavy chain (skMHC) type II-specific MAb (Fig. 6J). Taking all data 
together, we conclude that moderate MOIs of dual hcAd/AAV.F50 hybrid vectors suffice to 
effectively complement the genetic defect of myoblasts and myotubes from DMD patients. 
The ability of dual hcAd/AAV.F50 hybrid vectors to also direct synthesis of full-length 
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human dystrophin in differentiated, non-dividing, dystrophin-defective muscle cells was 
clearly established after adding the two-gene-encoding dual hcAd/AAV hybrid vector at an 
MOI of 30 HTU per cell to DMD myotube cultures and performing dystrophin 
immunocytochemistry (Figs. 6Q, R, S, T, U and V). 
The absence of dystrophin prevents the proper assembly of the DGC at the 
sarcolemma of muscle cells (Blake et al., 2002 [1]). An essential element of a functional 
membrane-associated DGC is the type I transmembrane protein β-dystroglycan. We therefore 
asked whether recombinant dystrophin synthesis directed by dual hcAd/AAV.F50 hybrid 
vectors resulted in rescue of DGC assembly by examining the distribution of β-dystroglycan 
in mock-infected (Figs. 7A, C, E and G) and vector-treated (Figs. 7B, D, F and H) DMD 
myotubes. Immunofluorescence microscopy revealed that in mock-infected DMD myotubes 
the β-dystroglycan staining was rather weak and diffuse (Figs. 7 C and G) whereas in 
genetically modified DMD myotubes it was stronger and more structured (Figs. 7D and H). 
Indeed, in vector- but not in mock-transduced DMD myotubes β-dystroglycan-specific 
staining lining the plasma membrane could clearly be discerned suggesting normal DGC 
formation (see arrowheads in Fig. 7H). 
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DISCUSSION 
To guide the development of dystrophin-encoding dual hcAd/AAV hybrid vectors for the 
effective genetic complementation of DMD myoblasts, we analyzed the expression of 
attachment receptors for human Ads on the surface of these therapeutically relevant muscle 
precursor cells. The plasma membranes of DMD myoblasts were found to contain hardly any 
CAR and significant amounts of CD46, which can serve as receptors for Ad5 and Ad50, 
respectively (Bergelson et al., 1997 [6]; Tomko et al., 1997 [7]; Segerman et al., 2003 [8]; 
Gaggar et al., 2003 [9]). These data were consistent with the outcome of transduction 
experiments of DMD myoblasts using E1-deleted Ad5 vectors displaying unmodified fibers 
or chimeric fibers carrying shaft and knob sequences from Ad50. Dystrophin-defective 
myotubes were also much more efficiently transduced by the fiber-modified than by 
conventional Ad5 vectors. These results were subsequently translated into a context involving 
dual hcAd/AAV hybrid vectors encoding the 427-kDa muscle-specific isoform of the human 
dystrophin protein. Flow cytometry and immunofluorescence microscopy revealed that a 
tropism-modified version of dual hcAd/AAV hybrid vectors corrected very efficiently the 
genetic defect of DMD muscle cells resulting in the clustering of both the recombinant 
dystrophin and the endogenous β-dystroglycan proteins along the plasma membrane of 
myotubes. The relocation of β-dystroglycan to the periphery of myotubes is in accordance 
with previous results obtained in humans where the presence of the complete dystrophin 
protein was shown to be important for stable membrane integration of this DGC component 
(Helliwell et al., 1994 [14]). 
 183
An important aspect of the present study is the use of human instead of rodent muscle 
cells. So far, the vast majority of studies on Ad-based gene transfer to skeletal muscle 
precursor cells deployed surrogate murine systems such as those based on the mouse 
myoblast cell line C2C12 and on primary myoblasts isolated from the DMD mouse model 
mdx. Although these systems are undoubtedly useful they cannot accurately mimic human 
cell-specific parameters. For instance, the molecular composition and expression levels of 
cellular receptors and co-receptors engaged by Adenoviridae members may differ between 
human and rodent cells. 
Early region-deleted Ad vectors are of limited use for DMD gene therapy because they 
cannot accommodate the full-length human dystrophin-coding sequence and encode 
immunogenic viral gene products. For these reasons, attention has been directed to hcAd 
vectors, which do not encode viral gene products and can induce the synthesis of the 
complete, and thus fully functional, dystrophin protein (Kochanek et al., 2001 [15]). 
However, hitherto hcAd vectors have mostly been based on Ad5, which uses CAR to enter 
cells. Hence, these vectors do not transduce muscle cells efficiently. Redirecting hcAd vectors 
to alternative cell surface molecules is an attractive approach to by-pass the CAR dependency. 
By using capsid-modified helper Ad vectors carrying an RGD peptide or a polyhistidine 
stretch in the HI loop of the fiber knob, Biermann and coworkers altered the tropism of hcAd 
vectors (Biermann et al., 2004 [16]). More recently, Bramson and colleagues generated hcAd 
particles incorporating RGD or polylysine sequences into the same fiber loop (Bramson et al., 
2004 [17]). These authors demonstrated that vectors with the polylysine-modified knobs 
yielded 12- and 21-fold higher reporter gene activities in mouse C2C12 myoblasts and 
myotubes, respectively, than control vectors. The effect of the latter fiber modification on the 
gene transfer activity in skeletal muscle was less pronounced. Another genetic method to alter 
the tropism of hcAd vectors consists of endowing them with fibers derived from alternative 
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Ad serotypes. Using hcAd vectors displaying Ad serotype 35 fiber domains, Balamotis and 
colleagues showed efficient transduction of human cancer and blood cell types with reporter 
genes (Balamotis et al., 2004 [18]). To by-pass the CAR dependency, we provided dual 
hcAd/AAV hybrid vector particles with Ad50 fiber domains. In side-by-side rescue and 
propagation experiments, fiber-modified and control vectors encoding different heterologous 
DNA combinations including recombinant dystrophin expression units reached comparable 
titers. Moreover, we demonstrated that two-gene-encoding dual hcAd/AAV hybrid vectors 
particles can be produced as good as single-gene-encoding versions. This feature can be 
exploited to, for instance, combine full-length human dystrophin synthesis with expression of 
myogenic or cell survival genes to enhance muscle regeneration or preserve myoblast survival 
after transplantation, respectively. 
The very efficient genetic complementation of dystrophin-defective human muscle 
cells by tropism-modified dual hcAd/AAV hybrid vectors encoding the complete human 
dystrophin protein constitute an important step towards an autologous cell therapy for DMD. 
Potentially useful target cells for DMD cell therapy are satellite cells and their myoblast 
progeny (Skuk and Tremblay, 2003 [19]) but also recently isolated and characterized stem 
cells that have the capacity to differentiate into or fuse with muscle cells (Cossu and 
Sampaolesi, 2004 [20]). Stable transduction of these myogenic cells is best accomplished 
through targeted host DNA integration to minimize positional effects on therapeutic gene 
expression and to dispel the emergence of insertional oncogenesis. Conventional hcAd 
vectors do not fulfill this requirement. Dual hcAd/AAV hybrid vectors, on the other hand, can 
stably transduce human cells through AAV Rep-mediated site-specific insertion of foreign 
DNA into the host cell genome (Gonçalves et al., 2005 [5]). Ongoing research in our 
laboratory focuses on the development of methods to introduce and express in cells with 
myogenic potential AAV Rep activities in a transient manner. 
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MATERIALS AND METHODS 
Recombinant DNA. The construction of the hybrid vector shuttle plasmids 
pAd/AAV.EGFP and pAd/AAV.eDYS has been detailed elsewhere (Gonçalves et al., 2005 
[5]). The DsRed- and human dystrophin-encoding construct pAd/AAV.DsRed.DYS was 
made by insertion of a human UbiC promoter fragment into the unique NruI site of the hybrid 
vector shuttle plasmid pAd/AAV.eDYS (Gonçalves et al., 2005 [5]). The NruI recognition 
sequence precedes the dystrophin ORF and lies immediately downstream of the simian virus 
40 pA of the DsRed expression unit. The UbiC promoter fragment was amplified from 
plasmid pUbCR#1 (Nenoi et al., 1996 [21]) (a kind gift from M. Nenoi) by polymerase chain 
reaction using the Platinum Taq DNA polymerase High Fidelity enzyme mixture (Invitrogen) 
together with primers hUbiCR (5'-CGTAAGCTTGTCTAACAAAAAAGCCAAAAACGG-
3') and M13F (5'-GACGTTGTAAAACGACGGCCAGT-3'). The amplified DNA was 
digested with HindIII (Fermentas) and blunt-ended with the large fragment of Escherichia 
coli DNA polymerase I (Fermentas) and the resulting 2,2-kb product was ligated to NruI-
linearized and shrimp alkaline phosphatase-treated pAd/AAV.DsRed. 
 
Cells. HeLa (American Type Culture Collection) and 911 (Fallaux et al., 1996 [22]) cells 
were kept in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 
5% fetal bovine serum (FBS) (Invitrogen). For the production of dual hcAd/AAV hybrid 
vectors we used Per.tTA.Cre76 cells. These Ad5 E1- and bacteriophage P1 cre-expressing 
cells were cultured as detailed before (Gonçalves et al., 2002 [23]). Cultures of primary DMD 
myoblasts were kindly provided by P.A. 't Hoen. The growth and differentiation conditions 
for the TERT- and BmiI-immortalized DMD myoblasts have been described elsewhere 
(Cudré-Mauroux et al., 2003 [12]). These cells have been shown to maintain a diploid 
 186
karyotype and the ability to form myotubes upon extensive subculturing (Cudré-Mauroux et 
al., 2003 [12]). Importantly, cultures of TERT- and BmiI-immortalized DMD myoblasts are 
devoid of fibroblasts. In contrast, primary myoblast cultures are often contaminated with 
fibroblasts, which tend to outgrow the muscle progenitor cells and may confound 
interpretation of gene transfer experiments. Their human origin together with the features 
mentioned above makes cultures of the immortalized dystrophin-defective myoblasts an 
excellent ex vivo model to test strategies aiming at the rescue of dystrophin synthesis. 
 
Immunophenotyping. The expression of CAR and CD46 on the surface of HeLa cells and 
of DMD myoblasts was determined by flow cytometry. Aliquots of each cell type were 
incubated with MAbs directed against CAR (Hsu et al., 1988 [24]) or CD46 (Becton 
Dickinson). The CAR-specific MAb is of the IgG1 isotype and was isolated from cell line 
RmcB, whereas the anti-CD46 antibody is of the IgG2a isotype and was derived from 
hybridoma E4.3. The CD46-specific MAb was coupled to the fluorescein isothiocyanate 
(FITC) fluorochrome, allowing direct detection. The CAR-specific MAb was detected with a 
secondary FITC-conjugated goat anti-mouse antibody (Becton Dickinson). This secondary 
antibody was added to the cells immediately after the addition of the primary CAR-specific 
MAb. As controls for non-specific binding, we used either fluorescently labeled isotype-
matched MAbs specific for a non-human antigen (negative control for CD46 staining) 
(Becton Dickinson) or incubated the cells exclusively with the FITC-labeled secondary 
antibody (negative control for CAR staining). After a 30-min incubation at 4°C the cells were 
washed with phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin 
(Sigma-Aldrich) and were analyzed directly using a FACSort flow cytometer (Becton 
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Dickinson). Typically, 10,000 events were acquired and the data were stored in list mode files 
and processed using CellQuest Software (Becton Dickinson). 
 
Replication-defective Ad vectors with the E1 deleted. The production and titration of the 
E1-deleted Ad vectors Ad5 and Ad5F50 have been described previously (Knaän-Shanzer et 
al., 2001 [25]). The number of virus particles (VP) per ml was determined using the 
spectrophotometric method described by Maizel and colleagues (Maizel et al., 1968 [26]). 
The number of IU per ml was determined by TCID50 assays using the E1-complementing 911 
cells (Fallaux et al., 1996 [22]). The VP/IU ratios of the Ad5 and Ad5F50 vector stocks were 
11 and 5, respectively. Details about the generation and characterization of the helper Ad 
vector Ad.floxedΨ have been specified elsewhere (Gonçalves et al. 2002 [23]). The fiber-
modified recombinant helper Ad Ad.floxedΨ.F50 was produced in the same manner has 
Ad.floxedΨ except that the shuttle plasmid pAd.floxedΨ (Gonçalves et al., 2002 [23]) was 
transfected together with cosmid pWE/Ad.Afl-rITR.pac.RFib50 instead of pWE/Ad.Afl-
rITR.pac.RFib5 (Knaän-Shanzer et al., 2001 [25]). 
 
Production of dual hcAd/AAV hybrid vectors. Dual hcAd/AAV hybrid vector stocks 
were obtained as previously described (Gonçalves et al., 2005 [5]). Titres were determined 
through limiting dilutions on HeLa indicator cells followed by flow cytometry (Gonçalves et 
al., 2005 [5]). 
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Vector DNA extraction and Southern blot analysis. The extraction, purification and 
Southern blot analysis of dual hcAd/AAV hybrid vector DNA have been specified elsewhere 
(Gonçalves et al., 2005 [5]). 
 
Transduction conditions. Gene transfer into DMD myoblasts by the EGFP-encoding Ad5 
and A5F50 vectors was tested as follows. One hundred thousand immortalized DMD 
myoblasts were seeded in triplicate in wells of 24-well plates (Greiner). The next day, the 
cells were incubated for 3 h at 37°C either with Ad5 or Ad5F50 vector particles at 1, 3, 10, 30 
and 100 IU per cell. Both direct fluorescence microscopy and flow cytometry were performed 
at 48 h post-infection. Gene transfer into DMD myoblasts by dual hcAd/AAV hybrid vectors 
was carried out as follows. Immortalized DMD myoblasts were seeded at a density of 3.3 × 
105 cells per well of 6-well plates (Greiner). After overnight incubation in a humidified air-5% 
CO2 atmosphere, the cells were transduced with the DsRed- and dystrophin-encoding dual 
hcAd/AAV.F50 hybrid vector at 30 HTU per cell for 3 h at 37°C. The next day, infected and 
mock-infected cultures were either exposed to myotube differentiation medium and cultured 
in a 10% CO2 atmosphere or were maintained in normal growth medium in a 5% CO2 
atmosphere. Direct fluorescence microscopy (to visualize DsRed) and immunofluorescence 
microscopy following staining with dystrophin- or skMHC type II-specific MAbs were 
performed at 6 days post-infection. 
DMD myotube formation was induced by culturing 1.2 × 106 immortalized DMD myoblasts 
in wells of 6-well plates (Greiner) for 5 to 6 days in differentiation medium in a 10% CO2 
atmosphere. The resulting DMD myotube cultures were exposed for 3 h to Ad5, Ad5F50 or 
the dual hcAd/AAV.F50 hybrid vector encoding both DsRed and dystrophin. The Ad5 and 
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Ad5F50 vectors were applied at an MOI of 100 IU per cell, whereas the dual hcAd/AAV.F50 
hybrid vector was used at an MOI of 30 HTU per cell. These dosages were calculated on the 
basis of the number of myoblasts present immediately prior to the start of the differentiation 
process. Mock-transduced cultures provided negative controls for (immuno)fluorescence 
microscopy. 
 
Dystrophin, β-dystroglycan and skMHC type II immunostaining. Dystrophin was 
detected using NCL-DYS2 (Novocastra), a carboxy terminus-specific MAb of the IgG1 
isotype together with the Alexa Fluor 488 goat anti-mouse IgG1 secondary antibody 
(Molecular Probes). These primary and secondary antibodies were diluted 40- and 500-fold, 
respectively, in PBS containing 10 mM glycine and 5% FBS. The presence of fast-twitch 
skMHC was investigated with the aid of the IgG1 molecules secreted by hybridoma MY-32 
(Sigma) in combination with the Alexa Fluor 568 goat anti-mouse IgG1 secondary antibody 
(Molecular Probes). These primary and secondary antibodies were used at dilutions of 1:200 
and 1:500, respectively. The β-dystroglycan immunofluorescence assays were performed with 
a 50-fold dilution of the IgG1 MAb NCL-b-DG (Novocastra) and the aforementioned Alexa 
Fluor 488 antibody. Except for the use of other antibodies, a reduction in the concentration of 
Triton-X to 0.1% (vol/vol) and the fixation with 10% formalin for 30 min, the protocol of 
Gonçalves et al. (2005) [5] was followed. 
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LEGENDS 
FIG. 1. Analysis of the expression of CAR and CD46 on the surface of DMD myoblasts. 
Presented are histograms of flow cytometry data from HeLa cells (upper panels) and from 
representative primary (middle panels) and immortalized (lower panels) DMD myoblasts 
stained with antibodies directed against CAR (left panels) and CD46 (right panels). The black 
lines represent background fluorescence of samples incubated with control antibodies. 
 
FIG. 2. Comparative analysis of the transduction of (A, B) DMD myoblasts and (C) 
myotubes by Ad5 or Ad5F50 vectors encoding EGFP using (A, C) direct fluorescence 
microscopy and (B) flow cytometry. The flow cytometry data are presented as the frequency 
of EGFP-positive cells (upper graph) and their MFI values (lower graph). Target cells were 
incubated with each vector for 3 h at the indicated dosages and analyzed at 48 h post-
infection. 
 
FIG. 3. Strategy used to retarget dual hcAd/AAV hybrid vectors. (A) The genome of the E1-
deleted (ΔE1) helper Ad vector Ad.floxedΨ.F50 differs from the Ad.floxedΨ DNA in that the 
Ad5 sequence encoding most of the shaft and the complete knob domain is substituted by 
homologous sequences derived from Ad50. In both helper Ad vectors, the packaging elements 
(Ψ) are framed by a direct repeat of bacteriophage P1 loxP sites (solid triangles). This 
construction allows negative selection against the assembly of helper Ad particles in 
bacteriophage P1 cre-expressing cells. In hybrid vector shuttle plasmids, the eukaryotic 
foreign DNA is flanked at one end by the 5’ Ad5 sequence encompassing the Ad origin of 
DNA replication and packaging signal (shaded box designated Ad.ITR/Ψ) plus the AAV 
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integration efficiency element (solid circle labeled p5IEE) and at the other end by an AAV 
ITR (solid oval designated AAV.ITR). The β-lactamase (amp) and the prokaryotic origin of 
replication (ori) are also indicated. Rescue of the hybrid vector DNA into Ad capsids is 
initiated by releasing it from the plasmid backbone at the indicated restriction enzyme 
recognition sites (RE) and transfecting the digestion products into Per.tTA.Cre76 cells. These 
cells are subsequently infected with Ad.floxedΨ.F50 to supply in trans all Ad DNA 
replication activities and Ad structural proteins (among these the chimeric fiber proteins) 
needed for the amplification and packaging of the dual hcAd/AAV hybrid vector DNA, 
respectively. Replication- and packaging-competent tail-to-tail dimers are assembled from 
input monomers due to Ad-dependent DNA replication in concert with AAV ITR-mediated 
dimerization (Gonçalves et al., 2005 [5]). The resulting hybrid vector particles display on 
their surface Ad50 fiber domains and can be amplified by serial propagation in 
Ad.floxedΨF50-infected producer cells. (B) In the present study, hybrid vector shuttle 
plasmids containing three different combinations of foreign DNA were used. Construct 
pAd/AAV.EGFP has an expression unit consisting of the human elongation factor 1α (EF1α) 
gene promoter (open box with broken arrow), the EGFP open reading frame (ORF) (solid 
box) and the human growth hormone gene polyadenylation signal (pA) (arrowhead). In this 
construct the human dystrophin-coding sequence is used as stuffer DNA (open box). Plasmid 
pAd/AAV.eDYS contains an expression module that encodes a fusion product (eDYS) 
between the EGFP (solid box) and full-length human dystrophin (open box). This sequence is 
framed by the EF1α gene promoter (open box with broken arrow) and the rabbit β-globin 
gene pA (arrowhead). Construct pAd/AAV.DsRed.DYS harbors two transcription units. The 
first of these units consist of the EF1α gene promoter (open box with broken arrow), the 
DsRed ORF (shaded box) and the simian virus 40 pA (arrowhead). The second expression 
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cassette is composed of the human ubiquitin C  (UbiC) promoter (solid box with broken 
arrow), the full-length human dystrophin-coding sequence (open box) and the rabbit β-globin 
gene pA (arrowhead). 
FIG. 4. (A) Structural characterization of dual hcAd/AAV hybrid vector genomes packaged 
in Ad5 capsids (F5) or in Ad5 capsids with fiber shaft and knob sequences derived from Ad50 
(F50). DNA extracted from purified hybrid vector particles obtained after four rounds of 
propagation on Per.tTA.Cre76 cells infected with Ad.floxedΨ (right lane) or with 
Ad.floxedΨ.F50 (middle lane) was digested with HincII, subjected to agarose gel 
electrophoresis and analyzed by Southern blot hybridisation with a mixture of probes 6563 
and 2832. Lane M, GeneRuler DNA Ladder Mix molecular weight marker (Fermentas). (B) 
HincII restriction map of dimeric hybrid vector molecules with a tail-to-tail genomic 
organization. Solid bars represent DNA probes 6563 and 2832 drawn in relation to their target 
DNA sequences. Numerals correspond to restriction DNA fragment sizes in kilobases. 
 
FIG. 5. Comparative analysis of the transduction of DMD myoblasts by unmodified (F5) or 
fiber-modified (F50) dual hcAd/AAV hybrid vectors encoding eDYS. Target cells were 
incubated for 3 h with the specified vector dosages. At 72 h post-infection, the percentages of 
dystrophin-positive cells were determined by flow cytometry using the amino-terminal EGFP 
tag of eDYS for detection. Mock-infected myoblasts were used to establish background 
fluorescence. 
 
FIG. 6. Genetic complementation of DMD muscle cells by fiber-modified dual hcAd/AAV 
hybrid vectors.  DMD myoblasts were either mock-infected (A, B, C) or incubated with a dual 
hcAd/AAV.F50 hybrid vector coding for DsRed and dystrophin at 30 HTU per cell (D, E, F). 
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Direct (A, D) and indirect (B, E) fluorescence microscopy were performed after culturing the 
myoblasts for 6 days in growth medium. DsRed- and dystrophin-specific signals were also 
merged (C, F). DMD myotubes differentiated from mock-infected (G, H, I, J) or from dual 
hcAd/AAV.F50 hybrid vector-transduced myoblasts (K, L, M, N, O, P) were analyzed at 6 
days post-infection by direct fluorescence microscopy (G, K, N) and by immunofluorescence 
microscopy following staining with MAbs directed against dystrophin (H, L, O) or skMHC 
type II (J). In panels I, M and P, the DsRed- and dystrophin-specific signals were merged. 
Differentiated DMD myotubes were also directly transduced with the two-gene-containing 
dual hcAd/AAV.F50 hybrid vector at 30 HTU per cell and analyzed by direct (Q, T) and 
indirect (R, U) fluorescence microscopy at 32 h post-infection. DsRed- and dystrophin-
specific signals were also merged (S, V). The nuclei in each of the DMD myotube cultures 
were stained with the blue-emitting fluorochrome Hoechst 33342. 
 
FIG. 7. Rescue of β-dystroglycan membrane association in DMD myotubes following 
transduction with fiber-modified dual hcAd/AAV hybrid vectors coding for DsRed and full-
length human dystrophin. Differentiated DMD myotubes were either mock-infected (A, C, E 
and G) or transduced with the two-gene-containing dual hcAd/AAV.F50 hybrid vector at 30 
HTU per cell (B, D, F and H) and analyzed at 32 h post-infection by direct fluorescence 
microscopy (A, B, E and F) and by immunofluorescence microscopy using a MAb specific 
for β-dystroglycan (C, D, G and H). The arrowheads in panel H point to β-dystroglycan 
accumulation along the plasma membrane of hybrid vector-treated DMD myotubes. Nuclei 
were stained with the blue-emitting fluorochrome Hoechst 33342. 
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3.3 CONCLUSION OF THE SECOND STUDY  
 
In an attempt to improve delivery of dual hc Ad/AAV vectors in DMD muscle cells, surface 
labelings of these cells were done with antibodies directed against CAR and CD46, which are, 
respectively, receptors for the Ad5 and Ad50 fibers. It was found that CAR is poorly 
expressed at the surface of DMD muscle cell. In the contrary, CD46 is well expressed on 
DMD muscle cells. Similar observations could be done with human DMD myotubes. 
Consequently, the envelope of the dual hc Ad/AAV vectors were modified to bind to CD46. 
This was done by modifying the Helper Adenovirus used for production of the vectors. 
Briefly, the sequences of the Ad5 Heloper Adenovirus were replaced by those of the Ad50 
Virus, which are able to bind to CD46.  
The newly designed Ad50 fibers dual hc Ad/AAV vector could be produced at similar 
efficiency as the former Ad5 fibers dual hc Ad/AAV vectors, and it was used for 
complementation of dystrophin in our human DMD cell line. This resulted in a high 
transduction of these cells, at rates highly superior of that of the former control dual hc 
Ad/AAV vector. This suggested that high transduction levels can be done in myoblasts with 
Adeno vectors surrounded of fibre 50 proteins. The resulting complemented DMD muscle 
cells were characterized. It was controlled that dystrophin was present in these cells, but not in 
mock-transfected cultures. When the complemented cells were induced for differentiation, not 
only Dystrophin could be seen in myotubes, but also modifications in the Dystroglycan 
Complex were observed. Particularly, after complementation of dystrophin, DMD myotubes 
were found to have membrane-positioning of β-dystroglycan. In the contrary, the staining of 
uncomplemented DMD muscles for β-dystroglycan was weak and diffuse. This suggested that 
Dystrophin cDNAs brought by dual hc Ad/AAV vectors were able to correct the phenotype of 
DMD in vitro. Indeed, sufficient amounts of Dystrophin are known to contribute to the 
formation of a proper DGC complex at the sarcolemma of muscle cells (Blake et al., 2002).  
These experiments proved the value of the newly designed Ad50 fibers dual hc Ad/AAV 
particles to correct our DMD immortalized cell line with Dystrophin. As a result, these 
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experiments also showed the value of our Duchenne cell line for the study of the in vitro 
correction of the DMD phenotype. Until now, most of the time, only the murine cell line 
C2C12 was used for studies of DMD. However, it is known that muscle cells from human or 
mice have different regulation mechanisms. Then, our human Duchenne cell line permits a 
new way to study DMD. Particularly, it allows studying DMD in a human system, without to 
have to extract cells from human Duchenne muscle biopsies.  
Thus, this article has demonstrated the potentiality of our Duchenne cell line for cell studies, 
particularly for studies aiming at the correction of the human Duchenne phenotype. It has also 
demonstrated that fibre 50 dual hc Ad/AAV vectors may be a tool of choice for correction of 
DMD. However, additional experiments are needed to prove the utility of these vectors in 
other systems, and particularly in vivo. Before that, ongoing research in the laboratory of our 
collaborators is aiming at expressing AAV Rep proteins in a transient manner in host cells. 
This would allow to have specific integration of the transgenes in the AAV1 locus, but without 
to express the Rep proteins when they are not needed.  
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CHAPTER 4: GENERAL CONCLUSIONS 
Aiming at the fabrication of a model for Duchenne Muscular Dystrophy, the articles presented 
in this thesis have shown, first, the generation of a new human DMD cell line which has 
normal phenotypic properties, and second, complementation of this cell line with Dystrophin, 
to obtain a normal muscle cell line with the same genetic background as our Duchenne cell 
line.  
We could obtain a DMD cell line after addition of different oncogenes into human primary 
DMD myoblasts. Lentiviral vectors were used for these immortalization purposes. We have 
used these vectors because they have sufficient packaging capacities and because they have 
integrational properties that allow long term expression of a transgene in dividing cells. After 
addition of different cocktails of lentivectors containing the transgenes TAg, Bmi-1, hTERT 
and Bcl-2, we found that myoblasts immortalized with Bmi-1 and hTERT were superior to 
other immortalized cells. Not only these cells had normal shapes and proliferation capacities 
as compared to the primary myoblasts, they also had normal growth arrest and differentiation 
once placed in differentiation medium. Additional experiments have verified that these cells 
had a normal karyotype, and this was not the case for cells immortalized with TAg, or with 
TAg + hTERT. None of the cell lines tested here was shown to be tumorigenic in nude mice. 
This does not mean, however, that these cell lines may not acquire carcinogenic properties. 
Particularly, we think that the unstable karyotype of TAg-immortalized cells might be 
particularly able to trigger the mutations that are necessary to lead to carcinogenesis. In the 
contrary, it has been shown that Bmi-1 + hTERT immortalized cells have stable karyotypes. 
This may suggest that these cells have normal anti-tumorigenic properties, and, therefore, 
these cells may be largely protected from the acquisition and perpetuation of mutations 
leading to tumorigenesis.  
In our study, a Duchenne cell line was obtained, after immortalization with Bmi-1 and 
telomerase. The resulting cell line was able to fuse at normal rates, and has been observed to 
conserve the normal phenotypic properties of myoblasts even after more than one year in 
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culture. We believe that this cell line will be useful for sudies aiming to correct DMD in gene 
therapy purposes, but also to test various drugs for DMD.  
In the second article, we show that the DMD immortalized cell line could be complemented 
with Dystrophin, to lead to a new human normal muscle cell line, with the same genetic 
background as our Duchenne cell line. For this purpose, an existing dual high capacity 
Ad/AAV vector was used. Lentiviral vectors and AAV vectors alone are not able to carry the 
full-length cDNA of dystrophin, which is the longest human gene currently known. However, 
the AAV capacities to integrate in the AAV1 locus of chromosme 19 could be exploited here, 
as well as the Adenovirus vector property to package very large transgenes. So, a dual hc 
Ad/AAV vector was used. This vector was further modified to target a receptor abundantly 
found on myoblast cells. Indeed, the existing dual hc Ad/AAV were dependint upon their Ad5 
fibre for entry, and then dependant upon presence of CAR receptors on target cells. However, 
it was shown that CAR receptors are not abundantly distributed on myoblast cells, but CD46 
receptors were. For this reason, the Adeno Helper virus used to produce dual hc Ad/AAV 
vectors were modified to be surrounded by the part of the Ad50 fibre which can bind to 
CD46. The resulting pseudotyped vector was shown to be as efficiently produced as the 
control vector from which it originated.  
The dual Dys hc Ad/AAV vectror was used for transduction of our Duchenne cell line that 
was immortalized with Bmi-1 and hTERT. This led to correction of the DMD phenotype in 
vitro, with correct expression of dystrophin at the plasma membrane, in the contrary of 
control mock-transduced DMD myotubes. Because relocalization of beta-dystroglycan was 
also observed at the plasma membrane, this suggests that our DMD cell line could be 
complemented with Dystrophin to allow formation of a functional DGC complex.  
Currently, our collaborators aim to express Rep proteins in a transient manner in myotubes, to 
still ensure that the transgenes are introduced into the AAV1 locus, but also to prevent the cells 
from the danger associated with the ongoing expression of these viral genes. However, even if 
Rep transient expression if achieved, this might not be sufficient to ensure that no mistaken 
integration occurs outside of the AAV1 locus. For this reason, we are going now to talk about 
the long-term perspectives linked to find a cure to DMD. We are also going to talk more 
broadly about immortalization purposes.  
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4.1 Long-term perspectives  
 
After the immortalization of myoblats with Bmi-1 and hTERT, new cell lines have been 
established in our laboratory with these same transgenes, but all cell types could not be 
immortalized with this regimen of oncogenes. Therefore, still additional research should be 
pursued before we are able to immortalize all cell types. Immortalization of additional cell 
types will enable not only to obtain new cell lines, but also cell lines with therapeutic 
purposes. For instance, obtention of a hepatic cell line is of importance to help to cure liver-
related diseases. Moreover, obtention of pancreatic beta cells would be useful in attempts to 
cure Type I diabetes. However, obtention of immortalized cells does not mean that all 
diseases can be easily corrected.  
For instance, if a Duchenne phenotype has been corrected in vitro, some people might think 
that there is only one step to cross to correct the DMD phenotype in patients. However, in 
vivo correction of DMD is still a long-term goal. Moreover, even though immortalized cells 
could be used for this purpose, it could be better and easier to use other types of cells, which 
could be used with less genetic modifications.  
This is why, until now, in vivo correction of DMD is envisaged through transplantation of 
cells that can finally express dystrophin. These cells may be stem cells, satellite cells or 
progenitor muscular cells. Nonetheless, the problem, until now, is that the transplantated cells 
have poor survival capacities and only a small fraction of them cells contribute to muscle 
regeneration. These limitations have to be overcome before to envisage in vivo correction of 
DMD in patients.  
Before any clinical trials are begun with gene therapy, different possible adverse effects 
should be considered. They relate to the correction of the muscle cells before transplantation. 
Indeed, it is often viral-derived vectors that are used to correct in the long-term genetic 
defects, in our case Dystrophin deficiency. Nevertheless, these vectors may integrate in 
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regions where there are tumor suppressors or oncogenes, which may knock down some tumor 
suppressors or enhance the expression of oncogenes.  
 
In the second article presented here, a strategy has been proposed to insert dystrophin into the 
AAV1 locus of chromosome 19. However, it is probable that this technique can not avoid 
insertional mutagenesis because of mistakenly integrations outside of the AAV1 locus. Thus, 
this adverse possibility remains to be investigated.  
To ensure proper integration, it may be an interesting to try to achieve a targeted integration in 
the exact region to be corrected. This has already been attempted with rAAV, but at the 
moment only 1 targeted integration occurs for 10 non-targeted integrations (Chamberlain et 
al., 2004). Adenoviral vectors have also been recently used for this purpose, but they are also 
not yet very efficient for targeted integration (Ohbayashi et al., 2005).  
Despite the current difficulty to reach targeted integration, it is desirable that such a method is 
made available. Indeed, this may be a very adequate mechanism for gene therapy purposes. 
However, random transgene integration in different areas of the genome may also be 
beneficial. However, it remains to be defined where exactly the integrations are not 
detrimental for the host. Once this is known, it will be able to test (by PCR methods) all the 
integration events in a gene therapy experiment, before to transplant the modified cells into a 
host. In fact, it is probable that in the long-term, only cells with properly defined insertional 
events will be suitable for transplantation into hosts. Until this is achieved, before to begin a 
gene therapy experiment, it should be at least ensured that the risk associated with gene 
therapy purposes should be lower than the risk associated with the disease.  
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